Eli Lilly and (LLY) 10-K 19 Feb 16 2015 FY Annual report Financial data

Document and Entity Information

Document and Entity Information - USD ($)	12 Months Ended
	Dec. 31, 2015	Feb. 12, 2016	Jun. 30, 2015
Document Information [Line Items]
Document Type	10-K
Amendment Flag	false
Document Period End Date	Dec. 31, 2015
Document Fiscal Year Focus	2,015
Document Fiscal Period Focus	FY
Entity Registrant Name	Lilly Eli & Co
Entity Central Index Key	59,478
Current Fiscal Year End Date	--12-31
Entity Well-known Seasoned Issuer	Yes
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Filer Category	Large Accelerated Filer
Entity Public Float			$ 81,473,000,000
Entity Common Stock, Shares Outstanding		1,106,093,485

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($) shares in Thousands, $ in Millions	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Revenue	$ 19,958.7	$ 19,615.6	$ 23,113.1
Cost of sales	5,037.2	4,932.5	4,908.1
Research and development	4,796.4	4,733.6	5,531.3
Marketing, selling, and administrative	6,533	6,620.8	7,125.6
Acquired in-process research and development	535	200.2	57.1
Asset impairment, restructuring, and other special charges	367.7	468.7	120.6
Other-net, (income) expense	(100.6)	(340.5)	(518.9)
Cost of sales, operating expenses, and other-net	17,168.7	16,615.3	17,223.8
Income before income taxes	2,790	3,000.3	5,889.3
Income taxes	381.6	609.8	1,204.5
Net income	$ 2,408.4	$ 2,390.5	$ 4,684.8
Earnings Per Share:
Basic	$ 2.27	$ 2.23	$ 4.33
Diluted	$ 2.26	$ 2.23	$ 4.32
Shares used in calculation of earnings per share:
Basic	1,061,913	1,069,932	1,080,874
Diluted	1,065,720	1,074,286	1,084,766

Consolidated Statements of Comp

Consolidated Statements of Comprehensive Income (Loss) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Net income	$ 2,408.4	$ 2,390.5	$ 4,684.8
Other comprehensive income (loss)
Change in foreign currency translation gains (losses)	(859.8)	(961.4)	36.2
Change in net unrealized gains and losses on securities	(138.1)	(162.2)	204.3
Change in defined benefit pension and retiree health benefit plans	572.9	(1,327.6)	2,592.2
Change in effective portion of cash flow hedges	(42)	(14.5)	(123.8)
Other comprehensive income (loss) before income taxes	(467)	(2,465.7)	2,708.9
Provision for income taxes related to other comprehensive income (loss) items	(121.9)	476.6	(914.5)
Other comprehensive income (loss)	(588.9)	(1,989.1)	1,794.4
Comprehensive income	$ 1,819.5	$ 401.4	$ 6,479.2

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Millions	Dec. 31, 2015	Dec. 31, 2014
Current Assets
Cash and cash equivalents	$ 3,666.4	$ 3,871.6
Short-term investments	785.4	955.4
Accounts receivable, net of allowances of $44.3 (2015) and $55.0 (2014)	3,513	3,234.6
Other receivables	558.6	566.7
Inventories	3,445.8	2,740
Prepaid expenses and other	604.4	560
Total current assets	12,573.6	11,928.3
Other Assets
Restricted cash	0	5,405.6
Investments	3,646.6	4,568.9
Goodwill	4,039.9	1,758.1
Other intangibles, net	5,034.8	2,884.2
Sundry	2,220.5	1,798.6
Total other assets	14,941.8	16,415.4
Property and equipment, net	8,053.5	7,963.9
Total assets	35,568.9	36,307.6
Current Liabilities
Short-term borrowings and current maturities of long-term debt	6.1	2,688.7
Accounts payable	1,338.2	1,128.1
Employee compensation	967	759
Sales rebates and discounts	2,560.1	2,068.8
Dividends payable	539	530.3
Income taxes payable	358.9	93.5
Other current liabilities	2,460.3	2,472.6
Total current liabilities	8,229.6	9,741
Other Liabilities
Long-term debt	7,972.4	5,332.8
Accrued retirement benefits	2,160.3	2,562.9
Long-term income taxes payable	868.9	998.5
Other noncurrent liabilities	1,747.4	2,284.3
Total other liabilities	12,749	11,178.5
Eli Lilly and Company Shareholders' Equity
Common stock	691.3	694.6
Additional paid-in capital	5,552.1	5,292.3
Retained earnings	16,011.8	16,482.7
Employee benefit trust	(3,013.2)	(3,013.2)
Accumulated other comprehensive loss	(4,580.7)	(3,991.8)
Cost of common stock in treasury	(90)	(91.4)
Total Eli Lilly and Company shareholders' equity	14,571.3	15,373.2
Noncontrolling interests	19	14.9
Total equity	14,590.3	15,388.1
Total liabilities and equity	$ 35,568.9	$ 36,307.6

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - USD ($) shares in Thousands, $ in Millions	Dec. 31, 2015	Dec. 31, 2014
Accounts receivable, allowances	$ 44.3	$ 55
Issued shares, shares in thousands	1,106,063	1,111,437
Common stock shares in treasury, shares in thousands	796	810

Consolidated Statements of Shar

Consolidated Statements of Shareholders' Equity Statement - USD ($) shares in Thousands, $ in Millions	Total	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Accumulated Other Comprehensive Income (Loss) [Member]	Treasury Stock [Member]	Trust for Benefit of Employees [Member]
Shares, Beginning Balance at Dec. 31, 2012		1,146,493				2,850
Shareholders' equity, Beginning Balance at Dec. 31, 2012	$ 14,765.2	$ 716.6	$ 4,963.1	$ 16,088.2	$ (3,797.1)	$ (192.4)	$ (3,013.2)
Increase (Decrease) in Shareholders' Equity [Roll Forward]
Net income	4,684.8			4,684.8
Other comprehensive income (loss)	1,794.4				1,794.4
Cash dividends	2,102.8			2,102.8
Retirement of treasury stock, shares		(32,406)				(32,406)
Retirement of treasury stock, value	0	$ 20.3		1,677.8		$ 1,698.1
Purchase for treasury, shares						30,400
Purchase for treasury	(1,600)					$ (1,600)
Issuance of stock under employee stock plans-net, shares		(3,541)				(11)
Issuance of stock under employee stock plans-net, value	55.1	$ 2.2	58			$ 0.7
Stock-based compensation	144.9		144.9
Shareholders' equity, Ending Balance at Dec. 31, 2013	17,631.4	$ 698.5	5,050	16,992.4	(2,002.7)	$ (93.6)	(3,013.2)
Shares, Ending Balance at Dec. 31, 2013		1,117,628				833
Increase (Decrease) in Shareholders' Equity [Roll Forward]
Net income	2,390.5			2,390.5
Other comprehensive income (loss)	(1,989.1)				(1,989.1)
Cash dividends	2,108.1			2,108.1
Retirement of treasury stock, shares		(12,579)				(12,579)
Retirement of treasury stock, value	0	$ 7.9		792.1		$ 800
Purchase for treasury, shares						12,579
Purchase for treasury	(800)					$ (800)
Issuance of stock under employee stock plans-net, shares		(6,388)				(23)
Issuance of stock under employee stock plans-net, value	92.5	$ 4	86.3			$ 2.2
Stock-based compensation	156		156
Shareholders' equity, Ending Balance at Dec. 31, 2014	15,373.2	$ 694.6	5,292.3	16,482.7	(3,991.8)	$ (91.4)	(3,013.2)
Shares, Ending Balance at Dec. 31, 2014		1,111,437				810
Increase (Decrease) in Shareholders' Equity [Roll Forward]
Net income	2,408.4			2,408.4
Other comprehensive income (loss)	(588.9)				(588.9)
Cash dividends	2,136			2,136
Retirement of treasury stock, shares		(9,877)				(9,877)
Retirement of treasury stock, value	0	$ 6.2		743.3		$ 749.5
Purchase for treasury, shares						9,877
Purchase for treasury	(749.5)					$ (749.5)
Issuance of stock under employee stock plans-net, shares		(4,503)				(14)
Issuance of stock under employee stock plans-net, value	46.3	$ 2.9	42			$ 1.4
Stock-based compensation	217.8		217.8
Shareholders' equity, Ending Balance at Dec. 31, 2015	$ 14,571.3	$ 691.3	$ 5,552.1	$ 16,011.8	$ (4,580.7)	$ (90)	$ (3,013.2)
Shares, Ending Balance at Dec. 31, 2015		1,106,063				796

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Cash Flows from Operating Activities
Net income	$ 2,408.4	$ 2,390.5	$ 4,684.8
Adjustments to Reconcile Net Income to Cash Flows from Operating Activities:
Depreciation and amortization	1,427.7	1,379	1,445.6
Change in deferred income taxes	(748.4)	36.8	265.9
Stock-based compensation expense	217.8	156	144.9
Acquired in-process research and development	535	200.2	57.1
Income related to termination of the exenatide collaboration with Amylin	0	0	(495.4)
Net proceeds from (payments for) terminations of interest rate swaps	(186.1)	340.7	0
Other non-cash operating activities, net	36.4	13.8	25.1
Other changes in operating assets and liabilities, net of acquisitions and divestitures:
Receivables - (increase) decrease	(304.5)	117.4	(152.7)
Inventories - (increase) decrease	(736.3)	(307.1)	(286.5)
Other assets - (increase) decrease	(338.8)	411.5	116.5
Accounts payable and other liabilties-increase (decrease)	461.6	(371.7)	(70.3)
Net Cash Provided by Operating Activities	2,772.8	4,367.1	5,735
Cash Flows from Investing Activities
Purchases of property and equipment	(1,066.2)	(1,162.6)	(1,012.1)
Disposals of property and equipment	92.6	15.3	179.4
Cash released (restricted) for pending acquisition	5,405.6	(5,405.6)	0
Proceeds from sales and maturities of short-term investments	2,161.8	4,054.1	3,320.1
Purchases of short-term investments	(842.2)	(1,637.8)	(1,531)
Proceeds from sales of noncurrent investments	3,068.4	11,009.4	11,235
Purchases of noncurrent investments	(3,226.5)	(9,802.7)	(14,041.9)
Proceeds from sale of product rights	410	0	0
Purchase of product rights	0	(308.3)	(24.1)
Purchases of in-process research and development	(560)	(95)	(57.1)
Cash paid for acquisitions, net of cash acquired	(5,283.1)	(551.4)	(43.7)
Other investing activities, net	(133.6)	(24.5)	(97.4)
Net Cash Provided by (Used for) Investing Activities	26.8	(3,909.1)	(2,072.8)
Cash Flows from Financing Activities
Dividends paid	(2,127.3)	(2,101.2)	(2,120.7)
Net change in short-term borrowings	(2,680.6)	2,680.6	0
Proceeds from issuance of long-term debt	4,454.7	992.9	0
Repayments of long-term debt	(1,955.7)	(1,034.8)	(10.5)
Purchases of common stock	(749.5)	(800)	(1,698.1)
Other financing activities, net	139.2	187.4	0
Net Cash Used for Financing Activities	(2,919.2)	(75.1)	(3,829.3)
Effect of exchange rate changes on cash and cash equivalents	(85.6)	(341.5)	(21.5)
Net increase (decrease) in cash and cash equivalents	(205.2)	41.4	(188.6)
Cash and cash equivalents at beginning of year	3,871.6	3,830.2	4,018.8
Cash and Cash Equivalents at End of Year	$ 3,666.4	$ 3,871.6	$ 3,830.2

Summary of Significant Accounti

Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2015
Accounting Policies [Abstract]
Basis of Presentation [Text Block]	Note 1: Summary of Significant Accounting Policies Basis of presentation The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (GAAP). The accounts of all wholly-owned and majority-owned subsidiaries are included in the consolidated financial statements. Where our ownership of consolidated subsidiaries is less than 100 percent, the noncontrolling shareholders’ interests are reflected as a separate component of equity. All intercompany balances and transactions have been eliminated. The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues, expenses, and related disclosures at the date of the financial statements and during the reporting period. Actual results could differ from those estimates. We issued our financial statements by filing with the Securities and Exchange Commission and have evaluated subsequent events up to the time of the filing. Certain reclassifications have been made to prior periods in the consolidated financial statements and accompanying notes to conform with the current presentation. All per-share amounts, unless otherwise noted in the footnotes, are presented on a diluted basis, that is, based on the weighted-average number of outstanding common shares plus the effect of incremental shares from our stock-based compensation programs. Revenue recognition We recognize revenue from sales of products at the time title of goods passes to the buyer and the buyer assumes the risks and rewards of ownership. Provisions for returns, discounts, and rebates are established in the same period the related sales are recognized. In arrangements involving the delivery of more than one element (e.g., research and development), marketing and selling, manufacturing, and distribution), each required deliverable is evaluated to determine whether it qualifies as a separate unit of accounting. Our determination is based on whether the deliverable has "standalone value" to the customer. If a deliverable does not qualify as a separate unit of accounting, it is combined with the other applicable undelivered item(s) within the arrangement and these combined deliverables are treated as a single unit of accounting. The arrangement's consideration that is fixed or determinable is then allocated to each separate unit of accounting based on the relative selling price of each deliverable. Initial fees we receive in collaborative and other similar arrangements from the partnering of our compounds under development are generally deferred and amortized into income through the expected product approval date. Initial fees may also be received for out-licensing agreements that include both an out-license of our marketing rights to commercialized products and a related commitment to supply the products. When we have determined that the marketing rights do not have standalone value, the initial fees received are generally deferred and amortized to income as net product sales over the term of the supply agreement. Royalty revenue from licensees, which is based on third-party sales of licensed products and technology, is recorded as earned in accordance with the contract terms when third-party sales can be reasonably measured and collection of the funds is reasonably assured. This royalty revenue is included in collaboration and other revenue. Profit-sharing due from our collaboration partners, which is based upon gross margins reported to us by our partners, is recognized as collaboration and other revenue as earned. Developmental milestone payments earned by us are generally recorded in other–net, (income) expense. We immediately recognize the full amount of developmental milestone payments due to us upon the achievement of the milestone event if the event is objectively determinable and the milestone is substantive in its entirety. A milestone is considered substantive if the consideration earned 1) relates solely to past performance, 2) is commensurate with the enhancement in the pharmaceutical or animal health product's value associated with the achievement of the important event in its development life cycle, and 3) is reasonable relative to all of the deliverables and payment terms within the arrangement. If a milestone payment to us is part of a multiple-element commercialization arrangement and is triggered by the initiation of the commercialization period (e.g., regulatory approval for marketing or launch of the product) or the achievement of a sales-based threshold, we amortize the payment to income as we perform under the terms of the arrangement. See Note 4 for specific agreement details. Research and development expenses and acquired in-process research and development Research and development expenses include the following: • Research and development costs, which are expensed as incurred. • Milestone payment obligations incurred prior to regulatory approval of the product, which are accrued when the event requiring payment of the milestone occurs. Acquired in-process research and development (IPR&D) expense includes the initial costs of IPR&D projects, acquired directly in a transaction other than a business combination, that do not have an alternative future use. Earnings per share We calculate basic earnings per share (EPS) based on the weighted-average number of common shares outstanding and incremental shares from potential participating securities. We calculate diluted EPS based on the weighted-average number of common shares outstanding, including incremental shares from our stock-based compensation programs. Foreign Currency Translation Operations in our subsidiaries outside the United States (U.S.) are recorded in the functional currency of each subsidiary which is determined by a review of the environment where each subsidiary primarily generates and expends cash. The results of operations for our subsidiaries outside the U.S. are translated from functional currencies into U.S. dollars using the weighted average currency rate for the period. Assets and liabilities are translated using the period end exchange rates. The U.S. dollar effects that arise from translating the net assets of these subsidiaries are recorded in other comprehensive income (loss). Other significant accounting policies Our other significant accounting policies are described in the remaining appropriate notes to the consolidated financial statements.

Implementation of New Financial

Implementation of New Financial Accounting Pronouncements	12 Months Ended
	Dec. 31, 2015
New Accounting Pronouncements and Changes in Accounting Principles [Abstract]
New Accounting Pronouncements and Changes in Accounting Principles [Text Block]	Note 2: Implementation of New Financial Accounting Pronouncements The following table provides a brief description of accounting standards that have not yet been adopted that could have a material effect on our financial statements: Standard Description Effective Date Effect on the financial statements or other significant matters Accounting Standards Update 2014-09, Revenue from Contracts with Customers This standard will replace existing revenue recognition standards and will require entities to recognize revenues to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. An entity can apply the new revenue standard retrospectively to each prior reporting period presented or with the cumulative effect of initially applying the standard recognized at the date of initial application in retained earnings. This standard is effective January 1, 2018, but we are permitted to adopt this standard one year earlier if we choose. We are evaluating our anticipated date of adoption. There are areas within the standard that are currently under review and reconsideration by the Financial Accounting Standards Board, including accounting for licensing transactions, which could lead to updates to the standard. As the outcomes of this review and reconsideration could lead to significant changes to the standard, we are still in the process of determining our approach to the adoption of the standard, as well as the anticipated impact to our consolidated financial statements. Accounting Standards Update 2016-01, Financial Instruments - Overall: Recognition and Measurement of Financial Assets and Financial Liabilities This standard will require entities to recognize changes in the fair value of equity investments with readily determinable fair values in net income (except for investments accounted for under the equity method of accounting or those that result in consolidation of the investee). An entity should apply the new standard through a cumulative effect adjustment to retained earnings as of the beginning of the fiscal year of adoption. This standard is effective January 1, 2018. Early adoption of the majority of the amendments in this standard is not permitted, however, early application of certain amendments is permitted. We intend to fully adopt this standard on January 1, 2018. We are currently unable to estimate the impact of adopting this standard as the significance of the impact will depend upon our equity investments on hand as of the date of adoption. The following table provides a brief description of an accounting standard that has been adopted: Standard Description Effective Date Effect on the financial statements or other significant matters Accounting Standards Update 2015-17, Income Taxes: Balance Sheet Classification of Deferred Taxes This standard simplifies the presentation of deferred income taxes and requires that deferred tax liabilities and assets be classified as noncurrent in a classified statement of financial position. An entity can apply this new standard either prospectively to all deferred tax liabilities and assets or retrospectively to all periods presented. We have adopted this standard for the annual period beginning on January 1, 2015. We applied this standard retrospectively. As a result of adopting this standard, all deferred tax liabilities and assets have been classified as noncurrent. The balance sheet as of December 31, 2014 was retrospectively adjusted which resulted in reductions to prepaid expenses and other of $251.5 million, sundry of $584.2 million, and deferred income tax liabilities of $1.47 billion. Other noncurrent liabilities as of December 31, 2014 were increased by $630.8 million as a result of the adoption of this standard.

Acquisitions

Acquisitions	12 Months Ended
	Dec. 31, 2015
Business Combinations [Abstract]
Acquisitions [Text Block]	Note 3: Acquisitions During 2015 and 2014, we completed the acquisitions of Novartis Animal Health (Novartis AH) and Lohmann SE (Lohmann AH), respectively. Additionally, on October 1, 2015, Bristol-Myers Squibb Company and E.R. Squibb (collectively, BMS) transferred to us their commercialization rights with respect to Erbitux ® in the U.S. and Canada (collectively, North America) through a modification of our existing arrangement. These transactions were accounted for as business combinations under the acquisition method of accounting. See Note 4 for additional information related to the Erbitux arrangement. The assets acquired and liabilities assumed were recorded at their respective fair values as of the acquisition date in our consolidated financial statements. The determination of estimated fair value required management to make significant estimates and assumptions. The excess of the purchase price over the fair value of the acquired net assets, where applicable, has been recorded as goodwill. The results of operations of these acquisitions are included in our consolidated financial statements from the date of acquisition. In addition to the acquisitions of businesses, we also acquired assets in development in 2015, 2014, and 2013 which are further discussed below in Product and Other Acquisitions and in Note 4. Upon acquisition, the acquired IPR&D related to these products was immediately written off as an expense because the products had no alternative future use. For the years ended December 31, 2015 , 2014 , and 2013 , we recorded acquired IPR&D charges of $535.0 million , $200.2 million , and $57.1 million , respectively. The charges were associated with the transactions discussed below in Product and Other Acquisitions, the 2015 upfront fee of $200.0 million related to tanezumab, and the 2014 charge of $55.2 million related to the transfer to us of Boehringer Ingelheim's rights to co-promote our new insulin glargine product in countries where it was not yet approved. See Note 4 for additional information related to the tanezumab and Boehringer Ingelheim arrangements. Acquisitions of Businesses Novartis AH Acquisition Overview of Transaction On January 1, 2015, we acquired from Novartis AG all of the shares of certain Novartis subsidiaries and all of the assets and liabilities of other Novartis subsidiaries that are exclusively related to the Novartis AH business in an all-cash transaction for a total purchase price of $5.28 billion . As of December 31, 2014, there was $5.41 billion of cash held in escrow for the pending acquisition of Novartis AH. This cash was classified as restricted cash, a noncurrent asset, on our consolidated balance sheet. As a condition to the clearance of the transaction under the Hart-Scott-Rodino Antitrust Improvements Act, following the closing of the acquisition of Novartis AH, we divested certain animal health assets in the U.S. related to the Sentinel ® canine parasiticide franchise to Virbac Corporation for approximately $410 million . The acquired Novartis AH business consists of the research and development, manufacture, marketing, sale and distribution of veterinary products to prevent and treat diseases in pets, farm animals, and farmed fish. Under the terms of the agreement, we acquired manufacturing sites, research and development facilities, a global commercial infrastructure and portfolio of products, a pipeline of projects in development, and employees. Assets Acquired and Liabilities Assumed The following table summarizes the amounts recognized for assets acquired and liabilities assumed as of the acquisition date: Estimated Fair Value at January 1, 2015 Inventories $ 380.2 Acquired in-process research and development 298.0 Marketed products (1) 1,953.0 Property and equipment 199.9 Assets held for sale (primarily the U.S. Sentinel rights) 422.7 Accrued retirement benefits (108.7 ) Deferred income taxes (60.1 ) Other assets and liabilities - net (73.0 ) Total identifiable net assets 3,012.0 Goodwill (2) 2,271.1 Total consideration transferred - net of cash acquired $ 5,283.1 (1) These intangible assets, which will be amortized to cost of sales on a straight-line basis over their estimated useful lives, are expected to have a weighted average useful life of 19 years . (2) The goodwill recognized from this acquisition is attributable primarily to expected synergies that we believe will result from combining the operations of Novartis AH with our legacy animal health business, future unidentified projects and products, and the assembled workforce of Novartis AH. Approximately $950 million of the goodwill associated with this acquisition is estimated to be deductible for tax purposes. Actual and Supplemental Pro Forma Information Our consolidated statement of operations for the year ended December 31, 2015 includes Novartis AH revenue of $1.02 billion . Novartis AH has been partially integrated into our animal health segment and as a result of these integration efforts, certain parts of the animal health business are operating on a combined basis, and we cannot distinguish the operations between Novartis AH and our legacy animal health business. The following unaudited pro forma financial information presents the combined consolidated results of our operations with Novartis AH as if the portion of Novartis AH that we retained after the sale to Virbac had been acquired as of January 1, 2014. We have adjusted the historical consolidated financial information to give effect to pro forma events that are directly attributable to the acquisition. The unaudited pro forma financial information is not necessarily indicative of what our consolidated results of operations would have been had we completed the acquisition at the beginning of 2014. In addition, the unaudited pro forma financial information does not attempt to project the future results of operations of our combined company. Unaudited Pro Forma Consolidated Results 2015 2014 Revenue $ 19,958.7 $ 20,696.7 Net income 2,518.1 2,127.9 Diluted earnings per share 2.36 1.98 The unaudited pro forma financial information above reflects primarily the following pro forma pretax adjustments: • Additional amortization expense of approximately $104 million for the year ended December 31, 2014, related to the fair value of identifiable intangible assets acquired. • Additional cost of sales in 2014, and a corresponding reduction in cost of sales in 2015, of approximately $153 million related to the fair value adjustments to acquisition date inventory that has been sold in the year ended December 31, 2015 . • A decrease to pro forma net income of approximately $112 million in the year ended December 31, 2014, associated with an increase to interest expense related to the incremental debt that we issued to partially finance the acquisition and a reduction of interest income associated with investments which would have been used to partially fund the acquisition. In addition, all of the above adjustments were adjusted for the applicable tax impact. The taxes associated with the adjustments above reflect the statutory tax rates in the various jurisdictions where the fair value adjustments occurred. Lohmann AH Acquisition On April 30, 2014, we acquired Lohmann AH, a privately-held company headquartered in Cuxhaven, Germany, through a stock purchase for a total purchase price of $591.2 million , comprised of $551.4 million of net cash plus $39.8 million of assumed debt. Lohmann AH was a global leader in poultry vaccines. As part of this transaction, we acquired the rights to a range of vaccines, commercial capabilities, and manufacturing sites in Germany and the U.S. The acquisition was not material to our consolidated financial statements. The following table summarizes the amounts recognized for assets acquired and liabilities assumed as of the acquisition date: Estimated Fair Value at April 30, 2014 Marketed products $ 275.4 Other intangible assets 23.9 Property and equipment 81.9 Deferred income taxes (92.7 ) Other assets and liabilities - net 51.1 Total identifiable net assets 339.6 Goodwill (1) 251.6 Total consideration transferred - net of cash acquired $ 591.2 (1) Goodwill associated with this acquisition is not deductible for tax purposes. Product and Other Acquisitions The following table summarizes our product and other acquisitions which are discussed in detail below: Counterparty Compound(s) or Therapy Acquisition Month Phase of Development (1) Acquired IPR&D Expense Innovent Biologics, Inc. (Innovent) Monoclonal antibody targeting protein CD-20 Immuno-oncology molecule cMet monoclonal antibody March 2015 Pre-clinical (2) $ 56.0 Hanmi Pharmaceutical Co., Ltd. (Hanmi) BTK Inhibitor - HM71224 April 2015 Phase I 50.0 BioNTech AG (BioNTech) Cancer immunotherapies May 2015 Pre-clinical 30.0 Locemia Solutions Intranasal glucagon October 2015 Phase III 149.0 Undisclosed Technology collaboration December 2015 N/A 25.0 Halozyme Therapeutics, Inc. (Halozyme) Recombinant human hyaluronidase enzyme - rHuPH20 December 2015 N/A 25.0 Immunocore Limited (Immunocore) T cell-based cancer therapies July 2014 Pre-clinical 45.0 AstraZeneca UK Limited (AstraZeneca) Oral beta-secretase cleaving enzyme inhibitor - AZD3293 September 2014 Phase I 50.0 Adocia BioChaperone Lispro December 2014 Phase I 50.0 Arteaus Therapeutics Calcitonin gene-related peptide (CGRP) monoclonal antibody December 2013 Phase II 57.1 (1) The phase of development presented is as of the date of the arrangement. (2) Prior to acquisition, Innovent's monoclonal antibody targeting protein CD-20 had received investigational new drug approval in China to begin Phase I development. In connection with the arrangements described herein, our partners may be entitled to future royalties based on sales should these products be approved for commercialization and/or milestones based on the successful progress of the drug candidate through the development process. Our collaboration agreement with Innovent is to develop and commercialize a portfolio of cancer treatments. In China, we will be responsible for the commercialization efforts, while Innovent will lead the development and manufacturing efforts. Innovent also has co-promotion rights in China. We will be responsible for development, manufacturing, and commercialization efforts of Innovent's pre-clinical immuno-oncology molecules outside of China. Separate from the collaboration, we will continue the development of our cMet monoclonal antibody gene outside of China. Our collaboration agreement with Hanmi is to develop and commercialize Hanmi's compound being investigated for the treatment of autoimmune and other diseases. We received rights to the molecule for all indications on a worldwide basis excluding China, Hong Kong, Taiwan, and Korea. We will be responsible for leading development, regulatory, manufacturing, and commercial efforts in our territories. Our research collaboration with BioNTech is to discover novel cancer immunotherapies. Our global collaboration and license agreement with Halozyme is to develop and commercialize products combining our proprietary compounds with Halozyme's ENHANZE ™ platform to aid in the dispersion and absorption of other injected therapeutic drugs. Our co-discovery and co-development collaboration with Immunocore is to research and potentially develop pre-clinical novel T cell-based cancer therapies. Our collaboration agreement with AstraZeneca is for the worldwide co-development and co-commercialization of AstraZeneca’s molecule being investigated for the potential treatment of Alzheimer’s disease. We are responsible for leading development efforts, while AstraZeneca will be responsible for manufacturing efforts. If successful, both parties will take joint responsibility for commercialization of AZD3293. Under the agreement, both parties will share equally in the ongoing development costs, gross margins, and certain other costs associated with commercialization of the molecule. Our collaboration agreement with Adocia is for the worldwide development and commercialization of Adocia's ultra-rapid insulin, a molecule being developed for the treatment of patients with type 1 and type 2 diabetes. We will be responsible for leading development, manufacturing, and commercialization efforts. We acquired all development and commercial rights from Arteaus Therapeutics for a CGRP antibody being studied as a potential treatment for the treatment of cluster headache and migraine prevention.

Collaborations

Collaborations	12 Months Ended
	Dec. 31, 2015
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Collaborations [Text Block]	Note 4: Collaborations and Other Arrangements We often enter into collaborative and other similar arrangements to develop and commercialize drug candidates. Collaborative activities may include research and development, marketing and selling (including promotional activities and physician detailing), manufacturing, and distribution. These arrangements often require milestone and royalty or profit-share payments, contingent upon the occurrence of certain future events linked to the success of the asset in development, as well as expense reimbursements or payments to the collaboration partner. Elements within a collaboration are separated into individual units of accounting if they have standalone value from other elements within the arrangement. In these situations, the arrangement consideration is allocated to the elements on a relative selling price basis. Revenues related to products we sell pursuant to these arrangements are included in net product revenues, while other sources of revenue (e.g., royalties and profit sharing due from our partner) are included in collaboration and other revenue. The following table summarizes our collaboration and other revenue recognized: 2015 2014 2013 Collaboration and other revenue $ 808.1 $ 788.4 $ 707.5 Operating expenses for costs incurred pursuant to these arrangements are reported in their respective expense line items, net of any payments due to or reimbursements due from our collaboration partners, with such reimbursements being recognized at the time the party becomes obligated to pay. Each collaboration is unique in nature, and our more significant arrangements are discussed below. Boehringer Ingelheim Diabetes Collaboration We and Boehringer Ingelheim have a global agreement to jointly develop and commercialize a portfolio of diabetes compounds. Currently, included in the collaboration are Boehringer Ingelheim’s oral diabetes products: Trajenta ® , Jentadueto ® , Jardiance ® , Glyxambi ® , and Synjardy ® , as well as our Basaglar ® . The table below summarizes significant regulatory and commercialization events and milestones (received) paid for the compounds included in this collaboration: Product Family Product Status Milestones (Earned) Expensed (1) Milestones (Deferred) Capitalized (2) U.S. Europe Japan Year Amount Year Amount Trajenta (3) Launched 2011 Launched 2011 Launched 2011 2015 $ — 2015 $ — 2014 — 2014 — 2013 — 2013 — Cumulative (6) 446.4 Jardiance (4) Launched 2014 Launched 2014 Launched 2015 2015 — 2015 — 2014 — 2014 299.5 2013 97.2 2013 — Cumulative (6) 299.5 Basaglar Approved (5) Launched 2015 Launched 2015 2015 — 2015 — 2014 — 2014 (62.5 ) 2013 (50.0 ) 2013 — Cumulative (6) (62.5 ) (1) Milestones earned for Basaglar as a result of regulatory submissions were recorded as income in other-net, (income) expense. Milestones expensed for Jardiance as a result of regulatory submissions were recorded as research and development expenses. (2) In connection with the regulatory approvals of Basaglar in Europe and Japan, milestone payments received were recorded as deferred revenue and are being amortized through the term of the collaboration (2029) to collaboration and other revenue. In connection with the regulatory approvals of Trajenta and Jardiance, milestone payments made were capitalized as intangible assets and are being amortized through the term of the collaboration to cost of sales. (3) Jentadueto is included in the Trajenta family of product results. (4) Glyxambi and Synjardy are included in the Jardiance family of product results. (5) In September 2015, we entered into a settlement agreement to resolve patent infringement litigation filed by Sanofi-Aventis U.S. LLC (Sanofi), which markets Lantus ® (insulin glargine). As part of the settlement agreement, the parties agreed that Basaglar can be launched in the U.S. beginning on December 15, 2016. Basaglar received U.S. Food and Drug Administration (FDA) approval in December 2015. As a result of receiving FDA approval, we received $187.5 million in 2016, which was recorded as deferred revenue and will be amortized through the term of the collaboration to collaboration and other revenue upon product launch. (6) The cumulative amount represents the total amounts as of the end of the reporting period that have been (deferred) or capitalized since the start of this collaboration. In October 2014, we and Boehringer Ingelheim agreed upon certain changes to the operational and financial structure of our diabetes collaboration. Under the revised agreement the companies have continued their co-promotion work in 17 countries, representing over 90 percent of the collaboration’s anticipated market opportunity. In the other countries, the companies exclusively commercialize the respective molecules they brought to the collaboration. The modifications became effective at the end of 2014 and changed the financial terms related to the modified countries; however, the financial impact resulting from the revised terms of the agreement in these countries has not been and is not anticipated to be material. As a result of these changes, we recorded a gain of $92.0 million in 2014 related to the transfer to Boehringer Ingelheim of our license rights to co-promote linagliptin and empagliflozin in these countries, which was recorded as income in other–net, (income) expense. We also incurred a charge of $55.2 million related to the transfer to us of Boehringer Ingelheim's rights to co-promote Basaglar in countries where it was not yet approved, which was recorded as acquired IPR&D expense. With the exception of the countries affected by the amendment to the collaboration agreement, the companies share equally the ongoing development costs, commercialization costs and gross margin for any product resulting from the collaboration. We record our portion of the gross margin associated with Boehringer Ingelheim's compounds as collaboration and other revenue. We record our sales of Basaglar to third parties as net product revenues with the payments made to Boehringer Ingelheim for their portion of the gross margin recorded as cost of sales. For all compounds under this collaboration, we record our portion of the commercialization costs as marketing, selling, and administrative expense. Each company will also be entitled to potential performance payments on sales of the molecules they contribute to the collaboration. The following table summarizes our revenue recognized with respect to the Trajenta family of products: 2015 2014 2013 Collaboration and other revenue $ 356.8 $ 328.8 $ 249.2 Our revenues related to the Jardiance family of products were not significant for the years ended December 31, 2015 and 2014 . Our revenues related to Basaglar were not significant for the year ended December 31, 2015 . Erbitux We have several collaborations with respect to Erbitux. The most significant collaborations are in Japan, and prior to the transfer of commercialization rights in the fourth quarter of 2015, the U.S. and Canada (Bristol-Myers Squibb Company); and worldwide except North America (Merck KGaA). Certain rights to Erbitux outside North America will remain with Merck KGaA (Merck) upon expiration of that agreement. The following table summarizes our revenue recognized with respect to Erbitux: 2015 2014 2013 Net product revenues - BMS $ 23.3 $ 46.1 $ 58.5 Net product revenues - third party 152.3 — — Collaboration and other revenue 309.4 327.2 315.2 Revenue $ 485.0 $ 373.3 $ 373.7 Bristol-Myers Squibb Company Pursuant to commercial agreements with BMS, we had been co-developing Erbitux in North America with BMS exclusively. A separate agreement grants co-exclusive rights among Merck, BMS, and us in Japan and expires in 2032. On October 1, 2015, BMS transferred their commercialization rights to us with respect to Erbitux in North America pursuant to a modification of our existing arrangement, and we began selling Erbitux at that time. This modification did not affect our rights with respect to Erbitux in other jurisdictions. In connection with the modification of terms, we will provide consideration to BMS based upon a tiered percentage of net sales of Erbitux in North America estimated to average 38 percent through September 2018. The transfer of the commercialization rights was accounted for as an acquisition of a business. The following table summarizes the preliminary amounts recognized for assets acquired and liabilities assumed as of the acquisition date: Estimated Fair Value at October 1, 2015 Marketed products (1) $ 602.1 Deferred tax asset 232.2 Deferred tax liability (228.2 ) Other assets and liabilities - net 57.2 Total identifiable net assets $ 663.3 Total consideration - contingent consideration liability (2) $ (663.3 ) (1) These intangible assets will be amortized to cost of sales using the straight-line method through the co-development period in North America as set forth in the original agreement, which was scheduled to expire in September 2018. (2) See Note 7 for discussion on the estimation of the contingent consideration liability. The final determination of these amounts will be completed as soon as possible but no later than one year from the acquisition date and may result in asset and liability fair values that differ from preliminary estimates, but it is not expected that these differences will be material to our consolidated financial statements. Including the Erbitux business as if we had acquired it on January 1, 2015, our combined consolidated unaudited pro forma revenue would have been approximately $20.2 billion for the year ended December 31, 2015 . This unaudited pro forma financial information adjusts the historical consolidated revenue to give effect to pro forma events that are directly attributable to the acquisition. There would have been no material change to our historical consolidated net income. The unaudited pro forma financial information is not necessarily indicative of what our consolidated revenues would have been had we completed the acquisition at the beginning of 2015. In addition, the unaudited pro forma financial information does not attempt to project the future results of operations of our combined company. Until the effective date of the transfer of the business, the arrangements between us and BMS were as set forth in this paragraph. Erbitux research and development and other costs were shared by both companies according to a predetermined ratio. Responsibilities associated with clinical and other ongoing studies were apportioned between the parties under the agreements. Collaborative reimbursements due to us for supply of clinical trial materials, for research and development, and for a portion of marketing, selling, and administrative expenses were recorded as a reduction to the respective expense line items on the consolidated statement of operations. We received a distribution fee in the form of a royalty from BMS, based on a percentage of net sales in North America, which was recorded in collaboration and other revenue. Royalties due to third parties were recorded as a reduction of collaboration and other revenue, net of any royalty reimbursements due from third parties. We were responsible for the manufacture and supply of all requirements of Erbitux in bulk-form active pharmaceutical ingredient (API) for clinical and commercial use in North America, and BMS purchased all of its requirements of API from us, subject to certain stipulations per the agreement. Sales of Erbitux API to BMS were reported in net product revenues. Merck KGaA A development and license agreement grants Merck exclusive rights to market Erbitux outside of North America until December 2018. A separate agreement grants co-exclusive rights among Merck, BMS, and us in Japan and expires in 2032. This agreement was amended in 2015 to grant Merck exclusive commercialization rights in Japan but did not result in any changes to our rights. Merck manufactures Erbitux for supply in its territory as well as for Japan. We receive a royalty on the sales of Erbitux outside of North America, which is included in collaboration and other revenue as earned. Royalties due to third parties are recorded as a reduction of collaboration and other revenue, net of any royalty reimbursements due from third parties. Effient ® We are in a collaborative arrangement with Daiichi Sankyo Co., Ltd. (Daiichi Sankyo) to develop, market, and promote Effient. Marketing rights for major territories are shown below. We and Daiichi Sankyo each have exclusive marketing rights in certain other territories. Territory Marketing Rights Selling Party U.S. Co-promotion Lilly Major European markets Co-promotion Pre-January 1, 2016, Lilly Post-January 1, 2016, Daiichi Sankyo Japan Exclusive Daiichi Sankyo Beginning January 1, 2016, while major European markets continue to be a co-promotion territory under the terms of our arrangement, Daiichi Sankyo exclusively promotes Effient in these markets. The economic results for the major European markets continue to be shared in the same proportion as they were previously. The parties share approximately 50 /50 in the profits, as well as in the costs of development and marketing in the co-promotion territories. A third party manufactures bulk product, and we continue to produce the finished product for our exclusive and co-promotion territories, as well as the major European markets. We record net product revenue in our exclusive and co-promotion territories where we are the selling party. Profit-share payments due to Daiichi Sankyo for co-promotion countries where we are the selling party are recorded as marketing, selling, and administrative expenses. Beginning January 1, 2016, any profit-share payments due to us from Daiichi Sankyo for the major European markets will be recorded as collaboration and other revenue. We also record our share of the expenses in these co-promotion territories as marketing, selling, and administrative expenses. In our exclusive territories, we pay Daiichi Sankyo a royalty specific to these territories. All royalties due to Daiichi Sankyo and the third-party manufacturer are recorded in cost of sales. The following table summarizes our revenue recognized with respect to Effient: 2015 2014 2013 Revenue $ 523.0 $ 522.2 $ 508.7 Baricitinib We have a worldwide license and collaboration agreement with Incyte Corporation (Incyte) which provides us the development and commercialization rights to its Janus tyrosine kinase inhibitor compound, now known as baricitinib, and certain follow-on compounds, for the treatment of inflammatory and autoimmune diseases. Incyte has the right to receive tiered, double-digit royalty payments on future global sales with rates ranging up to 20 percent if the product is successfully commercialized. The agreement provides Incyte with options to co-develop these compounds on an indication-by-indication basis by funding 30 percent of the associated development costs from the initiation of a Phase IIb trial through regulatory approval in exchange for increased tiered royalties ranging up to percentages in the high twenties. In 2010, Incyte exercised its option to co-develop baricitinib in rheumatoid arthritis. The agreement also provides Incyte with an option to co-promote in the U.S. and calls for us to make payments to Incyte associated with certain development, success-based regulatory, and sales-based milestones. In 2016, we incurred milestone-related expenses of $55.0 million in connection with regulatory submissions in the U.S. and Europe. These regulatory submission milestones will be recorded as research and development expenses in 2016. In the future, Incyte will be eligible to receive up to $360.0 million of additional payments from us contingent upon certain development and success-based regulatory milestones as well as an additional $150.0 million of potential sales-based milestones. Solanezumab We have an agreement with an affiliate of TPG-Axon Capital (TPG) whereby TPG funded a portion of the Phase III development of solanezumab. Under the agreement, TPG’s obligation to fund solanezumab costs ended in 2011. In exchange for its funding, TPG may receive success-based sales milestones totaling approximately $70 million and mid-single digit royalties contingent upon the successful development of solanezumab. The royalties would be paid for approximately 10 years after launch of a product. Tanezumab In October 2013, we entered into a collaboration agreement with Pfizer Inc. (Pfizer) to jointly develop and globally commercialize tanezumab for the treatment of osteoarthritis pain, chronic low back pain and cancer pain. Under the agreement, the companies share equally the ongoing development costs and, if successful, in gross margins and certain commercialization expenses. Following the FDA's decision in March 2015 to lift the partial clinical hold on tanezumab, certain Phase III trials resumed in July 2015. Upon the FDA's lifting of the partial clinical hold and the decision to continue the collaboration with Pfizer, we paid an upfront fee of $200.0 million which was expensed as acquired IPR&D. In addition to this fee, we may pay up to $350.0 million in success-based regulatory milestones and up to $1.23 billion in a series of sales-based milestones, contingent upon the commercial success of tanezumab. Both parties have the right to terminate the agreement under certain circumstances. Exenatide In November 2011, we agreed with Amylin Pharmaceuticals, Inc. (Amylin) to terminate our collaborative arrangement for the joint development, marketing, and selling of Byetta ® (exenatide injection) and other forms of exenatide such as Bydureon ® (exenatide extended-release for injectable suspension). Under the terms of the termination agreement, Amylin made a one-time, upfront payment to us of $250.0 million and agreed to make other payments. Upon completion of the acquisition of Amylin by Bristol-Myers Squibb Company in August 2012, Amylin's obligation of $1.26 billion was paid in full. We would also receive a $150.0 million milestone payment contingent upon FDA approval of a once-monthly suspension version of exenatide. Commercial operations were transferred to Amylin in the U.S. in late 2011. Outside the U.S., we transferred to Amylin exenatide commercial rights and control in all markets during the first quarter of 2013. All income allocated to the business outside the U.S. that was transferred during the first quarter of 2013 was recognized as a gain on the disposition of a business in other–net, (income) expense, net of the goodwill allocated to the business transferred. Under the terms of our prior arrangement, we reported as net product revenues 100 percent of sales outside the U.S. We paid Amylin a percentage of the gross margin of exenatide sales outside of the U.S., and these costs were recorded in cost of sales. This arrangement for the commercial operations outside the U.S. continued until those rights were transferred to Amylin during the first quarter of 2013. The following table summarizes the revenue and other income recognized with respect to exenatide for the year ended December 31, 2013: 2013 Revenue $ 133.1 Income related to termination of the exenatide collaboration with Amylin (1) 495.4 (1) Presented in other-net, (income) expense. Our revenue from exenatide was not significant in 2014. We have not recorded any additional revenue from exenatide in 2015 and will not do so in future periods. Summary of Commission and Profit-Share Payments The following table summarizes our aggregate amount of marketing, selling, and administrative expense associated with our commission and profit-sharing obligations for the collaborations and other arrangements described above: 2015 2014 2013 Marketing, selling, and administrative $ 213.2 $ 211.2 $ 203.7

Asset Impairments, Restructurin

Asset Impairments, Restructuring, and Other Special Charges	12 Months Ended
	Dec. 31, 2015
Extraordinary and Unusual Items [Abstract]
Asset Impairments, Restructuring, And Other Special Charges [Text Block]	Note 5: Asset Impairment, Restructuring, and Other Special Charges The components of the charges included in asset impairment, restructuring, and other special charges in our consolidated statements of operations are described below. 2015 2014 2013 Severance: Human pharmaceutical products $ 81.5 $ 225.5 $ 90.6 Animal health 59.5 — — Total severance 141.0 225.5 90.6 Asset impairment and other special charges: Human pharmaceutical products 24.6 204.4 30.0 Animal health 202.1 38.8 — Total asset impairment and other special charges 226.7 243.2 30.0 Asset impairment, restructuring, and other special charges $ 367.7 $ 468.7 $ 120.6 Severance costs recognized during the year ended December 31, 2015 resulted primarily from actions taken to reduce our cost structure and the integration of Novartis AH. Severance costs recognized during the years ended December 31, 2014 and 2013 related to ongoing cost containment efforts as we continued our initiatives to reduce our cost structure and global workforce. Substantially all of the severance costs incurred during the year ended December 31, 2015 are expected to be paid by the end of 2016 , and substantially all of the severance costs incurred during the years ended December 31, 2014 and 2013 have been paid. Asset impairment and other special charges recognized during year ended December 31, 2015 resulted primarily from integration costs and asset impairments due to product rationalization and site closures resulting from our acquisition and integration of Novartis AH. Asset impairment and other special charges recognized during the year ended December 31, 2014 resulted primarily from a $180.8 million asset impairment charge related to our decision to close and sell a manufacturing plant located in Puerto Rico. The manufacturing plant was written down to its estimated fair value, which was based primarily on recent sales of similar assets. Asset impairment and other special charges recognized during the year ended December 31, 2013 resulted from costs associated with the closure of a packaging and distribution facility in Germany. In January 2016, we approved a plan to close an animal health manufacturing plant located in Ireland. As a result of this action, we expect to record charges of approximately $100 million in our animal health business segment during the first quarter of 2016.

Inventories (Notes)

Inventories (Notes)	12 Months Ended
	Dec. 31, 2015
Inventory Disclosure [Abstract]
Inventory Disclosure [Text Block]	Note 6: Inventories We state all inventories at the lower of cost or market. We use the last-in, first-out (LIFO) method for the majority of our inventories located in the continental U.S. Other inventories are valued by the first-in, first-out (FIFO) method. FIFO cost approximates current replacement cost. Inventories at December 31 consisted of the following: 2015 2014 Finished products $ 1,053.4 $ 838.0 Work in process 2,058.1 1,715.4 Raw materials and supplies 403.0 315.0 Total (approximates replacement cost) 3,514.5 2,868.4 Reduction to LIFO cost (68.7 ) (128.4 ) Inventories $ 3,445.8 $ 2,740.0 Inventories valued under the LIFO method comprised $1.30 billion and $1.09 billion of total inventories at December 31, 2015 and 2014 , respectively.

Financial Instruments

Financial Instruments	12 Months Ended
	Dec. 31, 2015
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Financial Instruments [Text Block]	Note 7: Financial Instruments Financial instruments that potentially subject us to credit risk consist principally of trade receivables and interest-bearing investments. Wholesale distributors of life-science products account for a substantial portion of trade receivables; collateral is generally not required. The risk associated with this concentration is mitigated by our ongoing credit-review procedures and insurance. A large portion of our cash is held by a few major financial institutions. We monitor our exposures with these institutions and do not expect any of these institutions to fail to meet their obligations. Major financial institutions represent the largest component of our investments in corporate debt securities. In accordance with documented corporate policies, we monitor the amount of credit exposure to any one financial institution or corporate issuer. We are exposed to credit-related losses in the event of nonperformance by counterparties to risk-management instruments but do not expect any counterparties to fail to meet their obligations given their high credit ratings. We consider all highly liquid investments with a maturity of three months or less from the date of purchase to be cash equivalents. The cost of these investments approximates fair value. Substantially all of our investments in debt and marketable equity securities are classified as available-for-sale. Investment securities with maturity dates of less than one year from the date of the balance sheet are classified as short-term. Available-for-sale securities are carried at fair value with the unrealized gains and losses, net of tax, reported in other comprehensive income (loss). The credit portion of unrealized losses on our debt securities considered to be other-than-temporary is recognized in earnings. The remaining portion of the other-than-temporary impairment on our debt securities is then recorded, net of tax, in other comprehensive income (loss). The entire amount of other-than-temporary impairment on our equity securities is recognized in earnings. We do not evaluate cost-method investments for impairment unless there is an indicator of impairment. We review these investments for indicators of impairment on a regular basis. Investments in companies over which we have significant influence but not a controlling interest are accounted for using the equity method with our share of earnings or losses reported in other–net, (income) expense. We own no investments that are considered to be trading securities. Our derivative activities are initiated within the guidelines of documented corporate risk-management policies and offset losses and gains on the assets, liabilities, and transactions being hedged. Management reviews the correlation and effectiveness of our derivatives on a quarterly basis. For derivative contracts that are designated and qualify as fair value hedges, the derivative instrument is marked to market with gains and losses recognized currently in income to offset the respective losses and gains recognized on the underlying exposure. For derivative contracts that are designated and qualify as cash flow hedges, the effective portion of gains and losses on these contracts is reported as a component of accumulated other comprehensive loss and reclassified into earnings in the same period the hedged transaction affects earnings. Hedge ineffectiveness is immediately recognized in earnings. Derivative contracts that are not designated as hedging instruments are recorded at fair value with the gain or loss recognized in current earnings during the period of change. We may enter into foreign currency forward or option contracts to reduce the effect of fluctuating currency exchange rates (principally the euro, the British pound, and the Japanese yen). Foreign currency derivatives used for hedging are put in place using the same or like currencies and duration as the underlying exposures. Forward and option contracts are principally used to manage exposures arising from subsidiary trade and loan payables and receivables denominated in foreign currencies. These contracts are recorded at fair value with the gain or loss recognized in other–net, (income) expense. We may enter into foreign currency forward and option contracts and currency swaps as fair value hedges of firm commitments. Forward contracts generally have maturities not exceeding 12 months. At December 31, 2015 , we had outstanding foreign currency forward commitments to purchase 1.17 billion U.S. dollars and sell 1.06 billion euro; commitments to purchase 1.85 billion euro and sell 2.04 billion U.S. dollars; commitments to purchase 187.7 million British pounds and sell 258.4 million euro; commitments to purchase 288.3 million U.S. dollars and sell 190.6 million British pounds, and commitments to purchase 561.7 million U.S. dollars and sell 67.78 billion Japanese yen, which will all settle within 30 days . Foreign currency exchange risk is also managed through the use of foreign currency debt. Our euro-denominated notes issued in June 2015 and discussed in Note 10, which had a carrying amount of $2.27 billion as of December 31, 2015 , have been designated as, and are effective as, economic hedges of net investments in certain of our euro-denominated foreign operations. Accordingly, foreign currency translation gains or losses due to spot rate fluctuations on the euro-denominated notes are included as a component of other comprehensive income (loss). During the year ended December 31, 2015 , we recorded a pretax foreign currency translation gain of $5.6 million from the euro-denominated notes. In the normal course of business, our operations are exposed to fluctuations in interest rates which can vary the costs of financing, investing, and operating. We address a portion of these risks through a controlled program of risk management that includes the use of derivative financial instruments. The objective of controlling these risks is to limit the impact of fluctuations in interest rates on earnings. Our primary interest-rate risk exposure results from changes in short-term U.S. dollar interest rates. In an effort to manage interest-rate exposures, we strive to achieve an acceptable balance between fixed- and floating-rate debt and investment positions and may enter into interest rate swaps or collars to help maintain that balance. Interest rate swaps or collars that convert our fixed-rate debt to a floating rate are designated as fair value hedges of the underlying instruments. Interest rate swaps or collars that convert floating-rate debt to a fixed rate are designated as cash flow hedges. Interest expense on the debt is adjusted to include the payments made or received under the swap agreements. Cash proceeds from or payments to counterparties resulting from the termination of interest rate swaps are classified as operating activities in our consolidated statement of cash flows. At December 31, 2015 , substantially all of our total long-term debt is at a fixed rate. We have converted approximately 40 percent of our long-term fixed-rate notes to floating rates through the use of interest rate swaps. We may enter into forward contracts and designate them as cash flow hedges to limit the potential volatility of earnings and cash flow associated with forecasted sales of available-for-sale securities. We also may enter into forward-starting interest rate swaps, which we designate as cash flow hedges, as part of any anticipated future debt issuances in order to reduce the risk of cash flow volatility from future changes in interest rates. Upon completion of a debt issuance and termination of the swap, the change in fair value of these instruments is recorded as part of other comprehensive income (loss) and is amortized to interest expense over the life of the underlying debt. The Effect of Risk Management Instruments on the Consolidated Statement of Operations The following effects of risk-management instruments were recognized in other–net, (income) expense: 2015 2014 2013 Fair value hedges: Effect from hedged fixed-rate debt $ (11.9 ) $ 156.9 $ (308.2 ) Effect from interest rate contracts 11.9 (156.9 ) 308.2 Cash flow hedges: Effective portion of losses on equity contracts reclassified from accumulated other comprehensive loss (1) — 129.0 — Effective portion of losses on interest rate contracts reclassified from accumulated other comprehensive loss 13.7 9.0 9.0 Net (gains) losses on foreign currency exchange contracts not designated as hedging instruments (28.2 ) (20.4 ) 15.4 (1) Realized gains on the sale of underlying equity securities recognized in other-net, (income) expense were $260.8 million during the year ended December 31, 2014 . There were no realized gains on the sale of underlying equity securities during the years ended December 31, 2015 and 2013 . During the years ended December 31, 2015 , 2014 , and 2013 , net losses related to ineffectiveness, as well as net losses related to the portion of our risk-management hedging instruments, fair value hedges, and cash flow hedges that were excluded from the assessment of effectiveness, were not material. Fair Value Hedges During the years ended December 31, 2015 and 2014 , we terminated certain interest rate swaps designated as fair value hedges with an aggregate notional amount of $876.0 million and $1.30 billion , respectively. The termination of certain interest rate swaps in 2015 was in connection with the note purchase and redemption discussed at Note 10. As a result of the termination, we received cash of $20.2 million and $340.7 million in 2015 and 2014 , respectively, which represented the fair value of the interest rate swaps at the time of termination. In 2015 , the related fair value adjustment was recorded as an increase to the carrying value of the underlying notes and was included as a component of the debt extinguishment loss. In 2014 , the related fair value was recorded as an increase to the carrying value of the underlying notes and is being amortized into earnings as a reduction of interest expense over the remaining life of the underlying debt. Cash Flow Hedges The effective portion of equity contracts and forward-starting interest rate swaps in designated cash flow hedging relationships recorded in other comprehensive income (loss) was as follows: 2015 2014 2013 Equity contracts $ — $ 149.6 $ (149.6 ) Forward-starting interest rate swaps (56.7 ) (164.7 ) 16.7 Upon issuance of the underlying fixed-rate notes in March 2015, which are discussed in Note 10, we terminated forward-starting interest rate contracts in designated cash flow hedging instruments with an aggregate notional amount of $1.35 billion and paid $206.3 million in cash to the counterparties for settlement. The settlement amount represented the fair value of the forward-starting interest rate contracts at the time of termination and was recorded in other comprehensive income (loss). During the year ended December 31, 2014 , we sold all of the underlying equity securities that had been in designated cash flow hedging relationships. At the time of the sales, we reclassified to earnings the accumulated other comprehensive loss related to the cash flow hedges and the previously unrealized gains on the underlying equity securities. During the next 12 months, we expect to reclassify from accumulated other comprehensive loss to earnings $14.8 million of pretax net losses on cash flow hedges of the variability in expected future interest payments on our floating rate debt. Fair Value of Financial Instruments The following tables summarize certain fair value information at December 31 for assets and liabilities measured at fair value on a recurring basis, as well as the carrying amount and amortized cost of certain other investments: Fair Value Measurements Using Description Carrying Amount Cost (1) Quoted Prices in Active Markets for Identical Assets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Fair Value December 31, 2015 Cash equivalents $ 1,644.4 $ 1,644.4 $ 1,637.0 $ 7.4 $ — $ 1,644.4 Short-term investments: U.S. government and agency securities $ 153.2 $ 153.4 $ 153.2 $ — $ — $ 153.2 Corporate debt securities 625.8 626.9 — 625.8 — 625.8 Asset-backed securities 3.3 3.3 — 3.3 — 3.3 Other securities 3.1 3.1 — 3.1 — 3.1 Short-term investments $ 785.4 $ 786.7 Noncurrent investments: U.S. government and agency securities $ 284.5 $ 286.0 $ 283.5 $ 1.0 $ — $ 284.5 Corporate debt securities 1,962.6 1,995.8 — 1,962.6 — 1,962.6 Mortgage-backed securities 153.3 154.7 — 153.3 — 153.3 Asset-backed securities 441.9 443.1 — 441.9 — 441.9 Other securities 4.1 4.1 — 4.1 — 4.1 Marketable equity securities 128.9 74.8 128.9 — — 128.9 Other investments (2) 671.3 671.3 Noncurrent investments $ 3,646.6 $ 3,629.8 December 31, 2014 Cash equivalents $ 2,443.5 $ 2,443.5 $ 2,415.5 $ 28.0 $ — $ 2,443.5 Short-term investments: U.S. government and agency securities $ 185.5 $ 185.6 $ 156.5 $ 29.0 $ — $ 185.5 Corporate debt securities 767.4 766.7 — 767.4 — 767.4 Other securities 2.5 2.5 — 2.5 — 2.5 Short-term investments $ 955.4 $ 954.8 Noncurrent investments: U.S. government and agency securities $ 756.7 $ 757.5 $ 747.5 $ 9.2 $ — $ 756.7 Corporate debt securities 2,462.7 2,468.9 — 2,462.7 — 2,462.7 Mortgage-backed securities 217.0 217.6 — 217.0 — 217.0 Asset-backed securities 477.8 478.0 — 477.8 — 477.8 Other securities 3.2 3.2 — 3.2 — 3.2 Marketable equity securities 204.8 44.0 204.8 — — 204.8 Other investments (2) 446.7 446.7 Noncurrent investments $ 4,568.9 $ 4,415.9 (1) For available-for-sale debt securities, amounts disclosed represent the securities' amortized cost. (2) Primarily includes investments accounted for under the cost method and equity method for which fair value disclosures are not applicable. Fair Value Measurements Using Description Carrying Amount Quoted Prices in Active Markets for Identical Assets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Fair Value Short-term commercial paper borrowings December 31, 2015 $ — $ — $ — $ — $ — December 31, 2014 (2,680.6 ) — (2,680.6 ) — (2,680.6 ) Long-term debt, including current portion December 31, 2015 $ (7,978.5 ) $ — $ (8,172.0 ) $ — $ (8,172.0 ) December 31, 2014 (5,340.9 ) — (5,722.1 ) — (5,722.1 ) Fair Value Measurements Using Description Carrying Amount Quoted Prices in Active Markets for Identical Assets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Fair Value December 31, 2015 Risk-management instruments Interest rate contracts designated as hedging instruments: Sundry $ 70.1 $ — 70.1 $ — $ 70.1 Other noncurrent liabilities (0.4 ) — (0.4 ) — (0.4 ) Foreign exchange contracts not designated as hedging instruments: Other receivables 13.1 — 13.1 — 13.1 Other current liabilities (17.3 ) — (17.3 ) — (17.3 ) Contingent consideration liability (1) : Other current liabilities (243.7 ) — — (243.7 ) (243.7 ) Other noncurrent liabilities (427.2 ) — — (427.2 ) (427.2 ) December 31, 2014 Risk-management instruments Interest rate contracts designated as hedging instruments: Sundry $ 102.5 $ — $ 102.5 $ — $ 102.5 Other current liabilities (149.5 ) — (149.5 ) — (149.5 ) Other noncurrent liabilities (0.7 ) — (0.7 ) — (0.7 ) Foreign exchange contracts not designated as hedging instruments: Other receivables 9.1 — 9.1 — 9.1 Other current liabilities (14.0 ) — (14.0 ) — (14.0 ) (1) The contingent consideration liability relates to the Erbitux arrangement with BMS discussed in Note 4. Risk-management instruments above are disclosed on a gross basis. There are various rights of setoff associated with certain of the risk-management instruments above that are subject to an enforceable master netting arrangement or similar agreements. Although various rights of setoff and master netting arrangements or similar agreements may exist with the individual counterparties to the risk-management instruments above, individually, these financial rights are not material. We determine our Level 1 and Level 2 fair value measurements based on a market approach using quoted market values, significant other observable inputs for identical or comparable assets or liabilities, or discounted cash flow analyses. The fair value of equity method investments and other investments is not readily available. The fair value of the Erbitux contingent consideration liability was estimated using a discounted cash flow analysis and Level 3 inputs, including projections representative of a market participant view for net sales in North America over the three-year period ending in September 2018 and an estimated discount rate. The amount to be paid is calculated as a tiered percentage of net sales (see Note 4) and will, therefore, vary directly with increases and decreases in net sales of Erbitux in North America. There is no cap on the amount that may be paid pursuant to this arrangement. The table below summarizes the contractual maturities of our investments in debt securities measured at fair value as of December 31, 2015 : Maturities by Period Total Within 1 Year After 1 Year Through 5 Years After 5 Years Through 10 Years After 10 Years Fair value of debt securities $ 3,631.8 $ 785.4 $ 2,516.8 $ 164.0 $ 165.6 A summary of the fair value of available-for-sale securities in an unrealized gain or loss position and the amount of unrealized gains and losses (pretax) in accumulated other comprehensive loss follows: 2015 2014 Unrealized gross gains $ 68.0 $ 171.9 Unrealized gross losses 52.5 18.3 Fair value of securities in an unrealized gain position 764.5 1,778.8 Fair value of securities in an unrealized loss position 2,933.4 3,129.2 We periodically assess our investment securities for other-than-temporary impairment losses. Other-than-temporary impairment losses recognized during the year ended December 31, 2015 totaled $42.6 million and related primarily to our equity method and other investments. Other-than-temporary impairment losses recognized during the years ended December 31, 2014 , and 2013 totaled $12.5 million and $11.3 million , respectively. For fixed-income securities, the amount of credit losses are determined by comparing the difference between the present value of future cash flows expected to be collected on these securities and the amortized cost. Factors considered in assessing the credit losses include the position in the capital structure, vintage and amount of collateral, delinquency rates, current credit support, and geographic concentration. For equity securities, factors considered in assessing other-than-temporary impairment losses include the length of time and the extent to which the fair value has been less than cost, the financial condition and near term prospects of the issuer, our intent and ability to retain the securities for a period of time sufficient to allow for recovery in fair value, and general market conditions and industry specific factors. As of December 31, 2015 , the securities in an unrealized loss position include primarily fixed-rate debt securities of varying maturities. The value of fixed-income securities is sensitive to changes in the yield curve and other market conditions. Approximately 85 percent of the securities in a loss position are investment-grade debt securities. As of December 31, 2015 , we do not intend to sell, and it is not more likely than not that we will be required to sell, the securities in a loss position before the market values recover or the underlying cash flows have been received, and there is no indication of default on interest rate or principal payments for any of our debt securities. Activity related to our investment portfolio, substantially all of which related to available-for-sale securities, was as follows: 2015 2014 2013 Proceeds from sales $ 4,733.3 $ 14,609.5 $ 13,753.5 Realized gross gains on sales 255.1 353.5 49.5 Realized gross losses on sales 10.3 29.4 15.4 Realized gains and losses on sales of investments are computed based upon specific identification of the initial cost adjusted for any other-than-temporary declines in fair value that were recorded in earnings.

Goodwill and Other Intangibles

Goodwill and Other Intangibles	12 Months Ended
	Dec. 31, 2015
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill and Intangible Assets Disclosure [Text Block]	Note 8: Goodwill and Other Intangibles Goodwill Goodwill by segment at December 31 was as follows: 2015 2014 Human pharmaceutical products $ 1,366.5 $ 1,359.4 Animal health 2,673.4 398.7 Total goodwill $ 4,039.9 $ 1,758.1 Goodwill results from excess consideration in a business combination over the fair value of identifiable net assets acquired. Goodwill is not amortized but is reviewed for impairment at least annually and when impairment indicators are present. When required, a comparison of implied fair value to the carrying amount of goodwill is performed to determine the amount of any impairment. The increase in goodwill for the animal health segment in 2015 is a result of the acquisition of Novartis AH (Note 3). No impairments occurred with respect to the carrying value of goodwill for the years ended December 31, 2015 , 2014 , and 2013 . Other Intangibles The components of intangible assets other than goodwill at December 31 were as follows: 2015 2014 Description Carrying Amount— Gross Accumulated Amortization Carrying Amount— Net Carrying Amount— Gross Accumulated Amortization Carrying Amount— Net Finite-lived intangible assets: Marketed products $ 7,528.0 $ (2,706.4 ) $ 4,821.6 $ 5,684.3 $ (2,915.6 ) $ 2,768.7 Other 151.1 (115.5 ) 35.6 149.3 (45.2 ) 104.1 Total finite-lived intangible assets 7,679.1 (2,821.9 ) 4,857.2 5,833.6 (2,960.8 ) 2,872.8 Indefinite-lived intangible assets: Acquired in-process research and development 177.6 — 177.6 11.4 — 11.4 Other intangibles $ 7,856.7 $ (2,821.9 ) $ 5,034.8 $ 5,845.0 $ (2,960.8 ) $ 2,884.2 Marketed products consist of the amortized cost of the rights to assets acquired in business combinations and approved for marketing in a significant global jurisdiction (U.S., Europe, and Japan) and capitalized milestone payments. For transactions other than a business combination, we capitalize milestone payments incurred at or after the product has obtained regulatory approval for marketing. Other finite-lived intangibles consist primarily of the amortized cost of licensed platform technologies that have alternative future uses in research and development, manufacturing technologies, and customer relationships from business combinations. Acquired IPR&D consists of the related costs capitalized, adjusted for subsequent impairments, if any. The costs of acquired IPR&D projects acquired directly in a transaction other than a business combination are capitalized if the projects have an alternative future use; otherwise, they are expensed immediately. The fair values of acquired IPR&D projects acquired in business combinations are capitalized as other intangible assets. Several methods may be used to determine the estimated fair value of other intangibles acquired in a business combination. We utilize the “income method,” which is a Level 3 fair value measurement and applies a probability weighting that considers the risk of development and commercialization to the estimated future net cash flows that are derived from projected revenues and estimated costs. These projections are based on factors such as relevant market size, patent protection, historical pricing of similar products, and expected industry trends. The estimated future net cash flows are then discounted to the present value using an appropriate discount rate. This analysis is performed for each asset independently. The acquired IPR&D assets are treated as indefinite-lived intangible assets until completion or abandonment of the projects, at which time the assets are tested for impairment and amortized over the remaining useful life or written off, as appropriate. See Note 3 for further discussion of intangible assets acquired in recent business combinations and Note 4 for additional discussion of recent capitalized milestone payments. The increases in marketed products and acquired IPR&D assets in 2015 are primarily due to the acquisition of Novartis AH and the transfer of the Erbitux commercialization rights discussed in Notes 3 and 4, respectively. Other indefinite-lived intangible assets are reviewed for impairment at least annually and when impairment indicators are present. When required, a comparison of fair value to the carrying amount of assets is performed to determine the amount of any impairment. When determining the fair value of indefinite-lived acquired IPR&D assets for impairment testing purposes, we utilize the "income method" discussed above. Finite-lived intangible assets are reviewed for impairment when an indicator of impairment is present. No material impairments occurred with respect to the carrying value of other intangible assets for the years ended December 31, 2015 , 2014 and 2013 . Intangible assets with finite lives are capitalized and are amortized over their estimated useful lives, ranging from 3 to 20 years. As of December 31, 2015 , the remaining weighted-average amortization period for finite-lived intangible assets is approximately 12 years . Amortization expense related to finite-lived intangible assets was as follows: 2015 2014 2013 Amortization expense $ 631.8 $ 535.9 $ 555.0 The estimated amortization expense associated with our current finite-lived intangible assets for each of the next five years is as follows: 2016 2017 2018 2019 2020 Estimated amortization expense $ 674.7 $ 641.8 $ 480.4 $ 302.7 $ 301.4 Amortization expense is included in either cost of sales, marketing, selling, and administrative or research and development depending on the nature of the intangible asset being amortized.

Property and Equipment (Notes)

Property and Equipment (Notes)	12 Months Ended
	Dec. 31, 2015
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment Disclosure [Text Block]	Note 9: Property and Equipment Property and equipment is stated on the basis of cost. Provisions for depreciation of buildings and equipment are computed generally by the straight-line method at rates based on their estimated useful lives ( 12 to 50 years for buildings and 3 to 25 years for equipment). We review the carrying value of long-lived assets for potential impairment on a periodic basis and whenever events or changes in circumstances indicate the carrying value of an asset may not be recoverable. Impairment is determined by comparing projected undiscounted cash flows to be generated by the asset to its carrying value. If an impairment is identified, a loss is recorded equal to the excess of the asset’s net book value over its fair value, and the cost basis is adjusted. At December 31, property and equipment consisted of the following: 2015 2014 Land $ 220.6 $ 205.2 Buildings 6,786.5 6,516.2 Equipment 7,988.5 7,609.7 Construction in progress 1,665.3 1,698.2 16,660.9 16,029.3 Less accumulated depreciation (8,607.4 ) (8,065.4 ) Property and equipment, net $ 8,053.5 $ 7,963.9 Depreciation expense related to property and equipment and rental expense for all leases, including contingent rentals (not material), was as follows: 2015 2014 2013 Depreciation expense $ 717.6 $ 759.1 $ 774.8 Rental expense 225.7 227.3 227.2 Capitalized interest costs were not material for the years ended December 31, 2015 , 2014 , and 2013 . Assets under capital leases included in property and equipment, net on the consolidated balance sheets, capital lease obligations entered into, and future minimum rental commitments are not material.

Borrowings

Borrowings	12 Months Ended
	Dec. 31, 2015
Long-term Debt, Current and Noncurrent [Abstract]
Debt Disclosure [Text Block]	Note 10: Borrowings Debt at December 31 consisted of the following: 2015 2014 Short-term commercial paper borrowings $ — $ 2,680.6 1.00 to 7.13 percent long-term notes (due 2017-2045) 7,700.1 4,872.8 Other long-term debt, including capitalized leases 23.1 33.1 Unamortized debt issuance costs (37.1 ) (20.4 ) Fair value adjustment on hedged long-term notes 292.4 455.4 Total debt 7,978.5 8,021.5 Less current portion (6.1 ) (2,688.7 ) Long-term debt $ 7,972.4 $ 5,332.8 There were no outstanding borrowings under our commercial paper program at December 31, 2015 . We had $2.68 billion in outstanding borrowings under our commercial paper program at December 31, 2014 , with a weighted-average effective borrowing rate of 0.18 percent . At December 31, 2015 , we had a total of $1.30 billion of unused committed bank credit facilities, which consisted primarily of a $1.20 billion credit facility that expires in August 2020 and is available to support our commercial paper program. During the year ended December 31, 2015 , our $2.00 billion 364-day credit facility expired unused and was not renewed. There were no amounts outstanding under the revolving credit facilities during the years ended December 31, 2015 and 2014 . Compensating balances and commitment fees are not material, and there are no conditions that are probable of occurring under which the lines may be withdrawn. In March 2015, we issued $600.0 million of 1.25 percent fixed-rate notes due March 1, 2018, $800.0 million of 2.75 percent fixed-rate notes due June 1, 2025, and $800.0 million of 3.70 percent fixed-rate notes due March 1, 2045 with interest to be paid semi-annually. The proceeds from the issuance of the notes were used primarily to repay outstanding commercial paper issued in connection with our January 2015 acquisition of Novartis AH. In June 2015, we issued euro-denominated notes consisting of €600.0 million of 1.00 percent fixed-rate notes due June 2, 2022, €750.0 million of 1.63 percent fixed-rate notes due June 2, 2026, and €750.0 million of 2.13 percent fixed-rate notes due June 3, 2030 with interest to be paid annually. The net cash proceeds of the offering of $2.27 billion were used primarily to purchase and redeem certain higher interest rate U.S. dollar-denominated notes and to repay outstanding commercial paper. We paid $1.95 billion to purchase and redeem notes with an aggregate principal amount of $1.65 billion and a net carrying value of $1.78 billion in June 2015, resulting in a pretax debt extinguishment loss of $166.7 million , which was included in other–net, (income) expense in our consolidated statement of operations during the year ended December 31, 2015 . In February 2014, we issued $600.0 million of 1.95 percent and $400.0 million of 4.65 percent fixed-rate notes with interest to be paid semi-annually and maturity dates of March 15, 2019, and June 15, 2044, respectively. Current maturities of long-term notes of $1.00 billion were repaid in March 2014. The aggregate amounts of maturities on long-term debt for the next five years are as follows: 2016 2017 2018 2019 2020 Maturities on long-term debt $ 6.1 $ 635.2 $ 803.2 $ 601.8 $ 0.6 We have converted approximately 40 percent of our long-term fixed-rate notes to floating rates through the use of interest rate swaps. The weighted-average effective borrowing rates based on long-term debt obligations and interest rates at December 31, 2015 and 2014 , including the effects of interest rate swaps for hedged debt obligations, were 2.67 percent and 3.69 percent , respectively. The aggregate amount of cash payments for interest on borrowings, net of capitalized interest, are as follows: 2015 2014 2013 Cash payments for interest on borrowings $ 129.6 $ 140.4 $ 139.7 In accordance with the requirements of derivatives and hedging guidance, the portion of our fixed-rate debt obligations that is hedged as a fair value hedge, is reflected in the consolidated balance sheets as an amount equal to the sum of the debt’s carrying value plus the fair value adjustment representing changes in fair value of the hedged debt attributable to movements in market interest rates subsequent to the inception of the hedge.

Stock-Based Compensation

Stock-Based Compensation	12 Months Ended
	Dec. 31, 2015
Employee Service Share-based Compensation, Aggregate Disclosures [Abstract]
Stock-Based Compensation [Text Block]	Note 11: Stock-Based Compensation Our stock-based compensation expense consists of performance awards (PAs), shareholder value awards (SVAs), and restricted stock units (RSUs). We recognize the fair value of stock-based compensation as expense over the requisite service period of the individual grantees, which generally equals the vesting period. We provide newly issued shares of our common stock and treasury stock to satisfy the issuance of PA, SVA, and RSU shares. We classify tax benefits resulting from tax deductions in excess of the compensation cost recognized for stock-based compensation as a financing cash flow in the consolidated statements of cash flows. Stock-based compensation expense and the related tax benefits were as follows: 2015 2014 2013 Stock-based compensation expense $ 217.8 $ 156.0 $ 144.9 Tax benefit 76.2 54.6 50.7 At December 31, 2015 , additional stock-based compensation awards may be granted under the 2002 Lilly Stock Plan for not more than 100.6 million shares. Performance Award Program PAs are granted to officers and management and are payable in shares of our common stock. The number of PA shares actually issued, if any, varies depending on the achievement of certain pre-established earnings-per-share targets over a two -year period. PA shares are accounted for at fair value based upon the closing stock price on the date of grant and fully vest at the end of the measurement period. The fair values of PAs granted for the years ended December 31, 2015 , 2014 , and 2013 were $70.34 , $48.81 , and $50.19 , respectively. The number of shares ultimately issued for the PA program is dependent upon the earnings achieved during the vesting period. Pursuant to this program, approximately 0.5 million shares, 0.7 million shares, and 0.7 million shares were issued during the years ended December 31, 2015 , 2014 , and 2013 , respectively. Approximately 0.5 million shares are expected to be issued in 2016 . As of December 31, 2015 , the total remaining unrecognized compensation cost related to nonvested PAs was $69.5 million , which will be amortized over the weighted-average remaining requisite service period of 12 months. Shareholder Value Award Program SVAs are granted to officers and management and are payable in shares of our common stock. The number of shares actually issued, if any, varies depending on our stock price at the end of the three -year vesting period compared to pre-established target stock prices. We measure the fair value of the SVA unit on the grant date using a Monte Carlo simulation model. The model utilizes multiple input variables that determine the probability of satisfying the market condition stipulated in the award grant and calculates the fair value of the award. Expected volatilities utilized in the model are based on implied volatilities from traded options on our stock, historical volatility of our stock price, and other factors. Similarly, the dividend yield is based on historical experience and our estimate of future dividend yields. The risk-free interest rate is derived from the U.S. Treasury yield curve in effect at the time of grant. The weighted-average fair values of the SVA units granted during the years ended December 31, 2015 , 2014 , and 2013 were $54.81 , $41.97 , and $45.17 , respectively, determined using the following assumptions: (Percents) 2015 2014 2013 Expected dividend yield 2.50 % 3.50 % 3.50 % Risk-free interest rate 0.79 .08-.71 .08-.43 Volatility 20.37 18.87-21.56 18.95-22.37 Pursuant to this program, approximately 1.4 million shares, 1.4 million shares, and 1.5 million shares were issued during the years ended December 31, 2015 , 2014 , and 2013 , respectively. Approximately 1.0 million shares are expected to be issued in 2016 . As of December 31, 2015 , the total remaining unrecognized compensation cost related to nonvested SVAs was $59.9 million , which will be amortized over the weighted-average remaining requisite service period of 20 months. Restricted Stock Units RSUs are granted to certain employees and are payable in shares of our common stock. RSU shares are accounted for at fair value based upon the closing stock price on the date of grant. The corresponding expense is amortized over the vesting period, typically three years. The fair values of RSU awards granted during the years ended December 31, 2015 , 2014 , and 2013 were $71.69 , $52.72 , and $54.10 , respectively. The number of shares ultimately issued for the RSU program remains constant with the exception of forfeitures. Pursuant to this program, 0.9 million , 1.2 million , and 1.1 million shares were granted and approximately 0.9 million , 0.9 million , and 0.8 million shares were issued during the years ended December 31, 2015 , 2014 , and 2013 , respectively. Approximately 0.6 million shares are expected to be issued in 2016 . As of December 31, 2015 , the total remaining unrecognized compensation cost related to nonvested RSUs was $103.0 million , which will be amortized over the weighted-average remaining requisite service period of 24 months.

Shareholders' Equity

Shareholders' Equity	12 Months Ended
	Dec. 31, 2015
Stockholders' Equity Note [Abstract]
Shareholders' Equity [Text Block]	Note 12: Shareholders' Equity During 2015 , 2014 , and 2013 , we repurchased $749.5 million , $800.0 million and $500.0 million , respectively, of shares associated with our $5.00 billion share repurchase program announced in 2013. As of December 31, 2015 , there were $2.95 billion of shares remaining in that program. During 2013 , we repurchased $1.10 billion of shares, completing our $1.50 billion share repurchase program announced in 2012. We have 5.0 million authorized shares of preferred stock. As of December 31, 2015 and 2014 , no preferred stock has been issued. We have an employee benefit trust that held 50.0 million shares of our common stock at both December 31, 2015 and 2014 , to provide a source of funds to assist us in meeting our obligations under various employee benefit plans. The cost basis of the shares held in the trust was $3.01 billion at both December 31, 2015 and 2014 , and is shown as a reduction in shareholders’ equity. Any dividend transactions between us and the trust are eliminated. Stock held by the trust is not considered outstanding in the computation of EPS. The assets of the trust were not used to fund any of our obligations under these employee benefit plans during the years ended December 31, 2015 , 2014 , and 2013 .

Income Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2015
Income Tax Disclosure [Abstract]
Income Taxes [Text Block]	Note 13: Income Taxes Deferred taxes are recognized for the future tax effects of temporary differences between financial and income tax reporting based on enacted tax laws and rates. Federal income taxes are provided on the portion of the income of foreign subsidiaries that is expected to be remitted to the U.S. and be taxable. When foreign earnings are expected to be indefinitely reinvested outside the U.S., no accrual for U.S. income taxes is provided. We recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by the taxing authorities, based on the technical merits of the position. The tax benefits recognized in the financial statements from such a position are measured based on the largest benefit that has a greater than 50 percent likelihood of being realized upon ultimate resolution. Following is the composition of income tax expense: 2015 2014 2013 Current: Federal $ 660.5 $ 168.9 $ 259.1 Foreign 422.0 406.2 553.2 State 47.5 (2.1 ) 126.3 Total current tax expense 1,130.0 573.0 938.6 Deferred: Federal (689.6 ) (83.3 ) 297.0 Foreign (66.0 ) 120.2 (28.2 ) State 7.2 (0.1 ) (2.9 ) Total deferred tax (benefit) expense (748.4 ) 36.8 265.9 Income taxes $ 381.6 $ 609.8 $ 1,204.5 Significant components of our deferred tax assets and liabilities as of December 31 are as follows: 2015 2014 Deferred tax assets: Compensation and benefits $ 1,034.6 $ 976.3 Purchases of intangible assets 637.2 473.3 Tax credit carryforwards and carrybacks 294.2 279.4 Tax loss carryforwards and carrybacks 247.8 265.5 Contingent consideration 214.6 — Product return reserves 212.1 241.8 Other comprehensive loss on hedging transactions 129.7 115.3 Debt 111.3 176.0 Other 628.6 623.2 Total gross deferred tax assets 3,510.1 3,150.8 Valuation allowances (590.3 ) (601.1 ) Total deferred tax assets 2,919.8 2,549.7 Deferred tax liabilities: Inventories (771.3 ) (684.6 ) Intangibles (756.3 ) (582.6 ) Property and equipment (411.6 ) (424.7 ) Prepaid employee benefits (317.8 ) (275.8 ) Unremitted earnings (218.8 ) (737.1 ) Financial instruments (152.6 ) (276.8 ) Total deferred tax liabilities (2,628.4 ) (2,981.6 ) Deferred tax assets (liabilities) - net $ 291.4 $ (431.9 ) The deferred tax asset and related valuation allowance amounts for U.S. federal and state net operating losses and tax credits shown above have been reduced for differences between financial reporting and tax return filings. Based on filed tax returns, we have tax credit carryforwards and carrybacks of $668.5 million available to reduce future income taxes; $180.5 million , if unused, will expire by 2021 . The remaining portion of the tax credit carryforwards is related to federal tax credits of $93.4 million , international tax credits of $100.6 million , and state tax credits of $294.0 million , all of which are substantially reserved. At December 31, 2015 , based on filed tax returns we had net operating losses and other carryforwards for international and U.S. federal income tax purposes of $462.0 million : $38.0 million will expire by 2020 ; $354.0 million will expire between 2020 and 2035 ; and $70.0 million of the carryforwards will never expire. Net operating losses and other carryforwards for international and U.S. federal income tax purposes are partially reserved. Deferred tax assets related to state net operating losses of $93.2 million and other state carryforwards of $8.8 million are fully reserved. Domestic and Puerto Rican companies contributed approximately 35 percent , 20 percent , and 60 percent for the years ended December 31, 2015 , 2014 , and 2013 , respectively, to consolidated income before income taxes. We have a subsidiary operating in Puerto Rico under a tax incentive grant effective through the end of 2016 . A similar, new tax incentive grant will begin in 2017 and will be in effect for 15 years . At December 31, 2015 , U.S. income taxes have not been provided on approximately $26.5 billion of unremitted earnings of foreign subsidiaries as we consider these unremitted earnings to be indefinitely invested for continued use in our foreign operations. Additional tax provisions will be required if these earnings are repatriated in the future to the U.S. Due to complexities in the tax laws and assumptions that we would have to make, it is not practicable to determine the amount of the related unrecognized deferred income tax liability. Cash payments of income taxes were as follows: 2015 2014 2013 Cash payments of income taxes $ 969.0 $ 729.7 $ 1,255.6 Following is a reconciliation of the income tax expense applying the U.S. federal statutory rate to income before income taxes to reported income tax expense: 2015 2014 2013 Income tax at the U.S. federal statutory tax rate $ 976.5 $ 1,050.1 $ 2,061.3 Add (deduct): International operations, including Puerto Rico (565.2 ) (344.8 ) (778.3 ) General business credits (69.2 ) (44.3 ) (175.6 ) Other 39.5 (51.2 ) 97.1 Income taxes $ 381.6 $ 609.8 $ 1,204.5 The American Taxpayer Relief Act of 2012, which included the reinstatement of the research tax credit for the year 2012, was enacted in early 2013. Therefore, the research tax credits for the years 2012 and 2013 are both included in 2013 with general business credits. A reconciliation of the beginning and ending amount of gross unrecognized tax benefits is as follows: 2015 2014 2013 Beginning balance at January 1 $ 1,338.8 $ 1,136.4 $ 1,534.3 Additions based on tax positions related to the current year 131.3 126.4 142.5 Additions for tax positions of prior years 116.6 132.6 251.5 Reductions for tax positions of prior years (45.2 ) (32.1 ) (358.2 ) Settlements (446.2 ) (4.2 ) (404.9 ) Lapses of statutes of limitation (4.0 ) (3.5 ) (24.9 ) Changes related to the impact of foreign currency translation (24.7 ) (16.8 ) (3.9 ) Ending balance at December 31 $ 1,066.6 $ 1,338.8 $ 1,136.4 The total amount of unrecognized tax benefits that, if recognized, would affect our effective tax rate was $404.1 million and $638.8 million at December 31, 2015 and 2014 , respectively. We file income tax returns in the U.S. federal jurisdiction and various state, local, and non-U.S. jurisdictions. We are no longer subject to U.S. federal, state and local, or non-U.S. income tax examinations in most major taxing jurisdictions for years before 2007. During 2013, we reached resolution on the remaining matters related to tax years 2008–2009 that were not settled as part of a previous U.S. examination. Considering the impact of this resolution on periods that have not yet been examined, as well as its impact on tax asset carryforwards, there was an immaterial benefit to our consolidated results of operations. We made cash payments of approximately $135 million related to tax years 2008–2009 after application of available tax credit carryforwards and carrybacks. The U.S. examination of tax years 2010 - 2012 commenced during the fourth quarter of 2013 and is expected to conclude in the first quarter of 2016. In December 2015, we executed a closing agreement with the Internal Revenue Service which effectively settled certain matters for tax years 2010 - 2012 . Accordingly, we have reduced our gross uncertain tax positions by approximately $320 million in 2015. There was an immaterial impact to our consolidated results of operations during the fourth quarter related to issues settled in the closing agreement. In the first quarter of 2016, we anticipate reaching resolution on the remaining issues under examination and estimate that our gross uncertain tax positions will further be reduced by approximately $100 million to $150 million . Additionally, we do not anticipate that resolution of the U.S. examination will result in a material change to our consolidated financial position, and we expect that up to $250 million of cash payments will be due upon resolution of these tax years. We expect the U.S. examination of tax years 2013 - 2014 , and possibly 2015 , to begin in 2016. We recognize both accrued interest and penalties related to unrecognized tax benefits in income tax expense. We recognized income tax (benefit) expense related to interest and penalties as follows: 2015 2014 2013 Income tax (benefit) expense $ 13.2 $ 35.9 $ (10.9 ) At December 31, 2015 and 2014 , our accruals for the payment of interest and penalties totaled $216.3 million and $207.2 million , respectively. Following is the composition of income tax expense: 2015 2014 2013 Current: Federal $ 660.5 $ 168.9 $ 259.1 Foreign 422.0 406.2 553.2 State 47.5 (2.1 ) 126.3 Total current tax expense 1,130.0 573.0 938.6 Deferred: Federal (689.6 ) (83.3 ) 297.0 Foreign (66.0 ) 120.2 (28.2 ) State 7.2 (0.1 ) (2.9 ) Total deferred tax (benefit) expense (748.4 ) 36.8 265.9 Income taxes $ 381.6 $ 609.8 $ 1,204.5

Retirement Benefits

Retirement Benefits	12 Months Ended
	Dec. 31, 2015
Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Abstract]
Retirement Benefits [Text Block]	Note 14: Retirement Benefits We use a measurement date of December 31 to develop the change in benefit obligation, change in plan assets, funded status, and amounts recognized in the consolidated balance sheets at December 31 for our defined benefit pension and retiree health benefit plans, which were as follows: Defined Benefit Pension Plans Retiree Health Benefit Plans 2015 2014 2015 2014 Change in benefit obligation: Benefit obligation at beginning of year $ 12,012.4 $ 9,976.4 $ 1,553.5 $ 1,757.2 Benefit obligation assumed in Novartis AH acquisition 334.7 — 9.9 — Service cost 315.7 240.9 45.1 33.0 Interest cost 476.8 472.6 62.6 85.6 Actuarial (gain) loss (812.4 ) 1,996.3 (113.5 ) 293.5 Benefits paid (437.8 ) (421.2 ) (77.5 ) (76.1 ) Plan amendments (0.4 ) (2.4 ) — (533.6 ) Foreign currency exchange rate changes and other adjustments (169.8 ) (250.2 ) (12.7 ) (6.1 ) Benefit obligation at end of year 11,719.2 12,012.4 1,467.4 1,553.5 Change in plan assets: Fair value of plan assets at beginning of year 9,835.7 9,481.7 1,918.7 1,879.6 Fair value of plan assets assumed in Novartis AH acquisition 235.9 — — — Actual return on plan assets 90.4 813.6 85.1 157.4 Employer contribution 404.1 127.2 17.4 (42.2 ) Benefits paid (437.8 ) (421.2 ) (77.5 ) (76.1 ) Foreign currency exchange rate changes and other adjustments (132.7 ) (165.6 ) — — Fair value of plan assets at end of year 9,995.6 9,835.7 1,943.7 1,918.7 Funded status (1,723.6 ) (2,176.7 ) 476.3 365.2 Unrecognized net actuarial loss 4,552.7 5,114.9 347.9 439.5 Unrecognized prior service (benefit) cost 32.5 43.5 (574.8 ) (666.7 ) Net amount recognized $ 2,861.6 $ 2,981.7 $ 249.4 $ 138.0 Amounts recognized in the consolidated balance sheet consisted of: Sundry $ 261.6 $ 211.2 $ 722.1 $ 609.4 Other current liabilities (63.8 ) (62.3 ) (6.9 ) (6.9 ) Accrued retirement benefits (1,921.4 ) (2,325.6 ) (238.9 ) (237.3 ) Accumulated other comprehensive (income) loss before income taxes 4,585.2 5,158.4 (226.9 ) (227.2 ) Net amount recognized $ 2,861.6 $ 2,981.7 $ 249.4 $ 138.0 The unrecognized net actuarial loss and unrecognized prior service cost (benefit) have not yet been recognized in net periodic pension costs and are included in accumulated other comprehensive loss at December 31, 2015 . A change to our U.S. retiree health benefit plan was approved in 2014 and communicated to retirees in January 2015. Beginning in 2016, Medicare-eligible retirees and Medicare-eligible dependents will choose health care coverage from insurance providers through a private Medicare supplement marketplace, while still receiving financial support from us. This change decreased our retiree health benefit obligation and increased our unrecognized prior service benefit as of December 31, 2014 by $520.8 million . During 2016 , we expect the following components of accumulated other comprehensive loss to be recognized as components of net periodic benefit cost: Defined Benefit Pension Plans Retiree Health Benefit Plans Unrecognized net actuarial loss $ 285.9 $ 19.2 Unrecognized prior service (benefit) cost 11.9 (85.8 ) Total $ 297.8 $ (66.6 ) We do not expect any plan assets to be returned to us in 2016 . The following represents our weighted-average assumptions as of December 31: Defined Benefit Pension Plans Retiree Health Benefit Plans (Percents) 2015 2014 2013 2015 2014 2013 Discount rate for benefit obligation 4.3 4.0 4.9 4.5 4.1 5.0 Discount rate for net benefit costs 4.0 4.9 4.3 4.1 5.0 4.3 Rate of compensation increase for benefit obligation 3.4 3.4 3.4 Rate of compensation increase for net benefit costs 3.4 3.4 3.4 Expected return on plan assets for net benefit costs 7.4 8.1 8.4 8.0 8.5 8.8 We annually evaluate the expected return on plan assets in our defined benefit pension and retiree health benefit plans. In evaluating the expected rate of return, we consider many factors, with a primary analysis of current and projected market conditions; asset returns and asset allocations; and the views of leading financial advisers and economists. We may also review our historical assumptions compared with actual results, as well as the assumptions and trend rates utilized by similar plans, where applicable. Given the design of our retiree health benefit plans, heathcare-cost trend rates do not have a material impact on our financial condition or results of operations. The following benefit payments, which reflect expected future service, as appropriate, are expected to be paid as follows: 2016 2017 2018 2019 2020 2021-2025 Defined benefit pension plans $ 458.4 $ 465.2 $ 480.3 $ 498.8 $ 518.5 $ 2,987.5 Retiree health benefit plans 70.7 75.3 78.3 81.1 84.0 464.2 Amounts relating to defined benefit pension plans with projected benefit obligations in excess of plan assets were as follows at December 31: 2015 2014 Projected benefit obligation $ 10,054.1 $ 10,537.2 Fair value of plan assets 8,069.7 8,149.2 Amounts relating to defined benefit pension plans and retiree health benefit plans with accumulated benefit obligations in excess of plan assets were as follows at December 31: Defined Benefit Pension Plans Retiree Health Benefit Plans 2015 2014 2015 2014 Accumulated benefit obligation $ 2,028.1 $ 2,179.8 $ 245.8 $ 244.2 Fair value of plan assets 844.9 700.9 — — The total accumulated benefit obligation for our defined benefit pension plans was $10.75 billion and $10.88 billion at December 31, 2015 and 2014 , respectively. Net pension and retiree health benefit expense included the following components: Defined Benefit Pension Plans Retiree Health Benefit Plans 2015 2014 2013 2015 2014 2013 Components of net periodic (benefit) cost: Service cost $ 315.7 $ 240.9 $ 287.1 $ 45.1 $ 33.0 $ 49.9 Interest cost 476.8 472.6 437.2 62.6 85.6 98.1 Expected return on plan assets (782.3 ) (756.6 ) (701.9 ) (150.0 ) (146.4 ) (130.7 ) Amortization of prior service (benefit) cost 10.4 3.6 3.7 (91.1 ) (37.6 ) (35.6 ) Recognized actuarial loss 383.2 282.3 414.7 38.0 20.7 100.5 Net periodic (benefit) cost $ 403.8 $ 242.8 $ 440.8 $ (95.4 ) $ (44.7 ) $ 82.2 As of January 1, 2016, we changed the method used to estimate the service and interest cost components of the net periodic pension and retiree health benefit plan costs. This new method uses the spot yield curve approach to estimate the service and interest costs by applying the specific spot rates along the yield curve to the projected cash outflows of our obligations. Previously, those costs were determined using a single weighted-average discount rate. The new method provides a more precise measure of interest and service costs by improving the correlation between the projected benefit cash flows and the specific spot yield curve rates. The change does not affect the measurement of the total benefit obligations as the change in service and interest costs is recorded in the actuarial gains and losses recorded in accumulated other comprehensive loss. We will account for this change as a change in estimate prospectively beginning in the first quarter of 2016. The following represents the amounts recognized in other comprehensive income (loss) for the year ended December 31, 2015 : Defined Benefit Retiree Health Actuarial gain arising during period $ 120.4 $ 48.6 Plan amendments during period 0.4 — Amortization of prior service (benefit) cost included in net income 10.4 (91.1 ) Amortization of net actuarial loss included in net income 383.2 38.0 Foreign currency exchange rate changes and other 58.8 4.2 Total other comprehensive income (loss) during period $ 573.2 $ (0.3 ) We have defined contribution savings plans that cover our eligible employees worldwide. The purpose of these plans is generally to provide additional financial security during retirement by providing employees with an incentive to save. Our contributions to the plans are based on employee contributions and the level of our match. Expenses under the plans totaled $162.4 million , $153.3 million , and $147.7 million for the years ended December 31, 2015 , 2014 , and 2013 , respectively. We provide certain other postemployment benefits primarily related to disability benefits and accrue for the related cost over the service lives of employees. Expenses associated with these benefit plans for the years ended December 31, 2015 , 2014 , and 2013 were not material. Benefit Plan Investments Our benefit plan investment policies are set with specific consideration of return and risk requirements in relationship to the respective liabilities. U.S. and Puerto Rico plans represent approximately 75 percent of our global investments. Given the long-term nature of our liabilities, these plans have the flexibility to manage an above-average degree of risk in the asset portfolios. At the investment-policy level, there are no specifically prohibited investments. However, within individual investment manager mandates, restrictions and limitations are contractually set to align with our investment objectives, ensure risk control, and limit concentrations. We manage our portfolio to minimize concentration of risk by allocating funds within asset categories. In addition, within a category we use different managers with various management objectives to eliminate any significant concentration of risk. Our global benefit plans may enter into contractual arrangements (derivatives) to implement the local investment policy or manage particular portfolio risks. Derivatives are principally used to increase or decrease exposure to a particular public equity, fixed income, commodity, or currency market more rapidly or less expensively than could be accomplished through the use of the cash markets. The plans utilize both exchange-traded and over-the-counter instruments. The maximum exposure to either a market or counterparty credit loss is limited to the carrying value of the receivable, and is managed within contractual limits. We expect all of our counterparties to meet their obligations. The gross values of these derivative receivables and payables are not material to the global asset portfolio, and their values are reflected within the tables below. The defined benefit pension and retiree health benefit plan allocation for the U.S. and Puerto Rico currently comprises approximately 80 percent growth investments and 20 percent fixed-income investments. The growth investment allocation encompasses U.S. and international public equity securities, hedge funds, private equity-like investments, and real estate. These portfolio allocations are intended to reduce overall risk by providing diversification, while seeking moderate to high returns over the long term. Public equity securities are well diversified and invested in U.S. and international small-to-large companies across various asset managers and styles. The remaining portion of the growth portfolio is invested in private alternative investments. Fixed-income investments primarily consist of fixed-income securities in U.S. treasuries and agencies, emerging market debt obligations, corporate bonds, mortgage-backed securities, and commercial mortgage-backed obligations. Hedge funds are privately owned institutional investment funds that generally have moderate liquidity. Hedge funds seek specified levels of absolute return regardless of overall market conditions, and generally have low correlations to public equity and debt markets. Hedge funds often invest substantially in financial market instruments (stocks, bonds, commodities, currencies, derivatives, etc.) using a very broad range of trading activities to manage portfolio risks. Hedge fund strategies focus primarily on security selection and seek to be neutral with respect to market moves. Common groupings of hedge fund strategies include relative value, tactical, and event driven. Relative value strategies include arbitrage, when the same asset can simultaneously be bought and sold at different prices, achieving an immediate profit. Tactical strategies often take long and short positions to reduce or eliminate overall market risks while seeking a particular investment opportunity. Event strategy opportunities can evolve from specific company announcements such as mergers and acquisitions, and typically have little correlation to overall market directional movements. Our hedge fund investments are made through limited partnership interests primarily in fund-of-funds structures to ensure diversification across many strategies and many individual managers. Plan holdings in hedge funds are valued based on net asset values (NAVs) calculated by each fund or general partner, as applicable, and we have the ability to redeem these investments at NAV. Private equity-like investment funds typically have low liquidity and are made through long-term partnerships or joint ventures that invest in pools of capital invested in primarily non-publicly traded entities. Underlying investments include venture capital (early stage investing), buyout, and special situation investing. Private equity management firms typically acquire and then reorganize private companies to create increased long term value. Private equity-like funds usually have a limited life of approximately 10-15 years, and require a minimum investment commitment from their limited partners. Our private investments are made both directly into funds and through fund-of-funds structures to ensure broad diversification of management styles and assets across the portfolio. Plan holdings in private equity-like investments are valued using the value reported by the partnership, adjusted for known cash flows and significant events through our reporting date. Values provided by the partnerships are primarily based on analysis of and judgments about the underlying investments. Inputs to these valuations include underlying NAVs, discounted cash flow valuations, comparable market valuations, and may also include adjustments for currency, credit, liquidity and other risks as applicable. The vast majority of these private partnerships provide us with annual audited financial statements including their compliance with fair valuation procedures consistent with applicable accounting standards. Real estate is composed of both public and private holdings. Real estate investments in registered investment companies that trade on an exchange are classified as Level 1 on the fair value hierarchy. Real estate investments in funds measured at fair value on the basis of NAV provided by the fund manager are classified as Level 3. These NAVs are developed with inputs including discounted cash flow, independent appraisal, and market comparable analyses. Other assets include cash and cash equivalents and mark-to-market value of derivatives. The cash value of the trust-owned insurance contract is invested in investment-grade publicly traded equity and fixed-income securities. Other than hedge funds, private equity-like investments, and real estate, which are discussed above, we determine fair values based on a market approach using quoted market values, significant other observable inputs for identical or comparable assets or liabilities, or discounted cash flow analyses. The fair values of our defined benefit pension plan and retiree health plan assets as of December 31, 2015 by asset category are as follows: Fair Value Measurements Using Asset Class Total Quoted Prices in Active Markets for Significant Significant Defined Benefit Pension Plans Public equity securities: U.S. $ 414.8 $ 187.1 $ 227.7 $ — International 2,340.6 956.3 1,384.3 — Fixed income: Developed markets 1,316.6 175.7 1,140.9 — Emerging markets 385.7 10.1 375.3 0.3 Private alternative investments: Hedge funds 3,073.3 14.5 1,537.9 1,520.9 Equity-like funds 1,221.3 — 67.4 1,153.9 Real estate 516.3 329.5 10.8 176.0 Other 727.0 431.3 295.7 — Total $ 9,995.6 $ 2,104.5 $ 5,040.0 $ 2,851.1 Retiree Health Benefit Plans Public equity securities: U.S. $ 40.0 $ 18.2 $ 21.8 $ — International 144.7 51.5 93.2 — Fixed income: Developed markets 61.3 — 61.3 — Emerging markets 36.9 — 36.9 — Private alternative investments: Hedge funds 272.3 — 148.7 123.6 Equity-like funds 104.5 — — 104.5 Cash value of trust owned insurance contract 1,209.7 — 1,209.7 — Real estate 33.2 33.2 — — Other 41.1 25.0 16.1 — Total $ 1,943.7 $ 127.9 $ 1,587.7 $ 228.1 No material transfers between Level 1, Level 2, or Level 3 occurred during the year ended December 31, 2015 . The activity in the Level 3 investments during the year ended December 31, 2015 was as follows: Fixed Income: Emerging Markets Hedge Equity-like Real Total Defined Benefit Pension Plans Beginning balance at January 1, 2015 $ 1.8 $ 1,583.1 $ 1,071.4 $ 165.9 $ 2,822.2 Actual return on plan assets, including changes in foreign exchange rates: Relating to assets still held at the reporting date (0.1 ) 89.4 78.3 (6.1 ) 161.5 Relating to assets sold during the period — (111.5 ) — — (111.5 ) Purchases, sales, and settlements, net (0.3 ) (40.1 ) 4.2 16.2 (20.0 ) Transfers into (out of) Level 3 (1.1 ) — — — (1.1 ) Ending balance at December 31, 2015 $ 0.3 $ 1,520.9 $ 1,153.9 $ 176.0 $ 2,851.1 Retiree Health Benefit Plans Beginning balance at January 1, 2015 $ 0.2 $ 124.0 $ 92.3 $ — $ 216.5 Actual return on plan assets, including changes in foreign exchange rates: Relating to assets still held at the reporting date — 14.7 10.3 — 25.0 Relating to assets sold during the period — (11.2 ) — — (11.2 ) Purchases, sales, and settlements, net — (3.9 ) 1.9 — (2.0 ) Transfers into (out of) Level 3 (0.2 ) — — — (0.2 ) Ending balance at December 31, 2015 $ — $ 123.6 $ 104.5 $ — $ 228.1 The fair values of our defined benefit pension plan and retiree health plan assets as of December 31, 2014 by asset category are as follows: Fair Value Measurements Using Asset Class Total Quoted Prices in Active Markets for Identical Assets (Level 1) Significant Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Defined Benefit Pension Plans Public equity securities: U.S. $ 411.4 $ 183.8 $ 227.6 $ — International 2,337.8 999.7 1,338.1 — Fixed income: Developed markets 1,230.7 112.2 1,118.5 — Emerging markets 374.7 8.7 364.2 1.8 Private alternative investments: Hedge funds 3,277.6 — 1,694.5 1,583.1 Equity-like funds 1,146.6 — 75.2 1,071.4 Real estate 569.0 403.1 — 165.9 Other 487.9 229.8 258.1 — Total $ 9,835.7 $ 1,937.3 $ 5,076.2 $ 2,822.2 Retiree Health Benefit Plans Public equity securities: U.S. $ 39.2 $ 17.2 $ 22.0 $ — International 158.9 58.8 100.1 — Fixed income: Developed markets 61.8 — 61.8 — Emerging markets 35.5 — 35.3 0.2 Private alternative investments: Hedge funds 282.7 — 158.7 124.0 Equity-like funds 92.3 — — 92.3 Cash value of trust owned insurance contract 1,189.2 — 1,189.2 — Real estate 39.0 39.0 — — Other 20.1 7.6 12.5 — Total $ 1,918.7 $ 122.6 $ 1,579.6 $ 216.5 No material transfers between Level 1, Level 2, or Level 3 occurred during the year ended December 31, 2014 . The activity in the Level 3 investments during the year ended December 31, 2014 was as follows: Fixed Income: Developed Markets Fixed Income: Emerging Markets Hedge Funds Equity-like Funds Real Estate Total Defined Benefit Pension Plans Beginning balance at January 1, 2014 $ 15.9 $ — $ 1,440.4 $ 993.5 $ 153.4 $ 2,603.2 Actual return on plan assets, including changes in foreign exchange rates: Relating to assets still held at the reporting date (0.4 ) 0.1 44.6 108.2 0.2 152.7 Relating to assets sold during the period (0.8 ) — — — — (0.8 ) Purchases, sales, and settlements, net (3.3 ) 1.7 98.1 (30.3 ) 12.3 78.5 Transfers into (out of) Level 3 (11.4 ) — — — — (11.4 ) Ending balance at December 31, 2014 $ — $ 1.8 $ 1,583.1 $ 1,071.4 $ 165.9 $ 2,822.2 Retiree Health Benefit Plans Beginning balance at January 1, 2014 $ 1.6 $ — $ 120.6 $ 88.9 $ — $ 211.1 Actual return on plan assets, including changes in foreign exchange rates: Relating to assets still held at the reporting date (0.1 ) — 1.2 6.0 — 7.1 Relating to assets sold during the period (0.1 ) — — — — (0.1 ) Purchases, sales, and settlements, net (0.3 ) 0.2 2.2 (2.6 ) — (0.5 ) Transfers into (out of) Level 3 (1.1 ) — — — — (1.1 ) Ending balance at December 31, 2014 $ — $ 0.2 $ 124.0 $ 92.3 $ — $ 216.5 In 2016, we expect to contribute approximately $40 million to our defined benefit pension plans to satisfy minimum funding requirements for the year, along with approximately $5 million of additional discretionary contributions.

Contingencies

Contingencies	12 Months Ended
	Dec. 31, 2015
Loss Contingency, Information about Litigation Matters [Abstract]
Contingencies [Text Block]	Note 15: Contingencies We are a party to various legal actions and government investigations. The most significant of these are described below. It is not possible to determine the outcome of these matters, and we cannot reasonably estimate the maximum potential exposure or the range of possible loss in excess of amounts accrued for any of these matters; however, we believe that, except as noted below with respect to the Alimta ® patent litigation and administrative proceedings, the resolution of all such matters will not have a material adverse effect on our consolidated financial position or liquidity, but could possibly be material to our consolidated results of operations in any one accounting period. Litigation accruals, environmental liabilities, and the related estimated insurance recoverables are reflected on a gross basis as liabilities and assets, respectively, on our consolidated balance sheets. With respect to the product liability claims currently asserted against us, we have accrued for our estimated exposures to the extent they are both probable and reasonably estimable based on the information available to us. We accrue for certain product liability claims incurred but not filed to the extent we can formulate a reasonable estimate of their costs. We estimate these expenses based primarily on historical claims experience and data regarding product usage. Legal defense costs expected to be incurred in connection with significant product liability loss contingencies are accrued when both probable and reasonably estimable. Alimta Patent Litigation and Administrative Proceedings A number of generic manufacturers are seeking approvals in various countries to market generic forms of Alimta prior to the expiration of our vitamin regimen patents, alleging that those patents are invalid, not infringed, or both. We believe our Alimta vitamin regimen patents are valid and enforceable against these generic manufacturers. However, it is not possible to determine the ultimate outcome of the proceedings, and accordingly, we can provide no assurance that we will prevail. An unfavorable outcome could have a material adverse impact on our future consolidated results of operations, liquidity, and financial position. We expect that a loss of exclusivity for Alimta would result in a rapid and severe decline in future revenues for the product in the relevant market. U.S. Patent Litigation and Administrative Proceedings We are engaged in various U.S. patent litigation matters involving Alimta brought pursuant to procedures set out in the Drug Price Competition and Patent Term Restoration Act of 1984 (the Hatch-Waxman Act). More than ten Abbreviated New Drug Applications (ANDAs) seeking approval to market generic versions of Alimta prior to the expiration of our vitamin regimen patent (expiring in 2021 plus pediatric exclusivity expiring in 2022) have been filed by a number of companies, including Teva Parenteral Medicines, Inc. (Teva) and APP Pharmaceuticals, LLC (APP). These companies have also alleged the patent is invalid. In February 2016, we filed a lawsuit alleging infringement against Dr. Reddy's Laboratories in response to their recently filed abbreviated application. In October 2010, we filed a lawsuit in the U.S. District Court for the Southern District of Indiana against Teva, APP and two other defendants seeking rulings that the U.S. vitamin regimen patent is valid and infringed (the Teva/APP litigation). Teva and APP stipulated to infringement of our vitamin regimen patent, with the contingency that Teva and APP would be permitted to litigate the issue of infringement if the U.S. Supreme Court vacated an en banc decision of the U.S. Court of Appeals for the Federal Circuit that dealt with issues of liability related to infringement ( Akamai v. Limelight Networks ). Thus, the sole issue before the district court was to determine patent validity. Trial occurred in August 2013. In March 2014, the court ruled that the asserted claims of the vitamin regimen patent are valid. In June 2014, the U.S. Supreme Court vacated the Akamai decision, and the U.S. District Court for the Southern District of Indiana held a hearing on the issue of infringement in May 2015. In September 2015, the district court ruled that the vitamin regimen patent would be infringed by the generic challengers' proposed products. Teva and APP filed a notice of appeal with respect to all of the district court’s substantive decisions. A decision from the U.S. Court of Appeals for the Federal Circuit is expected in late 2016. Throughout the course of 2012 through 2015, we filed similar lawsuits against other ANDA defendants seeking a ruling that our patents are valid and infringed. Some of these cases have been stayed pending the outcome of the Teva/APP litigation, and these parties have agreed to be bound by the outcome of the Teva/APP litigation. In 2015, Neptune Generics LLC and Sandoz International GmbH each submitted petitions to the United States Patent and Trademark Office (USPTO), seeking inter partes review (IPR) of our vitamin regimen patent by the USPTO. The USPTO is expected to decide whether to institute an IPR by mid-2016. If instituted, then the final written decision on the merits will be issued by the USPTO by mid-2017. European Patent Litigation and Administrative Proceedings Generic manufacturers filed an opposition to the European Patent Office's (EPO) decision to grant us a vitamin regimen patent. The Opposition Division of the EPO upheld the patent and the generic manufacturers lodged an appeal. The EPO appeal hearing was scheduled for November 2015. In October 2015 the generic manufacturers withdrew the appeal, and the hearing was canceled. As a result, the original EPO decision upholding the patent is now final. In addition, in the United Kingdom (U.K.), Actavis Group ehf and other Actavis companies (collectively, Actavis) filed litigation asking for a declaratory judgment that commercialization of certain salt forms of pemetrexed (the active ingredient in Alimta) would not infringe the vitamin regimen patents in the U.K., Italy, France, and Spain. In May 2014, the trial court ruled that the vitamin regimen patents for Alimta would not be infringed by commercialization of alternative salt forms of pemetrexed, after expiration of the compound patents in December 2015. We appealed, and in June 2015, the U.K. Court of Appeal reversed the trial court, ruling that the Alimta vitamin regimen patent in the U.K. would be indirectly infringed by commercialization of Actavis' products as proposed prior to the patent's expiration in June 2021. The Court of Appeal also held there was no difference between the law in the U.K. and that in France, Italy, and Spain as it relates to indirect infringement, and so reversed the trial court's decision granting declarations of noninfringement over the Alimta vitamin regimen patents in those countries. In February 2016, the U.K. Supreme Court granted our and Actavis' requests for permission to appeal different aspects of the judgment. In February 2016, the trial court ruled that Actavis’ commercialization of a different proposed product would not infringe the patent in the U.K., Italy, France, and Spain. We will seek permission to appeal this ruling. We commenced separate infringement proceedings against certain Actavis companies in Germany. Following a trial, in April 2014, the German trial court ruled in our favor. The defendants appealed, and after a hearing in March 2015, the appellate court overturned the trial court and ruled that our vitamin regimen patent in Germany would not be infringed by a dipotassium salt form of pemetrexed. In January 2016, the German Federal Supreme court granted our request to appeal this matter. A hearing is scheduled for mid-2016. In separate proceedings, in December 2015 we applied for and obtained a preliminary injunction against Hexal AG (Hexal), which had stated their intention to launch a generic disodium salt product in Germany. Hexal has appealed. We are aware that a generic competitor has received approval to market a generic version of Alimta in a major European market, although we are not aware of whether the competitor's product has entered the market. Japanese Administrative Proceedings Three companies have filed separate demands for invalidation of our two vitamin regimen patents with the Japanese Patent Office (JPO). In November 2015, the JPO issued a written decision in the invalidation trial initiated by Sawai Pharmaceutical Co., Ltd. (Sawai), and joined by four other companies, upholding both vitamin regimen patents. These patents provide intellectual property protection for Alimta until June 2021. Sawai and Teva, one of the other companies in the Sawai invalidation trial, have filed appeals in both cases. The remaining invalidation trials initiated by the other parties are currently suspended. Notwithstanding our patents, generic versions of Alimta were approved in Japan in February 2016. We filed preliminary injunctions against four generic competitors. We do not anticipate generic competitors to proceed to launch prior to the completion of the Sawai invalidation trial. Effient Patent Litigation and Administrative Proceedings We, along with Daiichi Sankyo, Daiichi Sankyo, Inc., and Ube Industries (Ube) are engaged in U.S. patent litigation involving Effient brought pursuant to procedures set out in the Hatch-Waxman Act. More than ten different companies have submitted ANDAs seeking approval to market generic versions of Effient prior to the expiration of Daiichi Sankyo’s and Ube’s patents (expiring in 2023) covering methods of using Effient with aspirin, and alleging the patents are invalid. One of these ANDAs also alleges that the compound patent for Effient (expiring in April 2017) is invalid. Beginning in March 2014, we filed lawsuits in the U.S. District Court for the Southern District of Indiana against these companies, seeking a ruling that the patents are valid and infringed. These cases have been consolidated. Four generic companies have agreed to be bound by the outcome of the consolidated case. In 2015, several generic pharmaceutical companies filed petitions with the USPTO, requesting IPR of the method patents. In September 2015, the USPTO granted the generic pharmaceutical companies' request and scheduled review in mid-2016. In light of these petitions, the district court in the consolidated lawsuit stayed the case with respect to all parties. We believe the Effient patents are valid and enforceable against these generic manufacturers. However, it is not possible to determine the outcome of the proceedings, and accordingly, we can provide no assurance that we will prevail. We expect a loss of exclusivity for Effient would result in a rapid and severe decline in future revenues for the product in the relevant market. Actos ® Product Liability Litigation We have been named along with Takeda Chemical Industries, Ltd., and Takeda affiliates (collectively, Takeda) as a defendant in approximately 6,500 product liability cases in the U.S. related to the diabetes medication Actos, which we co-promoted with Takeda in the U.S. from 1999 until 2006. In general, plaintiffs in these actions allege that Actos caused or contributed to their bladder cancer. Almost all of the active cases have been consolidated in federal multi-district litigation (MDL) in the Western District of Louisiana or are pending in a coordinated state court proceeding in California or a coordinated state court proceeding in Illinois. In April 2015, Takeda announced they will pay approximately $2.4 billion to resolve the vast majority of the U.S. product liability lawsuits involving Actos, including the case of Allen, et al. v. Takeda Pharmaceuticals, et al., no. 6:12-md-00064, in which a judgment of approximately $28 million was entered against Takeda and a judgment of approximately $9 million was entered against us. In September 2015, Takeda announced that more than 96 percent of eligible claimants have opted into the resolution program that was announced in April 2015. Takeda is now evaluating the submissions to determine whether they satisfy various criteria specified under the terms of the resolution program. Takeda expects the resolution program to become effective upon completion of that review. Although the vast majority of U.S. product liability lawsuits involving Actos are included in the resolution program announced in April 2015, there may be additional cases pending against Takeda and us following completion of the resolution program. Our agreement with Takeda calls for Takeda to defend and indemnify us against our losses and expenses with respect to the U.S. litigation arising out of the manufacture, use, or sale of Actos and other related expenses in accordance with the terms of the agreement. We believe we are entitled to full indemnification of our losses and expenses in the U.S. cases ; however, there can be no guarantee we will ultimately be successful in obtaining full indemnification. We are also named along with Takeda as a defendant in four purported product liability class actions in Canada related to Actos, including two in Ontario ( Casseres et al. v. Takeda Pharmaceutical North America, Inc., et al. and Carrier et al. v. Eli Lilly et al. ), one in Quebec ( Whyte et al. v. Eli Lilly et al. ), and one in Alberta ( Epp v. Takeda Canada et al. ). We promoted Actos in Canada until 2009. We believe these lawsuits are without merit, and we and Takeda are prepared to defend against them vigorously. Byetta Product Liability Litigation We are named as a defendant in approximately 510 Byetta product liability lawsuits in the U.S. involving approximately 1,035 plaintiffs. Approximately 110 of these lawsuits, covering about 630 plaintiffs, are filed in California state court and coordinated in a Los Angeles Superior Court. Approximately 395 lawsuits, covering about 400 plaintiffs, are filed in federal court, the majority of which are coordinated in a MDL in the U.S. District Court for the Southern District of California. The remaining approximately five lawsuits, representing about five plaintiffs, are in various state courts. Approximately 450 of the lawsuits, involving approximately 690 plaintiffs, contain allegations that Byetta caused or contributed to the plaintiffs' cancer (primarily pancreatic cancer or thyroid cancer). The federal and state trial courts granted summary judgment in favor of us and co-defendants on the claims alleging pancreatic cancer; those rulings are being appealed by the plaintiffs. We are aware of approximately 10 additional claimants who have not yet filed suit. These additional claims allege damages for pancreatic cancer or thyroid cancer. We believe these lawsuits and claims are without merit and are prepared to defend against them vigorously. Cymbalta ® Product Liability Litigation In October 2012, we were named as a defendant in a purported class-action lawsuit in the U.S. District Court for the Central District of California ( Saavedra et al v. Eli Lilly and Company ) involving Cymbalta. The plaintiffs, purporting to represent a class of all persons within the U.S. who purchased and/or paid for Cymbalta, asserted claims under the consumer protection statutes of four states, California, Massachusetts, Missouri, and New York, and sought declaratory, injunctive, and monetary relief for various alleged economic injuries arising from discontinuing treatment with Cymbalta. In December 2014, the district court denied the plaintiffs' motion for class certification. Plaintiffs filed a petition with the U.S. Court of Appeals for the Ninth Circuit requesting permission to file an interlocutory appeal of the denial of class certification, which was denied. Plaintiffs filed a second motion for certification under the consumer protection acts of New York and Massachusetts. The district court denied that motion for class certification in July 2015. The district court dismissed the suit and plaintiffs are appealing to the U.S. Court of Appeals for the Ninth Circuit. Additionally, we are named in approximately 140 lawsuits involving approximately 1,300 plaintiffs filed in various federal and state courts alleging injuries arising from discontinuation of treatment with Cymbalta. Counsel for plaintiffs in the federal court proceedings filed a petition seeking to have then-filed cases and an unspecified number of future cases coordinated into a federal MDL in the U.S. District Court for the Central District of California. In December 2014, the Judicial Panel on Multidistrict Litigation (JPML) denied the plaintiffs' petition for creation of an MDL. Plaintiffs’ counsel subsequently filed a second petition seeking MDL consolidation, which petition was denied by the JPML in October 2015. There have been approximately 35 individual and multi-plaintiff cases filed in California state court. Most of those cases have been centralized in a California Judicial Counsel Coordination Proceeding pending in Los Angeles. The first individual product liability cases were tried in August 2015 and resulted in defense verdicts against four plaintiffs. Two of those plaintiffs are appealing the verdicts against them. We believe all these Cymbalta lawsuits and claims are without merit and are prepared to defend against them vigorously. Prozac ® Product Liability Litigation We are named as a defendant in approximately 10 U.S. lawsuits primarily related to allegations that the antidepressant Prozac caused or contributed to birth defects in the children of women who ingested the drug during pregnancy. We are aware of approximately 515 additional claims related to birth defects, which have not yet been filed. We believe these lawsuits and claims are without merit and are prepared to defend against them vigorously. Brazil–Employee Litigation Our subsidiary in Brazil, Eli Lilly do Brasil Limitada (Lilly Brasil), is named in a lawsuit brought by the Labor Attorney for 15th Region in the Labor Court of Paulinia, State of Sao Paulo, Brazil, alleging possible harm to employees and former employees caused by exposure to heavy metals at a former Lilly manufacturing facility in Cosmopolis, Brazil, operated by the company between 1977 and 2003. The plaintiffs allege that some employees at the facility were exposed to benzene and heavy metals; however, Lilly Brasil maintains that these alleged contaminants were never used in the facility. In May 2014, the labor court judge ruled against Lilly Brasil. The judge's ruling orders Lilly Brasil to undertake several actions of unspecified financial impact, including paying lifetime medical insurance for the employees and contractors who worked at the Cosmopolis facility more than six months during the affected years and their children born during and after this period. While we cannot currently estimate the range of reasonably possible financial losses that could arise in the event we do not ultimately prevail in the litigation, the judge has estimated the total financial impact of the ruling to be approximately 1.0 billion Brazilian real (approximately $255 million as of December 31, 2015 ) plus interest. We strongly disagree with the decision and filed an appeal in May 2014. We are also named in approximately 25 lawsuits filed in the same court by individual former employees making similar claims. We believe these lawsuits are without merit and are prepared to defend against them vigorously. Product Liability Insurance Because of the nature of pharmaceutical products, it is possible that we could become subject to large numbers of product liability and related claims in the future. Due to a very restrictive market for product liability insurance, we are self-insured for product liability losses for all our currently marketed products.

Other Comprehensive Income (Los

Other Comprehensive Income (Loss)	12 Months Ended
	Dec. 31, 2015
Other Comprehensive Income (Loss), Tax [Abstract]
Comprehensive Income (Loss) [Text Block]	Note 16: Other Comprehensive Income (Loss) The following table summarizes the activity related to each component of other comprehensive income (loss): (Amounts presented net of taxes) Foreign Currency Translation Gains (Losses) Unrealized Net Gains (Losses) on Securities Defined Benefit Pension and Retiree Health Benefit Plans Effective Portion of Cash Flow Hedges Accumulated Other Comprehensive Loss Beginning balance at January 1, 2013 $ 426.8 $ 72.5 $ (4,195.2 ) $ (101.2 ) $ (3,797.1 ) Other comprehensive income (loss) before reclassifications 36.2 138.9 1,387.1 (86.5 ) 1,475.7 Net amount reclassified from accumulated other comprehensive loss — (6.2 ) 319.0 5.9 318.7 Net other comprehensive income (loss) 36.2 132.7 1,706.1 (80.6 ) 1,794.4 Balance at December 31, 2013 463.0 205.2 (2,489.1 ) (181.8 ) (2,002.7 ) Other comprehensive income (loss) before reclassifications (961.4 ) 105.2 (1,098.5 ) (15.2 ) (1,969.9 ) Net amount reclassified from accumulated other comprehensive loss — (210.7 ) 185.6 5.9 (19.2 ) Net other comprehensive income (loss) (961.4 ) (105.5 ) (912.9 ) (9.3 ) (1,989.1 ) Balance at December 31, 2014 (498.4 ) 99.7 (3,402.0 ) (191.1 ) (3,991.8 ) Other comprehensive income (loss) before reclassifications (861.8 ) 38.6 155.0 (36.9 ) (705.1 ) Net amount reclassified from accumulated other comprehensive loss — (128.2 ) 234.9 9.5 116.2 Net other comprehensive income (loss) (861.8 ) (89.6 ) 389.9 (27.4 ) (588.9 ) Ending Balance at December 31, 2015 $ (1,360.2 ) $ 10.1 $ (3,012.1 ) $ (218.5 ) $ (4,580.7 ) The tax effects on the net activity related to each component of other comprehensive income (loss) for the years ended December 31, were as follows: Tax (expense) benefit 2015 2014 2013 Foreign currency translation gains (losses) $ (2.0 ) $ — $ — Unrealized net gains (losses) on securities 48.5 56.7 (71.6 ) Defined benefit pension and retiree health benefit plans (183.0 ) 414.7 (886.1 ) Effective portion of cash flow hedges 14.6 5.2 43.2 Provision for income taxes related to other comprehensive income (loss) items $ (121.9 ) $ 476.6 $ (914.5 ) Except for the tax effects of foreign currency translation gains (losses) related to our euro-denominated notes (see Note 7), income taxes were not provided for foreign currency translation. Reclassifications Out of Accumulated Other Comprehensive Loss Details about Accumulated Other Comprehensive Loss Components Year Ended December 31, Affected Line Item in the Consolidated Statements of Operations 2015 2014 2013 Amortization of defined benefit items: Prior service benefits, net $ (80.7 ) $ (34.0 ) $ (31.9 ) (1) Actuarial losses 421.2 303.0 515.2 (1) Total before tax 340.5 269.0 483.3 Tax benefit (105.6 ) (83.4 ) (164.3 ) Income taxes Net of tax 234.9 185.6 319.0 Unrealized gains/losses on available-for-sale securities: Realized gains, net (209.3 ) (324.1 ) (12.0 ) Other—net, (income) expense Impairment losses 12.0 — 2.4 Other—net, (income) expense Total before tax (197.3 ) (324.1 ) (9.6 ) Tax expense 69.1 113.4 3.4 Income taxes Net of tax (128.2 ) (210.7 ) (6.2 ) Other, net of tax 9.5 5.9 5.9 Other—net, (income) expense Total reclassifications for the period (net of tax) $ 116.2 $ (19.2 ) $ 318.7 (1) These accumulated other comprehensive loss components are included in the computation of net periodic pension cost (see Note 14).

Other-Net, Expense (Income)

Other-Net, Expense (Income)	12 Months Ended
	Dec. 31, 2015
Nonoperating Income (Expense) [Abstract]
Other - Net, Expense (Income) [Text Block]	Note 17: Other–Net, (Income) Expense Other–net, (income) expense consisted of the following: 2015 2014 2013 Income related to termination of the exenatide collaboration with Amylin (Note 4) $ — $ — $ (495.4 ) Interest expense 161.2 148.8 160.1 Interest income (87.0 ) (121.0 ) (119.7 ) Debt extinguishment loss (Note 10) 166.7 — — Other income (341.5 ) (368.3 ) (63.9 ) Other–net, (income) expense $ (100.6 ) $ (340.5 ) $ (518.9 ) For the year ended December 31, 2015 , other income is primarily related to net gains on investments (Note 7). For the year ended December 31, 2014 , other income is primarily related to net gains on investments (Note 7) and income related to the transfer to Boehringer Ingelheim of our license rights to co-promote linagliptin and empagliflozin in certain countries (Note 4).

Segment Information

Segment Information	12 Months Ended
	Dec. 31, 2015
Segment Reporting [Abstract]
Segment Reporting Disclosure [Text Block]	Note 18: Segment Information We operate in two business segments—human pharmaceutical products and animal health. Our business segments are distinguished by the ultimate end user of the product—humans or animals. Performance is evaluated based on profit or loss from operations before income taxes. The accounting policies of the individual segments are the same as those described throughout the notes to the consolidated financial statements. Our human pharmaceutical products segment includes the discovery, development, manufacturing, marketing, and sales of human pharmaceutical products worldwide in the following therapeutic areas: endocrinology, neuroscience, oncology, cardiovascular, and other. We lost U.S. patent exclusivity for Cymbalta in December 2013 and Evista ® in March 2014, which resulted in the immediate entry of generic competitors and a rapid and severe decline in revenue. Our animal health segment, operating through our Elanco animal health division, includes the development, manufacturing, marketing, and sales of animal health products worldwide for both food and companion animals. Animal health products include Rumensin ® , Posilac ® , Tylan ® , Denagard ® , Maxiban ®, Optaflexx ® , and other products for livestock and poultry, as well as Trifexis ® , Comfortis ® , and other products for companion animals. The animal health segment amounts for the year ended December 31, 2015 include the results of operations from Novartis AH, which was acquired on January 1, 2015 (Note 3). Most of our pharmaceutical products are distributed through wholesalers that serve pharmacies, physicians and other health care professionals, and hospitals. For the years ended December 31, 2015 , 2014 , and 2013 , our three largest wholesalers each accounted for between 8 percent and 19 percent of consolidated total revenue. Further, they each accounted for between 9 percent and 16 percent of accounts receivable as of December 31, 2015 and 2014 . Animal health products are sold primarily to wholesale distributors. We manage our assets on a total company basis, not by operating segment, as the assets of the animal health business are intermixed with those of the pharmaceutical products business. Therefore, our chief operating decision maker does not review any asset information by operating segment and, accordingly, we do not report asset information by operating segment. We are exposed to the risk of changes in social, political, and economic conditions inherent in foreign operations, and our results of operations and the value of our foreign assets are affected by fluctuations in foreign currency exchange rates. The following table summarizes our revenue activity: 2015 2014 2013 Segment revenue—to unaffiliated customers: Human pharmaceutical products: Endocrinology: Humalog ® $ 2,841.9 $ 2,785.2 $ 2,611.2 Forteo ® 1,348.3 1,322.0 1,244.9 Humulin ® 1,307.4 1,400.1 1,315.8 Trajenta 356.8 328.8 249.2 Trulicity ® 248.7 10.2 — Evista 237.3 419.8 1,050.4 Other Endocrinology 696.4 672.9 832.9 Total Endocrinology 7,036.8 6,939.0 7,304.4 2015 2014 2013 Neuroscience: Cymbalta 1,027.6 1,614.7 5,084.4 Zyprexa ® 940.3 1,037.3 1,194.8 Strattera ® 784.0 738.5 709.2 Other Neuroscience 183.5 206.0 227.8 Total Neuroscience 2,935.4 3,596.5 7,216.2 Oncology: Alimta 2,493.1 2,792.0 2,703.0 Erbitux 485.0 373.3 373.7 Cyramza ® 383.8 75.6 — Other Oncology 147.9 152.1 191.8 Total Oncology 3,509.8 3,393.0 3,268.5 Cardiovascular: Cialis ® 2,310.7 2,291.0 2,159.4 Effient 523.0 522.2 508.7 Other Cardiovascular 234.3 240.3 255.1 Total Cardiovascular 3,068.0 3,053.5 2,923.2 Other pharmaceuticals 227.7 287.0 249.3 Total human pharmaceutical products 16,777.7 17,269.0 20,961.6 Animal health 3,181.0 2,346.6 2,151.5 Revenue $ 19,958.7 $ 19,615.6 $ 23,113.1 Segment profits: Human pharmaceutical products $ 4,026.7 $ 3,604.6 $ 5,521.0 Animal health 597.9 621.8 605.6 Total segment profits $ 4,624.6 $ 4,226.4 $ 6,126.6 Reconciliation of total segment profits to consolidated income before taxes: Segment profits $ 4,624.6 $ 4,226.4 $ 6,126.6 Other profits (losses): Inventory fair value adjustment related to Novartis AH (Note 3) (153.0 ) — — Acquired in-process research and development (Notes 3 and 4) (535.0 ) (200.2 ) (57.1 ) Asset impairment, restructuring, and other special charges (Note 5) (367.7 ) (468.7 ) (120.6 ) Debt repurchase charges, net (1) (Note 10) (152.7 ) — — Amortization of intangible assets (2) (Note 8) (626.2 ) (530.2 ) (555.0 ) Income related to transfer of linagliptin and empagliflozin rights in certain countries to Boehringer Ingelheim (Note 4) — 92.0 — U.S. Branded Prescription Drug Fee — (119.0 ) — Income related to termination of the exenatide collaboration with Amylin Pharmaceuticals, Inc. (Note 4) — — 495.4 Consolidated income before taxes $ 2,790.0 $ 3,000.3 $ 5,889.3 (1) We recognized pretax net charges of $152.7 million for the year ended December 31, 2015 , attributable to the debt extinguishment loss of $166.7 million from the purchase and redemption of certain fixed-rate notes, partially offset by net gains from non-hedging interest rate swaps and foreign currency transactions associated with the related issuance of euro-denominated notes. (2) In 2015, the measurement of segment profitability was changed to exclude certain amortization of intangible assets. The prior periods have been adjusted to conform with the 2015 presentation. Depreciation and software amortization expense included in our segment profits was as follows: 2015 2014 2013 Human pharmaceutical products $ 720.7 $ 790.0 $ 838.8 Animal health 80.8 58.8 51.8 Total depreciation expense included in segment profits $ 801.5 $ 848.8 $ 890.6 For internal management reporting presented to the chief operating decision maker, certain costs are fully allocated to our human pharmaceutical products segment and therefore are not reflected in the animal health segment's profit. Such items include costs associated with treasury-related financing, global administrative services, certain acquisition-related transaction costs, and certain manufacturing costs. 2015 2014 2013 Geographic Information Revenue—to unaffiliated customers (1) : United States $ 10,097.4 $ 9,134.1 $ 12,889.7 Europe 3,943.6 4,506.7 4,338.4 Japan 2,033.1 2,027.1 2,063.8 Other foreign countries 3,884.6 3,947.7 3,821.2 Revenue $ 19,958.7 $ 19,615.6 $ 23,113.1 Long-lived assets (2) : United States $ 4,576.8 $ 4,566.2 $ 4,649.6 Europe 2,306.4 2,401.5 2,469.7 Japan 89.2 80.4 81.1 Other foreign countries 1,724.2 1,499.1 1,540.9 Long-lived assets $ 8,696.6 $ 8,547.2 $ 8,741.3 (1) Revenue is attributed to the countries based on the location of the customer. (2) Long-lived assets consist of property and equipment, net, and certain sundry assets.

Selected Quarterly Data (Notes)

Selected Quarterly Data (Notes)	12 Months Ended
	Dec. 31, 2015
Quarterly Financial Information Disclosure [Abstract]
Quarterly Financial Information [Text Block]	Note 19: Selected Quarterly Data (unaudited) 2015 Fourth Third Second First Revenue $ 5,375.6 $ 4,959.7 $ 4,978.7 $ 4,644.7 Cost of sales 1,389.2 1,236.9 1,218.4 1,192.7 Operating expenses (1) 3,242.6 2,719.1 2,804.9 2,562.8 Acquired in-process research and development 199.0 — 80.0 256.0 Asset impairment, restructuring, and other special charges 144.9 42.4 72.4 108.0 Other—net, (income) expense (44.7 ) (86.5 ) 123.3 (92.7 ) Income before income taxes 444.6 1,047.8 679.7 617.9 Net income 478.4 799.7 600.8 529.5 Earnings per share—basic 0.45 0.75 0.57 0.50 Earnings per share—diluted 0.45 0.75 0.56 0.50 Dividends paid per share 0.50 0.50 0.50 0.50 Common stock closing prices: High 87.52 89.98 86.59 76.36 Low 76.98 78.26 70.89 68.41 2014 Fourth Third Second First Revenue $ 5,121.3 $ 4,875.6 $ 4,935.6 $ 4,683.1 Cost of sales 1,253.1 1,267.0 1,189.7 1,222.7 Operating expenses (1) 2,985.6 2,915.3 2,859.3 2,594.2 Acquired in-process research and development 105.2 95.0 — — Asset impairment, restructuring, and other special charges 401.0 36.3 — 31.4 Other—net, (income) expense (137.2 ) (93.5 ) (53.8 ) (56.0 ) Income before income taxes 513.6 655.5 940.4 890.8 Net income 428.5 500.6 733.5 727.9 Earnings per share—basic 0.40 0.47 0.68 0.68 Earnings per share—diluted 0.40 0.47 0.68 0.68 Dividends paid per share 0.49 0.49 0.49 0.49 Common stock closing prices: High 72.83 66.59 63.10 59.85 Low 61.90 60.35 58.21 50.73 (1) Includes research and development and marketing, selling, and administrative expenses. Our common stock is listed on the New York Stock Exchange (NYSE), NYSE Euronext, and SIX Swiss Exchange.

Summary of Significant Accoun27

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2015
Accounting Policies [Abstract]
Cash and Cash Equivalents, Policy [Policy Text Block]	We consider all highly liquid investments with a maturity of three months or less from the date of purchase to be cash equivalents. The cost of these investments approximates fair value.
Inventory, Policy [Policy Text Block]	We state all inventories at the lower of cost or market. We use the last-in, first-out (LIFO) method for the majority of our inventories located in the continental U.S. Other inventories are valued by the first-in, first-out (FIFO) method. FIFO cost approximates current replacement cost.
Investment, Policy [Policy Text Block]	Substantially all of our investments in debt and marketable equity securities are classified as available-for-sale. Investment securities with maturity dates of less than one year from the date of the balance sheet are classified as short-term. Available-for-sale securities are carried at fair value with the unrealized gains and losses, net of tax, reported in other comprehensive income (loss). The credit portion of unrealized losses on our debt securities considered to be other-than-temporary is recognized in earnings. The remaining portion of the other-than-temporary impairment on our debt securities is then recorded, net of tax, in other comprehensive income (loss). The entire amount of other-than-temporary impairment on our equity securities is recognized in earnings. We do not evaluate cost-method investments for impairment unless there is an indicator of impairment. We review these investments for indicators of impairment on a regular basis. Investments in companies over which we have significant influence but not a controlling interest are accounted for using the equity method with our share of earnings or losses reported in other–net, (income) expense. We own no investments that are considered to be trading securities.
Derivatives, Policy [Policy Text Block]	We may enter into forward contracts and designate them as cash flow hedges to limit the potential volatility of earnings and cash flow associated with forecasted sales of available-for-sale securities. We also may enter into forward-starting interest rate swaps, which we designate as cash flow hedges, as part of any anticipated future debt issuances in order to reduce the risk of cash flow volatility from future changes in interest rates. Upon completion of a debt issuance and termination of the swap, the change in fair value of these instruments is recorded as part of other comprehensive income (loss) and is amortized to interest expense over the life of the underlying debt. In the normal course of business, our operations are exposed to fluctuations in interest rates which can vary the costs of financing, investing, and operating. We address a portion of these risks through a controlled program of risk management that includes the use of derivative financial instruments. The objective of controlling these risks is to limit the impact of fluctuations in interest rates on earnings. Our primary interest-rate risk exposure results from changes in short-term U.S. dollar interest rates. In an effort to manage interest-rate exposures, we strive to achieve an acceptable balance between fixed- and floating-rate debt and investment positions and may enter into interest rate swaps or collars to help maintain that balance. Interest rate swaps or collars that convert our fixed-rate debt to a floating rate are designated as fair value hedges of the underlying instruments. Interest rate swaps or collars that convert floating-rate debt to a fixed rate are designated as cash flow hedges. Interest expense on the debt is adjusted to include the payments made or received under the swap agreements. Cash proceeds from or payments to counterparties resulting from the termination of interest rate swaps are classified as operating activities in our consolidated statement of cash flows. Our derivative activities are initiated within the guidelines of documented corporate risk-management policies and offset losses and gains on the assets, liabilities, and transactions being hedged. Management reviews the correlation and effectiveness of our derivatives on a quarterly basis. For derivative contracts that are designated and qualify as fair value hedges, the derivative instrument is marked to market with gains and losses recognized currently in income to offset the respective losses and gains recognized on the underlying exposure. For derivative contracts that are designated and qualify as cash flow hedges, the effective portion of gains and losses on these contracts is reported as a component of accumulated other comprehensive loss and reclassified into earnings in the same period the hedged transaction affects earnings. Hedge ineffectiveness is immediately recognized in earnings. Derivative contracts that are not designated as hedging instruments are recorded at fair value with the gain or loss recognized in current earnings during the period of change. We may enter into foreign currency forward or option contracts to reduce the effect of fluctuating currency exchange rates (principally the euro, the British pound, and the Japanese yen). Foreign currency derivatives used for hedging are put in place using the same or like currencies and duration as the underlying exposures. Forward and option contracts are principally used to manage exposures arising from subsidiary trade and loan payables and receivables denominated in foreign currencies. These contracts are recorded at fair value with the gain or loss recognized in other–net, (income) expense. We may enter into foreign currency forward and option contracts and currency swaps as fair value hedges of firm commitments.
Goodwill and Intangible Assets, Policy [Policy Text Block]	The costs of acquired IPR&D projects acquired directly in a transaction other than a business combination are capitalized if the projects have an alternative future use; otherwise, they are expensed immediately. The fair values of acquired IPR&D projects acquired in business combinations are capitalized as other intangible assets. Several methods may be used to determine the estimated fair value of other intangibles acquired in a business combination. We utilize the “income method,” which is a Level 3 fair value measurement and applies a probability weighting that considers the risk of development and commercialization to the estimated future net cash flows that are derived from projected revenues and estimated costs. These projections are based on factors such as relevant market size, patent protection, historical pricing of similar products, and expected industry trends. The estimated future net cash flows are then discounted to the present value using an appropriate discount rate. This analysis is performed for each asset independently. The acquired IPR&D assets are treated as indefinite-lived intangible assets until completion or abandonment of the projects, at which time the assets are tested for impairment and amortized over the remaining useful life or written off, as appropriate. Other indefinite-lived intangible assets are reviewed for impairment at least annually and when impairment indicators are present. When required, a comparison of fair value to the carrying amount of assets is performed to determine the amount of any impairment. When determining the fair value of indefinite-lived acquired IPR&D assets for impairment testing purposes, we utilize the "income method" discussed above. Finite-lived intangible assets are reviewed for impairment when an indicator of impairment is present. For transactions other than a business combination, we capitalize milestone payments incurred at or after the product has obtained regulatory approval for marketing. Goodwill results from excess consideration in a business combination over the fair value of identifiable net assets acquired. Goodwill is not amortized but is reviewed for impairment at least annually and when impairment indicators are present. When required, a comparison of implied fair value to the carrying amount of goodwill is performed to determine the amount of any impairment.
Property, Plant and Equipment, Policy [Policy Text Block]	Property and equipment is stated on the basis of cost. Provisions for depreciation of buildings and equipment are computed generally by the straight-line method at rates based on their estimated useful lives ( 12 to 50 years for buildings and 3 to 25 years for equipment). We review the carrying value of long-lived assets for potential impairment on a periodic basis and whenever events or changes in circumstances indicate the carrying value of an asset may not be recoverable. Impairment is determined by comparing projected undiscounted cash flows to be generated by the asset to its carrying value. If an impairment is identified, a loss is recorded equal to the excess of the asset’s net book value over its fair value, and the cost basis is adjusted.
Commitments and Contingencies, Policy [Policy Text Block]	Litigation accruals, environmental liabilities, and the related estimated insurance recoverables are reflected on a gross basis as liabilities and assets, respectively, on our consolidated balance sheets. With respect to the product liability claims currently asserted against us, we have accrued for our estimated exposures to the extent they are both probable and reasonably estimable based on the information available to us. We accrue for certain product liability claims incurred but not filed to the extent we can formulate a reasonable estimate of their costs. We estimate these expenses based primarily on historical claims experience and data regarding product usage. Legal defense costs expected to be incurred in connection with significant product liability loss contingencies are accrued when both probable and reasonably estimable.
Revenue Recognition, Policy [Policy Text Block]	Revenue recognition We recognize revenue from sales of products at the time title of goods passes to the buyer and the buyer assumes the risks and rewards of ownership. Provisions for returns, discounts, and rebates are established in the same period the related sales are recognized. In arrangements involving the delivery of more than one element (e.g., research and development), marketing and selling, manufacturing, and distribution), each required deliverable is evaluated to determine whether it qualifies as a separate unit of accounting. Our determination is based on whether the deliverable has "standalone value" to the customer. If a deliverable does not qualify as a separate unit of accounting, it is combined with the other applicable undelivered item(s) within the arrangement and these combined deliverables are treated as a single unit of accounting. The arrangement's consideration that is fixed or determinable is then allocated to each separate unit of accounting based on the relative selling price of each deliverable. Initial fees we receive in collaborative and other similar arrangements from the partnering of our compounds under development are generally deferred and amortized into income through the expected product approval date. Initial fees may also be received for out-licensing agreements that include both an out-license of our marketing rights to commercialized products and a related commitment to supply the products. When we have determined that the marketing rights do not have standalone value, the initial fees received are generally deferred and amortized to income as net product sales over the term of the supply agreement. Royalty revenue from licensees, which is based on third-party sales of licensed products and technology, is recorded as earned in accordance with the contract terms when third-party sales can be reasonably measured and collection of the funds is reasonably assured. This royalty revenue is included in collaboration and other revenue. Profit-sharing due from our collaboration partners, which is based upon gross margins reported to us by our partners, is recognized as collaboration and other revenue as earned. Developmental milestone payments earned by us are generally recorded in other–net, (income) expense. We immediately recognize the full amount of developmental milestone payments due to us upon the achievement of the milestone event if the event is objectively determinable and the milestone is substantive in its entirety. A milestone is considered substantive if the consideration earned 1) relates solely to past performance, 2) is commensurate with the enhancement in the pharmaceutical or animal health product's value associated with the achievement of the important event in its development life cycle, and 3) is reasonable relative to all of the deliverables and payment terms within the arrangement. If a milestone payment to us is part of a multiple-element commercialization arrangement and is triggered by the initiation of the commercialization period (e.g., regulatory approval for marketing or launch of the product) or the achievement of a sales-based threshold, we amortize the payment to income as we perform under the terms of the arrangement. See Note 4 for specific agreement details.
Research and Development Expense, Policy [Policy Text Block]	Research and development expenses and acquired in-process research and development Research and development expenses include the following: • Research and development costs, which are expensed as incurred. • Milestone payment obligations incurred prior to regulatory approval of the product, which are accrued when the event requiring payment of the milestone occurs. Acquired in-process research and development (IPR&D) expense includes the initial costs of IPR&D projects, acquired directly in a transaction other than a business combination, that do not have an alternative future use.
Income Tax, Policy [Policy Text Block]	Deferred taxes are recognized for the future tax effects of temporary differences between financial and income tax reporting based on enacted tax laws and rates. Federal income taxes are provided on the portion of the income of foreign subsidiaries that is expected to be remitted to the U.S. and be taxable. When foreign earnings are expected to be indefinitely reinvested outside the U.S., no accrual for U.S. income taxes is provided. We recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by the taxing authorities, based on the technical merits of the position. The tax benefits recognized in the financial statements from such a position are measured based on the largest benefit that has a greater than 50 percent likelihood of being realized upon ultimate resolution.
Earnings Per Share, Policy [Policy Text Block]	Earnings per share We calculate basic earnings per share (EPS) based on the weighted-average number of common shares outstanding and incremental shares from potential participating securities. We calculate diluted EPS based on the weighted-average number of common shares outstanding, including incremental shares from our stock-based compensation programs.
Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]	We recognize the fair value of stock-based compensation as expense over the requisite service period of the individual grantees, which generally equals the vesting period. We provide newly issued shares of our common stock and treasury stock to satisfy the issuance of PA, SVA, and RSU shares. We classify tax benefits resulting from tax deductions in excess of the compensation cost recognized for stock-based compensation as a financing cash flow in the consolidated statements of cash flows.
Foreign Currency Transactions and Translations Policy [Policy Text Block]	Foreign Currency Translation Operations in our subsidiaries outside the United States (U.S.) are recorded in the functional currency of each subsidiary which is determined by a review of the environment where each subsidiary primarily generates and expends cash. The results of operations for our subsidiaries outside the U.S. are translated from functional currencies into U.S. dollars using the weighted average currency rate for the period. Assets and liabilities are translated using the period end exchange rates. The U.S. dollar effects that arise from translating the net assets of these subsidiaries are recorded in other comprehensive income (loss).

Acquisitions Acquisitions (Poli

Acquisitions Acquisitions (Policies)	12 Months Ended
	Dec. 31, 2015
Business Combinations [Abstract]
Business Combinations Policy [Policy Text Block]	These transactions were accounted for as business combinations under the acquisition method of accounting. See Note 4 for additional information related to the Erbitux arrangement. The assets acquired and liabilities assumed were recorded at their respective fair values as of the acquisition date in our consolidated financial statements. The determination of estimated fair value required management to make significant estimates and assumptions. The excess of the purchase price over the fair value of the acquired net assets, where applicable, has been recorded as goodwill. The results of operations of these acquisitions are included in our consolidated financial statements from the date of acquisition.

Inventories Inventories (Polici

Inventories Inventories (Policies) (Policies)	12 Months Ended
	Dec. 31, 2015
Inventory Disclosure [Abstract]
Inventory, Policy [Policy Text Block]	We state all inventories at the lower of cost or market. We use the last-in, first-out (LIFO) method for the majority of our inventories located in the continental U.S. Other inventories are valued by the first-in, first-out (FIFO) method. FIFO cost approximates current replacement cost.

Financial Instruments (Policies

Financial Instruments (Policies)	12 Months Ended
	Dec. 31, 2015
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Concentration Risk, Credit Risk, Policy [Policy Text Block]	Financial instruments that potentially subject us to credit risk consist principally of trade receivables and interest-bearing investments. Wholesale distributors of life-science products account for a substantial portion of trade receivables; collateral is generally not required. The risk associated with this concentration is mitigated by our ongoing credit-review procedures and insurance. A large portion of our cash is held by a few major financial institutions. We monitor our exposures with these institutions and do not expect any of these institutions to fail to meet their obligations. Major financial institutions represent the largest component of our investments in corporate debt securities. In accordance with documented corporate policies, we monitor the amount of credit exposure to any one financial institution or corporate issuer. We are exposed to credit-related losses in the event of nonperformance by counterparties to risk-management instruments but do not expect any counterparties to fail to meet their obligations given their high credit ratings.
Derivatives, Policy [Policy Text Block]	We may enter into forward contracts and designate them as cash flow hedges to limit the potential volatility of earnings and cash flow associated with forecasted sales of available-for-sale securities. We also may enter into forward-starting interest rate swaps, which we designate as cash flow hedges, as part of any anticipated future debt issuances in order to reduce the risk of cash flow volatility from future changes in interest rates. Upon completion of a debt issuance and termination of the swap, the change in fair value of these instruments is recorded as part of other comprehensive income (loss) and is amortized to interest expense over the life of the underlying debt. In the normal course of business, our operations are exposed to fluctuations in interest rates which can vary the costs of financing, investing, and operating. We address a portion of these risks through a controlled program of risk management that includes the use of derivative financial instruments. The objective of controlling these risks is to limit the impact of fluctuations in interest rates on earnings. Our primary interest-rate risk exposure results from changes in short-term U.S. dollar interest rates. In an effort to manage interest-rate exposures, we strive to achieve an acceptable balance between fixed- and floating-rate debt and investment positions and may enter into interest rate swaps or collars to help maintain that balance. Interest rate swaps or collars that convert our fixed-rate debt to a floating rate are designated as fair value hedges of the underlying instruments. Interest rate swaps or collars that convert floating-rate debt to a fixed rate are designated as cash flow hedges. Interest expense on the debt is adjusted to include the payments made or received under the swap agreements. Cash proceeds from or payments to counterparties resulting from the termination of interest rate swaps are classified as operating activities in our consolidated statement of cash flows. Our derivative activities are initiated within the guidelines of documented corporate risk-management policies and offset losses and gains on the assets, liabilities, and transactions being hedged. Management reviews the correlation and effectiveness of our derivatives on a quarterly basis. For derivative contracts that are designated and qualify as fair value hedges, the derivative instrument is marked to market with gains and losses recognized currently in income to offset the respective losses and gains recognized on the underlying exposure. For derivative contracts that are designated and qualify as cash flow hedges, the effective portion of gains and losses on these contracts is reported as a component of accumulated other comprehensive loss and reclassified into earnings in the same period the hedged transaction affects earnings. Hedge ineffectiveness is immediately recognized in earnings. Derivative contracts that are not designated as hedging instruments are recorded at fair value with the gain or loss recognized in current earnings during the period of change. We may enter into foreign currency forward or option contracts to reduce the effect of fluctuating currency exchange rates (principally the euro, the British pound, and the Japanese yen). Foreign currency derivatives used for hedging are put in place using the same or like currencies and duration as the underlying exposures. Forward and option contracts are principally used to manage exposures arising from subsidiary trade and loan payables and receivables denominated in foreign currencies. These contracts are recorded at fair value with the gain or loss recognized in other–net, (income) expense. We may enter into foreign currency forward and option contracts and currency swaps as fair value hedges of firm commitments.
Cash and Cash Equivalents, Policy [Policy Text Block]	We consider all highly liquid investments with a maturity of three months or less from the date of purchase to be cash equivalents. The cost of these investments approximates fair value.
Investment, Policy [Policy Text Block]	Substantially all of our investments in debt and marketable equity securities are classified as available-for-sale. Investment securities with maturity dates of less than one year from the date of the balance sheet are classified as short-term. Available-for-sale securities are carried at fair value with the unrealized gains and losses, net of tax, reported in other comprehensive income (loss). The credit portion of unrealized losses on our debt securities considered to be other-than-temporary is recognized in earnings. The remaining portion of the other-than-temporary impairment on our debt securities is then recorded, net of tax, in other comprehensive income (loss). The entire amount of other-than-temporary impairment on our equity securities is recognized in earnings. We do not evaluate cost-method investments for impairment unless there is an indicator of impairment. We review these investments for indicators of impairment on a regular basis. Investments in companies over which we have significant influence but not a controlling interest are accounted for using the equity method with our share of earnings or losses reported in other–net, (income) expense. We own no investments that are considered to be trading securities.

Goodwill and Other Intangibles

Goodwill and Other Intangibles Goodwill and Other Intangibles (Policies)	12 Months Ended
	Dec. 31, 2015
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill and Intangible Assets, Policy [Policy Text Block]	The costs of acquired IPR&D projects acquired directly in a transaction other than a business combination are capitalized if the projects have an alternative future use; otherwise, they are expensed immediately. The fair values of acquired IPR&D projects acquired in business combinations are capitalized as other intangible assets. Several methods may be used to determine the estimated fair value of other intangibles acquired in a business combination. We utilize the “income method,” which is a Level 3 fair value measurement and applies a probability weighting that considers the risk of development and commercialization to the estimated future net cash flows that are derived from projected revenues and estimated costs. These projections are based on factors such as relevant market size, patent protection, historical pricing of similar products, and expected industry trends. The estimated future net cash flows are then discounted to the present value using an appropriate discount rate. This analysis is performed for each asset independently. The acquired IPR&D assets are treated as indefinite-lived intangible assets until completion or abandonment of the projects, at which time the assets are tested for impairment and amortized over the remaining useful life or written off, as appropriate. Other indefinite-lived intangible assets are reviewed for impairment at least annually and when impairment indicators are present. When required, a comparison of fair value to the carrying amount of assets is performed to determine the amount of any impairment. When determining the fair value of indefinite-lived acquired IPR&D assets for impairment testing purposes, we utilize the "income method" discussed above. Finite-lived intangible assets are reviewed for impairment when an indicator of impairment is present. For transactions other than a business combination, we capitalize milestone payments incurred at or after the product has obtained regulatory approval for marketing. Goodwill results from excess consideration in a business combination over the fair value of identifiable net assets acquired. Goodwill is not amortized but is reviewed for impairment at least annually and when impairment indicators are present. When required, a comparison of implied fair value to the carrying amount of goodwill is performed to determine the amount of any impairment.

Property and Equipment Property

Property and Equipment Property and Equipment (Policies)	12 Months Ended
	Dec. 31, 2015
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment, Policy [Policy Text Block]	Property and equipment is stated on the basis of cost. Provisions for depreciation of buildings and equipment are computed generally by the straight-line method at rates based on their estimated useful lives ( 12 to 50 years for buildings and 3 to 25 years for equipment). We review the carrying value of long-lived assets for potential impairment on a periodic basis and whenever events or changes in circumstances indicate the carrying value of an asset may not be recoverable. Impairment is determined by comparing projected undiscounted cash flows to be generated by the asset to its carrying value. If an impairment is identified, a loss is recorded equal to the excess of the asset’s net book value over its fair value, and the cost basis is adjusted.

Stock-Based Compensation Stock-

Stock-Based Compensation Stock-Based Compensation (Policies)	12 Months Ended
	Dec. 31, 2015
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]	We recognize the fair value of stock-based compensation as expense over the requisite service period of the individual grantees, which generally equals the vesting period. We provide newly issued shares of our common stock and treasury stock to satisfy the issuance of PA, SVA, and RSU shares. We classify tax benefits resulting from tax deductions in excess of the compensation cost recognized for stock-based compensation as a financing cash flow in the consolidated statements of cash flows.

Income Taxes Income Taxes (Poli

Income Taxes Income Taxes (Policies)	12 Months Ended
	Dec. 31, 2015
Income Tax Disclosure [Abstract]
Income Tax, Policy [Policy Text Block]	Deferred taxes are recognized for the future tax effects of temporary differences between financial and income tax reporting based on enacted tax laws and rates. Federal income taxes are provided on the portion of the income of foreign subsidiaries that is expected to be remitted to the U.S. and be taxable. When foreign earnings are expected to be indefinitely reinvested outside the U.S., no accrual for U.S. income taxes is provided. We recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by the taxing authorities, based on the technical merits of the position. The tax benefits recognized in the financial statements from such a position are measured based on the largest benefit that has a greater than 50 percent likelihood of being realized upon ultimate resolution.

Contingencies Contingencies (Po

Contingencies Contingencies (Policies)	12 Months Ended
	Dec. 31, 2015
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies, Policy [Policy Text Block]	Litigation accruals, environmental liabilities, and the related estimated insurance recoverables are reflected on a gross basis as liabilities and assets, respectively, on our consolidated balance sheets. With respect to the product liability claims currently asserted against us, we have accrued for our estimated exposures to the extent they are both probable and reasonably estimable based on the information available to us. We accrue for certain product liability claims incurred but not filed to the extent we can formulate a reasonable estimate of their costs. We estimate these expenses based primarily on historical claims experience and data regarding product usage. Legal defense costs expected to be incurred in connection with significant product liability loss contingencies are accrued when both probable and reasonably estimable.

Summary of Significant Accoun36

Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2015
Accounting Policies [Abstract]
Inventory Disclosure [Text Block]	Note 6: Inventories We state all inventories at the lower of cost or market. We use the last-in, first-out (LIFO) method for the majority of our inventories located in the continental U.S. Other inventories are valued by the first-in, first-out (FIFO) method. FIFO cost approximates current replacement cost. Inventories at December 31 consisted of the following: 2015 2014 Finished products $ 1,053.4 $ 838.0 Work in process 2,058.1 1,715.4 Raw materials and supplies 403.0 315.0 Total (approximates replacement cost) 3,514.5 2,868.4 Reduction to LIFO cost (68.7 ) (128.4 ) Inventories $ 3,445.8 $ 2,740.0 Inventories valued under the LIFO method comprised $1.30 billion and $1.09 billion of total inventories at December 31, 2015 and 2014 , respectively.
Property, Plant and Equipment Disclosure [Text Block]	Note 9: Property and Equipment Property and equipment is stated on the basis of cost. Provisions for depreciation of buildings and equipment are computed generally by the straight-line method at rates based on their estimated useful lives ( 12 to 50 years for buildings and 3 to 25 years for equipment). We review the carrying value of long-lived assets for potential impairment on a periodic basis and whenever events or changes in circumstances indicate the carrying value of an asset may not be recoverable. Impairment is determined by comparing projected undiscounted cash flows to be generated by the asset to its carrying value. If an impairment is identified, a loss is recorded equal to the excess of the asset’s net book value over its fair value, and the cost basis is adjusted. At December 31, property and equipment consisted of the following: 2015 2014 Land $ 220.6 $ 205.2 Buildings 6,786.5 6,516.2 Equipment 7,988.5 7,609.7 Construction in progress 1,665.3 1,698.2 16,660.9 16,029.3 Less accumulated depreciation (8,607.4 ) (8,065.4 ) Property and equipment, net $ 8,053.5 $ 7,963.9 Depreciation expense related to property and equipment and rental expense for all leases, including contingent rentals (not material), was as follows: 2015 2014 2013 Depreciation expense $ 717.6 $ 759.1 $ 774.8 Rental expense 225.7 227.3 227.2 Capitalized interest costs were not material for the years ended December 31, 2015 , 2014 , and 2013 . Assets under capital leases included in property and equipment, net on the consolidated balance sheets, capital lease obligations entered into, and future minimum rental commitments are not material.

Implementation of New Financi37

Implementation of New Financial Accounting Pronouncements Implementation of New Financial Accounting Pronouncements (Tables)	12 Months Ended
	Dec. 31, 2015
New Accounting Pronouncement, Early Adoption [Line Items]
New Accounting Pronouncement, Early Adoption [Table Text Block]	The following table provides a brief description of an accounting standard that has been adopted: Standard Description Effective Date Effect on the financial statements or other significant matters Accounting Standards Update 2015-17, Income Taxes: Balance Sheet Classification of Deferred Taxes This standard simplifies the presentation of deferred income taxes and requires that deferred tax liabilities and assets be classified as noncurrent in a classified statement of financial position. An entity can apply this new standard either prospectively to all deferred tax liabilities and assets or retrospectively to all periods presented. We have adopted this standard for the annual period beginning on January 1, 2015. We applied this standard retrospectively. As a result of adopting this standard, all deferred tax liabilities and assets have been classified as noncurrent. The balance sheet as of December 31, 2014 was retrospectively adjusted which resulted in reductions to prepaid expenses and other of $251.5 million, sundry of $584.2 million, and deferred income tax liabilities of $1.47 billion. Other noncurrent liabilities as of December 31, 2014 were increased by $630.8 million as a result of the adoption of this standard.

Acquisitions Acquisitions (Tabl

Acquisitions Acquisitions (Tables)	12 Months Ended
	Dec. 31, 2015
Business Acquisition [Line Items]
Schedule of Research and Development Assets Acquired Other than Through Business Combination [Table Text Block]	The following table summarizes our product and other acquisitions which are discussed in detail below: Counterparty Compound(s) or Therapy Acquisition Month Phase of Development (1) Acquired IPR&D Expense Innovent Biologics, Inc. (Innovent) Monoclonal antibody targeting protein CD-20 Immuno-oncology molecule cMet monoclonal antibody March 2015 Pre-clinical (2) $ 56.0 Hanmi Pharmaceutical Co., Ltd. (Hanmi) BTK Inhibitor - HM71224 April 2015 Phase I 50.0 BioNTech AG (BioNTech) Cancer immunotherapies May 2015 Pre-clinical 30.0 Locemia Solutions Intranasal glucagon October 2015 Phase III 149.0 Undisclosed Technology collaboration December 2015 N/A 25.0 Halozyme Therapeutics, Inc. (Halozyme) Recombinant human hyaluronidase enzyme - rHuPH20 December 2015 N/A 25.0 Immunocore Limited (Immunocore) T cell-based cancer therapies July 2014 Pre-clinical 45.0 AstraZeneca UK Limited (AstraZeneca) Oral beta-secretase cleaving enzyme inhibitor - AZD3293 September 2014 Phase I 50.0 Adocia BioChaperone Lispro December 2014 Phase I 50.0 Arteaus Therapeutics Calcitonin gene-related peptide (CGRP) monoclonal antibody December 2013 Phase II 57.1 (1) The phase of development presented is as of the date of the arrangement. (2) Prior to acquisition, Innovent's monoclonal antibody targeting protein CD-20 had received investigational new drug approval in China to begin Phase I development.
Novartis Animal Health [Member]
Business Acquisition [Line Items]
Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]	The following table summarizes the amounts recognized for assets acquired and liabilities assumed as of the acquisition date: Estimated Fair Value at January 1, 2015 Inventories $ 380.2 Acquired in-process research and development 298.0 Marketed products (1) 1,953.0 Property and equipment 199.9 Assets held for sale (primarily the U.S. Sentinel rights) 422.7 Accrued retirement benefits (108.7 ) Deferred income taxes (60.1 ) Other assets and liabilities - net (73.0 ) Total identifiable net assets 3,012.0 Goodwill (2) 2,271.1 Total consideration transferred - net of cash acquired $ 5,283.1 (1) These intangible assets, which will be amortized to cost of sales on a straight-line basis over their estimated useful lives, are expected to have a weighted average useful life of 19 years . (2) The goodwill recognized from this acquisition is attributable primarily to expected synergies that we believe will result from combining the operations of Novartis AH with our legacy animal health business, future unidentified projects and products, and the assembled workforce of Novartis AH. Approximately $950 million of the goodwill associated with this acquisition is estimated to be deductible for tax purposes.
Business Acquisition, Pro Forma Information [Table Text Block]	The following unaudited pro forma financial information presents the combined consolidated results of our operations with Novartis AH as if the portion of Novartis AH that we retained after the sale to Virbac had been acquired as of January 1, 2014. We have adjusted the historical consolidated financial information to give effect to pro forma events that are directly attributable to the acquisition. The unaudited pro forma financial information is not necessarily indicative of what our consolidated results of operations would have been had we completed the acquisition at the beginning of 2014. In addition, the unaudited pro forma financial information does not attempt to project the future results of operations of our combined company. Unaudited Pro Forma Consolidated Results 2015 2014 Revenue $ 19,958.7 $ 20,696.7 Net income 2,518.1 2,127.9 Diluted earnings per share 2.36 1.98
Lohmann Animal Health [Member]
Business Acquisition [Line Items]
Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]	The following table summarizes the amounts recognized for assets acquired and liabilities assumed as of the acquisition date: Estimated Fair Value at April 30, 2014 Marketed products $ 275.4 Other intangible assets 23.9 Property and equipment 81.9 Deferred income taxes (92.7 ) Other assets and liabilities - net 51.1 Total identifiable net assets 339.6 Goodwill (1) 251.6 Total consideration transferred - net of cash acquired $ 591.2 (1) Goodwill associated with this acquisition is not deductible for tax purposes.

Collaborations (Tables)

Collaborations (Tables)	12 Months Ended
	Dec. 31, 2015
Erbitux Acquisition [Member]
Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]	The following table summarizes the preliminary amounts recognized for assets acquired and liabilities assumed as of the acquisition date: Estimated Fair Value at October 1, 2015 Marketed products (1) $ 602.1 Deferred tax asset 232.2 Deferred tax liability (228.2 ) Other assets and liabilities - net 57.2 Total identifiable net assets $ 663.3 Total consideration - contingent consideration liability (2) $ (663.3 ) (1) These intangible assets will be amortized to cost of sales using the straight-line method through the co-development period in North America as set forth in the original agreement, which was scheduled to expire in September 2018. (2) See Note 7 for discussion on the estimation of the contingent consideration liability.
Trajenta (BI) [Member]
Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions [Table Text Block]	The following table summarizes our revenue recognized with respect to the Trajenta family of products: 2015 2014 2013 Collaboration and other revenue $ 356.8 $ 328.8 $ 249.2
Diabetes Collaboration [Member]
Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions [Table Text Block]	The table below summarizes significant regulatory and commercialization events and milestones (received) paid for the compounds included in this collaboration: Product Family Product Status Milestones (Earned) Expensed (1) Milestones (Deferred) Capitalized (2) U.S. Europe Japan Year Amount Year Amount Trajenta (3) Launched 2011 Launched 2011 Launched 2011 2015 $ — 2015 $ — 2014 — 2014 — 2013 — 2013 — Cumulative (6) 446.4 Jardiance (4) Launched 2014 Launched 2014 Launched 2015 2015 — 2015 — 2014 — 2014 299.5 2013 97.2 2013 — Cumulative (6) 299.5 Basaglar Approved (5) Launched 2015 Launched 2015 2015 — 2015 — 2014 — 2014 (62.5 ) 2013 (50.0 ) 2013 — Cumulative (6) (62.5 ) (1) Milestones earned for Basaglar as a result of regulatory submissions were recorded as income in other-net, (income) expense. Milestones expensed for Jardiance as a result of regulatory submissions were recorded as research and development expenses. (2) In connection with the regulatory approvals of Basaglar in Europe and Japan, milestone payments received were recorded as deferred revenue and are being amortized through the term of the collaboration (2029) to collaboration and other revenue. In connection with the regulatory approvals of Trajenta and Jardiance, milestone payments made were capitalized as intangible assets and are being amortized through the term of the collaboration to cost of sales. (3) Jentadueto is included in the Trajenta family of product results. (4) Glyxambi and Synjardy are included in the Jardiance family of product results. (5) In September 2015, we entered into a settlement agreement to resolve patent infringement litigation filed by Sanofi-Aventis U.S. LLC (Sanofi), which markets Lantus ® (insulin glargine). As part of the settlement agreement, the parties agreed that Basaglar can be launched in the U.S. beginning on December 15, 2016. Basaglar received U.S. Food and Drug Administration (FDA) approval in December 2015. As a result of receiving FDA approval, we received $187.5 million in 2016, which was recorded as deferred revenue and will be amortized through the term of the collaboration to collaboration and other revenue upon product launch. (6) The cumulative amount represents the total amounts as of the end of the reporting period that have been (deferred) or capitalized since the start of this collaboration.
Erbitux [Member]
Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions [Table Text Block]	The following table summarizes our revenue recognized with respect to Erbitux: 2015 2014 2013 Net product revenues - BMS $ 23.3 $ 46.1 $ 58.5 Net product revenues - third party 152.3 — — Collaboration and other revenue 309.4 327.2 315.2 Revenue $ 485.0 $ 373.3 $ 373.7
Exenatide [Member]
Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions [Table Text Block]	The following table summarizes the revenue and other income recognized with respect to exenatide for the year ended December 31, 2013: 2013 Revenue $ 133.1 Income related to termination of the exenatide collaboration with Amylin (1) 495.4 (1) Presented in other-net, (income) expense.
Effient [Member]
Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions [Table Text Block]	We are in a collaborative arrangement with Daiichi Sankyo Co., Ltd. (Daiichi Sankyo) to develop, market, and promote Effient. Marketing rights for major territories are shown below. We and Daiichi Sankyo each have exclusive marketing rights in certain other territories. Territory Marketing Rights Selling Party U.S. Co-promotion Lilly Major European markets Co-promotion Pre-January 1, 2016, Lilly Post-January 1, 2016, Daiichi Sankyo Japan Exclusive Daiichi Sankyo The following table summarizes our revenue recognized with respect to Effient: 2015 2014 2013 Revenue $ 523.0 $ 522.2 $ 508.7
Selling, General and Administrative Expenses [Member]
Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions [Table Text Block]	The following table summarizes our aggregate amount of marketing, selling, and administrative expense associated with our commission and profit-sharing obligations for the collaborations and other arrangements described above: 2015 2014 2013 Marketing, selling, and administrative $ 213.2 $ 211.2 $ 203.7
Collaborative Arrangement [Member]
Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions [Table Text Block]	The following table summarizes our collaboration and other revenue recognized: 2015 2014 2013 Collaboration and other revenue $ 808.1 $ 788.4 $ 707.5

Asset Impairments, Restructur40

Asset Impairments, Restructuring, and Other Special Charges (Tables)	12 Months Ended
	Dec. 31, 2015
Extraordinary and Unusual Items [Abstract]
Schedule of Other Operating Cost and Expense, by Component [Table Text Block]	The components of the charges included in asset impairment, restructuring, and other special charges in our consolidated statements of operations are described below. 2015 2014 2013 Severance: Human pharmaceutical products $ 81.5 $ 225.5 $ 90.6 Animal health 59.5 — — Total severance 141.0 225.5 90.6 Asset impairment and other special charges: Human pharmaceutical products 24.6 204.4 30.0 Animal health 202.1 38.8 — Total asset impairment and other special charges 226.7 243.2 30.0 Asset impairment, restructuring, and other special charges $ 367.7 $ 468.7 $ 120.6

Inventories (Tables)

Inventories (Tables)	12 Months Ended
	Dec. 31, 2015
Inventory [Line Items]
Schedule of Inventory, Current [Table Text Block]	Inventories at December 31 consisted of the following: 2015 2014 Finished products $ 1,053.4 $ 838.0 Work in process 2,058.1 1,715.4 Raw materials and supplies 403.0 315.0 Total (approximates replacement cost) 3,514.5 2,868.4 Reduction to LIFO cost (68.7 ) (128.4 ) Inventories $ 3,445.8 $ 2,740.0

Financial Instruments (Tables)

Financial Instruments (Tables)	12 Months Ended
	Dec. 31, 2015
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Schedule of Cash Flow Hedges Included in Accumulated Other Comprehensive Income (Loss) [Table Text Block]	The effective portion of equity contracts and forward-starting interest rate swaps in designated cash flow hedging relationships recorded in other comprehensive income (loss) was as follows: 2015 2014 2013 Equity contracts $ — $ 149.6 $ (149.6 ) Forward-starting interest rate swaps (56.7 ) (164.7 ) 16.7
Fair Value, Liabilities Measured on Recurring and Nonrecurring Basis [Table Text Block]	The table below summarizes the contractual maturities of our investments in debt securities measured at fair value as of December 31, 2015 : Maturities by Period Total Within 1 Year After 1 Year Through 5 Years After 5 Years Through 10 Years After 10 Years Fair value of debt securities $ 3,631.8 $ 785.4 $ 2,516.8 $ 164.0 $ 165.6
Schedule of Derivatives Instruments Statements of Financial Performance and Financial Position, Location [Table Text Block]	The following effects of risk-management instruments were recognized in other–net, (income) expense: 2015 2014 2013 Fair value hedges: Effect from hedged fixed-rate debt $ (11.9 ) $ 156.9 $ (308.2 ) Effect from interest rate contracts 11.9 (156.9 ) 308.2 Cash flow hedges: Effective portion of losses on equity contracts reclassified from accumulated other comprehensive loss (1) — 129.0 — Effective portion of losses on interest rate contracts reclassified from accumulated other comprehensive loss 13.7 9.0 9.0 Net (gains) losses on foreign currency exchange contracts not designated as hedging instruments (28.2 ) (20.4 ) 15.4 (1) Realized gains on the sale of underlying equity securities recognized in other-net, (income) expense were $260.8 million during the year ended December 31, 2014 . There were no realized gains on the sale of underlying equity securities during the years ended December 31, 2015 and 2013 .
Fair Value, Assets Measured on Recurring Basis [Table Text Block]	The following tables summarize certain fair value information at December 31 for assets and liabilities measured at fair value on a recurring basis, as well as the carrying amount and amortized cost of certain other investments: Fair Value Measurements Using Description Carrying Amount Cost (1) Quoted Prices in Active Markets for Identical Assets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Fair Value December 31, 2015 Cash equivalents $ 1,644.4 $ 1,644.4 $ 1,637.0 $ 7.4 $ — $ 1,644.4 Short-term investments: U.S. government and agency securities $ 153.2 $ 153.4 $ 153.2 $ — $ — $ 153.2 Corporate debt securities 625.8 626.9 — 625.8 — 625.8 Asset-backed securities 3.3 3.3 — 3.3 — 3.3 Other securities 3.1 3.1 — 3.1 — 3.1 Short-term investments $ 785.4 $ 786.7 Noncurrent investments: U.S. government and agency securities $ 284.5 $ 286.0 $ 283.5 $ 1.0 $ — $ 284.5 Corporate debt securities 1,962.6 1,995.8 — 1,962.6 — 1,962.6 Mortgage-backed securities 153.3 154.7 — 153.3 — 153.3 Asset-backed securities 441.9 443.1 — 441.9 — 441.9 Other securities 4.1 4.1 — 4.1 — 4.1 Marketable equity securities 128.9 74.8 128.9 — — 128.9 Other investments (2) 671.3 671.3 Noncurrent investments $ 3,646.6 $ 3,629.8 December 31, 2014 Cash equivalents $ 2,443.5 $ 2,443.5 $ 2,415.5 $ 28.0 $ — $ 2,443.5 Short-term investments: U.S. government and agency securities $ 185.5 $ 185.6 $ 156.5 $ 29.0 $ — $ 185.5 Corporate debt securities 767.4 766.7 — 767.4 — 767.4 Other securities 2.5 2.5 — 2.5 — 2.5 Short-term investments $ 955.4 $ 954.8 Noncurrent investments: U.S. government and agency securities $ 756.7 $ 757.5 $ 747.5 $ 9.2 $ — $ 756.7 Corporate debt securities 2,462.7 2,468.9 — 2,462.7 — 2,462.7 Mortgage-backed securities 217.0 217.6 — 217.0 — 217.0 Asset-backed securities 477.8 478.0 — 477.8 — 477.8 Other securities 3.2 3.2 — 3.2 — 3.2 Marketable equity securities 204.8 44.0 204.8 — — 204.8 Other investments (2) 446.7 446.7 Noncurrent investments $ 4,568.9 $ 4,415.9 (1) For available-for-sale debt securities, amounts disclosed represent the securities' amortized cost. (2) Primarily includes investments accounted for under the cost method and equity method for which fair value disclosures are not applicable.
Fair Value, Liabilities Measured on Recurring Basis [Table Text Block]	Fair Value Measurements Using Description Carrying Amount Quoted Prices in Active Markets for Identical Assets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Fair Value Short-term commercial paper borrowings December 31, 2015 $ — $ — $ — $ — $ — December 31, 2014 (2,680.6 ) — (2,680.6 ) — (2,680.6 ) Long-term debt, including current portion December 31, 2015 $ (7,978.5 ) $ — $ (8,172.0 ) $ — $ (8,172.0 ) December 31, 2014 (5,340.9 ) — (5,722.1 ) — (5,722.1 )
Fair Value, by Balance Sheet Grouping [Table Text Block]	Fair Value Measurements Using Description Carrying Amount Quoted Prices in Active Markets for Identical Assets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Fair Value December 31, 2015 Risk-management instruments Interest rate contracts designated as hedging instruments: Sundry $ 70.1 $ — 70.1 $ — $ 70.1 Other noncurrent liabilities (0.4 ) — (0.4 ) — (0.4 ) Foreign exchange contracts not designated as hedging instruments: Other receivables 13.1 — 13.1 — 13.1 Other current liabilities (17.3 ) — (17.3 ) — (17.3 ) Contingent consideration liability (1) : Other current liabilities (243.7 ) — — (243.7 ) (243.7 ) Other noncurrent liabilities (427.2 ) — — (427.2 ) (427.2 ) December 31, 2014 Risk-management instruments Interest rate contracts designated as hedging instruments: Sundry $ 102.5 $ — $ 102.5 $ — $ 102.5 Other current liabilities (149.5 ) — (149.5 ) — (149.5 ) Other noncurrent liabilities (0.7 ) — (0.7 ) — (0.7 ) Foreign exchange contracts not designated as hedging instruments: Other receivables 9.1 — 9.1 — 9.1 Other current liabilities (14.0 ) — (14.0 ) — (14.0 ) (1) The contingent consideration liability relates to the Erbitux arrangement with BMS discussed in Note 4.
Available-for-sale Securities [Table Text Block]	A summary of the fair value of available-for-sale securities in an unrealized gain or loss position and the amount of unrealized gains and losses (pretax) in accumulated other comprehensive loss follows: 2015 2014 Unrealized gross gains $ 68.0 $ 171.9 Unrealized gross losses 52.5 18.3 Fair value of securities in an unrealized gain position 764.5 1,778.8 Fair value of securities in an unrealized loss position 2,933.4 3,129.2
Gain (Loss) on Investments [Table Text Block]	Activity related to our investment portfolio, substantially all of which related to available-for-sale securities, was as follows: 2015 2014 2013 Proceeds from sales $ 4,733.3 $ 14,609.5 $ 13,753.5 Realized gross gains on sales 255.1 353.5 49.5 Realized gross losses on sales 10.3 29.4 15.4

Goodwill and Other Intangible43

Goodwill and Other Intangibles (Tables)	12 Months Ended
	Dec. 31, 2015
Goodwill and Intangible Assets Disclosure [Abstract]
Finite-lived Intangible Assets Amortization Expense [Table Text Block]	Amortization expense related to finite-lived intangible assets was as follows: 2015 2014 2013 Amortization expense $ 631.8 $ 535.9 $ 555.0
Schedule of Indefinite-Lived Intangible Assets [Table Text Block]	Goodwill by segment at December 31 was as follows: 2015 2014 Human pharmaceutical products $ 1,366.5 $ 1,359.4 Animal health 2,673.4 398.7 Total goodwill $ 4,039.9 $ 1,758.1
Schedule of Intangible Assets and Goodwill [Table Text Block]	The components of intangible assets other than goodwill at December 31 were as follows: 2015 2014 Description Carrying Amount— Gross Accumulated Amortization Carrying Amount— Net Carrying Amount— Gross Accumulated Amortization Carrying Amount— Net Finite-lived intangible assets: Marketed products $ 7,528.0 $ (2,706.4 ) $ 4,821.6 $ 5,684.3 $ (2,915.6 ) $ 2,768.7 Other 151.1 (115.5 ) 35.6 149.3 (45.2 ) 104.1 Total finite-lived intangible assets 7,679.1 (2,821.9 ) 4,857.2 5,833.6 (2,960.8 ) 2,872.8 Indefinite-lived intangible assets: Acquired in-process research and development 177.6 — 177.6 11.4 — 11.4 Other intangibles $ 7,856.7 $ (2,821.9 ) $ 5,034.8 $ 5,845.0 $ (2,960.8 ) $ 2,884.2
Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]	The estimated amortization expense associated with our current finite-lived intangible assets for each of the next five years is as follows: 2016 2017 2018 2019 2020 Estimated amortization expense $ 674.7 $ 641.8 $ 480.4 $ 302.7 $ 301.4

Property and Equipment (Tables)

Property and Equipment (Tables)	12 Months Ended
	Dec. 31, 2015
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment [Table Text Block]	At December 31, property and equipment consisted of the following: 2015 2014 Land $ 220.6 $ 205.2 Buildings 6,786.5 6,516.2 Equipment 7,988.5 7,609.7 Construction in progress 1,665.3 1,698.2 16,660.9 16,029.3 Less accumulated depreciation (8,607.4 ) (8,065.4 ) Property and equipment, net $ 8,053.5 $ 7,963.9
Schedule of Rent Expense [Table Text Block]	Depreciation expense related to property and equipment and rental expense for all leases, including contingent rentals (not material), was as follows: 2015 2014 2013 Depreciation expense $ 717.6 $ 759.1 $ 774.8 Rental expense 225.7 227.3 227.2

Borrowings (Tables)

Borrowings (Tables)	12 Months Ended
	Dec. 31, 2015
Long-term Debt, Current and Noncurrent [Abstract]
Schedule of Additional Borrowings Disclosures [Table Text Block]	The aggregate amount of cash payments for interest on borrowings, net of capitalized interest, are as follows: 2015 2014 2013 Cash payments for interest on borrowings $ 129.6 $ 140.4 $ 139.7
Schedule of Maturities of Long-term Debt [Table Text Block]	The aggregate amounts of maturities on long-term debt for the next five years are as follows: 2016 2017 2018 2019 2020 Maturities on long-term debt $ 6.1 $ 635.2 $ 803.2 $ 601.8 $ 0.6
Schedule of Debt [Table Text Block]	at December 31 consisted of the following: 2015 2014 Short-term commercial paper borrowings $ — $ 2,680.6 1.00 to 7.13 percent long-term notes (due 2017-2045) 7,700.1 4,872.8 Other long-term debt, including capitalized leases 23.1 33.1 Unamortized debt issuance costs (37.1 ) (20.4 ) Fair value adjustment on hedged long-term notes 292.4 455.4 Total debt 7,978.5 8,021.5 Less current portion (6.1 ) (2,688.7 ) Long-term debt $ 7,972.4 $ 5,332.8

Stock-Based Compensation (Table

Stock-Based Compensation (Tables)	12 Months Ended
	Dec. 31, 2015
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Schedule of Additional Stock-Based Compensation Disclosures [Table Text Block]	Stock-based compensation expense and the related tax benefits were as follows: 2015 2014 2013 Stock-based compensation expense $ 217.8 $ 156.0 $ 144.9 Tax benefit 76.2 54.6 50.7
Share-based Compensation Awards, Fair Value Assumptions Used [Table Text Block]	The weighted-average fair values of the SVA units granted during the years ended December 31, 2015 , 2014 , and 2013 were $54.81 , $41.97 , and $45.17 , respectively, determined using the following assumptions: (Percents) 2015 2014 2013 Expected dividend yield 2.50 % 3.50 % 3.50 % Risk-free interest rate 0.79 .08-.71 .08-.43 Volatility 20.37 18.87-21.56 18.95-22.37

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2015
Income Tax Disclosure [Abstract]
Schedule of Additional Income Tax Disclosures [Table Text Block]	Cash payments of income taxes were as follows: 2015 2014 2013 Cash payments of income taxes $ 969.0 $ 729.7 $ 1,255.6
Income Taxes [Text Block]	Note 13: Income Taxes Deferred taxes are recognized for the future tax effects of temporary differences between financial and income tax reporting based on enacted tax laws and rates. Federal income taxes are provided on the portion of the income of foreign subsidiaries that is expected to be remitted to the U.S. and be taxable. When foreign earnings are expected to be indefinitely reinvested outside the U.S., no accrual for U.S. income taxes is provided. We recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by the taxing authorities, based on the technical merits of the position. The tax benefits recognized in the financial statements from such a position are measured based on the largest benefit that has a greater than 50 percent likelihood of being realized upon ultimate resolution. Following is the composition of income tax expense: 2015 2014 2013 Current: Federal $ 660.5 $ 168.9 $ 259.1 Foreign 422.0 406.2 553.2 State 47.5 (2.1 ) 126.3 Total current tax expense 1,130.0 573.0 938.6 Deferred: Federal (689.6 ) (83.3 ) 297.0 Foreign (66.0 ) 120.2 (28.2 ) State 7.2 (0.1 ) (2.9 ) Total deferred tax (benefit) expense (748.4 ) 36.8 265.9 Income taxes $ 381.6 $ 609.8 $ 1,204.5 Significant components of our deferred tax assets and liabilities as of December 31 are as follows: 2015 2014 Deferred tax assets: Compensation and benefits $ 1,034.6 $ 976.3 Purchases of intangible assets 637.2 473.3 Tax credit carryforwards and carrybacks 294.2 279.4 Tax loss carryforwards and carrybacks 247.8 265.5 Contingent consideration 214.6 — Product return reserves 212.1 241.8 Other comprehensive loss on hedging transactions 129.7 115.3 Debt 111.3 176.0 Other 628.6 623.2 Total gross deferred tax assets 3,510.1 3,150.8 Valuation allowances (590.3 ) (601.1 ) Total deferred tax assets 2,919.8 2,549.7 Deferred tax liabilities: Inventories (771.3 ) (684.6 ) Intangibles (756.3 ) (582.6 ) Property and equipment (411.6 ) (424.7 ) Prepaid employee benefits (317.8 ) (275.8 ) Unremitted earnings (218.8 ) (737.1 ) Financial instruments (152.6 ) (276.8 ) Total deferred tax liabilities (2,628.4 ) (2,981.6 ) Deferred tax assets (liabilities) - net $ 291.4 $ (431.9 ) The deferred tax asset and related valuation allowance amounts for U.S. federal and state net operating losses and tax credits shown above have been reduced for differences between financial reporting and tax return filings. Based on filed tax returns, we have tax credit carryforwards and carrybacks of $668.5 million available to reduce future income taxes; $180.5 million , if unused, will expire by 2021 . The remaining portion of the tax credit carryforwards is related to federal tax credits of $93.4 million , international tax credits of $100.6 million , and state tax credits of $294.0 million , all of which are substantially reserved. At December 31, 2015 , based on filed tax returns we had net operating losses and other carryforwards for international and U.S. federal income tax purposes of $462.0 million : $38.0 million will expire by 2020 ; $354.0 million will expire between 2020 and 2035 ; and $70.0 million of the carryforwards will never expire. Net operating losses and other carryforwards for international and U.S. federal income tax purposes are partially reserved. Deferred tax assets related to state net operating losses of $93.2 million and other state carryforwards of $8.8 million are fully reserved. Domestic and Puerto Rican companies contributed approximately 35 percent , 20 percent , and 60 percent for the years ended December 31, 2015 , 2014 , and 2013 , respectively, to consolidated income before income taxes. We have a subsidiary operating in Puerto Rico under a tax incentive grant effective through the end of 2016 . A similar, new tax incentive grant will begin in 2017 and will be in effect for 15 years . At December 31, 2015 , U.S. income taxes have not been provided on approximately $26.5 billion of unremitted earnings of foreign subsidiaries as we consider these unremitted earnings to be indefinitely invested for continued use in our foreign operations. Additional tax provisions will be required if these earnings are repatriated in the future to the U.S. Due to complexities in the tax laws and assumptions that we would have to make, it is not practicable to determine the amount of the related unrecognized deferred income tax liability. Cash payments of income taxes were as follows: 2015 2014 2013 Cash payments of income taxes $ 969.0 $ 729.7 $ 1,255.6 Following is a reconciliation of the income tax expense applying the U.S. federal statutory rate to income before income taxes to reported income tax expense: 2015 2014 2013 Income tax at the U.S. federal statutory tax rate $ 976.5 $ 1,050.1 $ 2,061.3 Add (deduct): International operations, including Puerto Rico (565.2 ) (344.8 ) (778.3 ) General business credits (69.2 ) (44.3 ) (175.6 ) Other 39.5 (51.2 ) 97.1 Income taxes $ 381.6 $ 609.8 $ 1,204.5 The American Taxpayer Relief Act of 2012, which included the reinstatement of the research tax credit for the year 2012, was enacted in early 2013. Therefore, the research tax credits for the years 2012 and 2013 are both included in 2013 with general business credits. A reconciliation of the beginning and ending amount of gross unrecognized tax benefits is as follows: 2015 2014 2013 Beginning balance at January 1 $ 1,338.8 $ 1,136.4 $ 1,534.3 Additions based on tax positions related to the current year 131.3 126.4 142.5 Additions for tax positions of prior years 116.6 132.6 251.5 Reductions for tax positions of prior years (45.2 ) (32.1 ) (358.2 ) Settlements (446.2 ) (4.2 ) (404.9 ) Lapses of statutes of limitation (4.0 ) (3.5 ) (24.9 ) Changes related to the impact of foreign currency translation (24.7 ) (16.8 ) (3.9 ) Ending balance at December 31 $ 1,066.6 $ 1,338.8 $ 1,136.4 The total amount of unrecognized tax benefits that, if recognized, would affect our effective tax rate was $404.1 million and $638.8 million at December 31, 2015 and 2014 , respectively. We file income tax returns in the U.S. federal jurisdiction and various state, local, and non-U.S. jurisdictions. We are no longer subject to U.S. federal, state and local, or non-U.S. income tax examinations in most major taxing jurisdictions for years before 2007. During 2013, we reached resolution on the remaining matters related to tax years 2008–2009 that were not settled as part of a previous U.S. examination. Considering the impact of this resolution on periods that have not yet been examined, as well as its impact on tax asset carryforwards, there was an immaterial benefit to our consolidated results of operations. We made cash payments of approximately $135 million related to tax years 2008–2009 after application of available tax credit carryforwards and carrybacks. The U.S. examination of tax years 2010 - 2012 commenced during the fourth quarter of 2013 and is expected to conclude in the first quarter of 2016. In December 2015, we executed a closing agreement with the Internal Revenue Service which effectively settled certain matters for tax years 2010 - 2012 . Accordingly, we have reduced our gross uncertain tax positions by approximately $320 million in 2015. There was an immaterial impact to our consolidated results of operations during the fourth quarter related to issues settled in the closing agreement. In the first quarter of 2016, we anticipate reaching resolution on the remaining issues under examination and estimate that our gross uncertain tax positions will further be reduced by approximately $100 million to $150 million . Additionally, we do not anticipate that resolution of the U.S. examination will result in a material change to our consolidated financial position, and we expect that up to $250 million of cash payments will be due upon resolution of these tax years. We expect the U.S. examination of tax years 2013 - 2014 , and possibly 2015 , to begin in 2016. We recognize both accrued interest and penalties related to unrecognized tax benefits in income tax expense. We recognized income tax (benefit) expense related to interest and penalties as follows: 2015 2014 2013 Income tax (benefit) expense $ 13.2 $ 35.9 $ (10.9 ) At December 31, 2015 and 2014 , our accruals for the payment of interest and penalties totaled $216.3 million and $207.2 million , respectively. Following is the composition of income tax expense: 2015 2014 2013 Current: Federal $ 660.5 $ 168.9 $ 259.1 Foreign 422.0 406.2 553.2 State 47.5 (2.1 ) 126.3 Total current tax expense 1,130.0 573.0 938.6 Deferred: Federal (689.6 ) (83.3 ) 297.0 Foreign (66.0 ) 120.2 (28.2 ) State 7.2 (0.1 ) (2.9 ) Total deferred tax (benefit) expense (748.4 ) 36.8 265.9 Income taxes $ 381.6 $ 609.8 $ 1,204.5
Schedule of Deferred Tax Assets and Liabilities [Table Text Block]	Significant components of our deferred tax assets and liabilities as of December 31 are as follows: 2015 2014 Deferred tax assets: Compensation and benefits $ 1,034.6 $ 976.3 Purchases of intangible assets 637.2 473.3 Tax credit carryforwards and carrybacks 294.2 279.4 Tax loss carryforwards and carrybacks 247.8 265.5 Contingent consideration 214.6 — Product return reserves 212.1 241.8 Other comprehensive loss on hedging transactions 129.7 115.3 Debt 111.3 176.0 Other 628.6 623.2 Total gross deferred tax assets 3,510.1 3,150.8 Valuation allowances (590.3 ) (601.1 ) Total deferred tax assets 2,919.8 2,549.7 Deferred tax liabilities: Inventories (771.3 ) (684.6 ) Intangibles (756.3 ) (582.6 ) Property and equipment (411.6 ) (424.7 ) Prepaid employee benefits (317.8 ) (275.8 ) Unremitted earnings (218.8 ) (737.1 ) Financial instruments (152.6 ) (276.8 ) Total deferred tax liabilities (2,628.4 ) (2,981.6 ) Deferred tax assets (liabilities) - net $ 291.4 $ (431.9 )
Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]	Following is a reconciliation of the income tax expense applying the U.S. federal statutory rate to income before income taxes to reported income tax expense: 2015 2014 2013 Income tax at the U.S. federal statutory tax rate $ 976.5 $ 1,050.1 $ 2,061.3 Add (deduct): International operations, including Puerto Rico (565.2 ) (344.8 ) (778.3 ) General business credits (69.2 ) (44.3 ) (175.6 ) Other 39.5 (51.2 ) 97.1 Income taxes $ 381.6 $ 609.8 $ 1,204.5
Summary of Income Tax Contingencies [Table Text Block]	A reconciliation of the beginning and ending amount of gross unrecognized tax benefits is as follows: 2015 2014 2013 Beginning balance at January 1 $ 1,338.8 $ 1,136.4 $ 1,534.3 Additions based on tax positions related to the current year 131.3 126.4 142.5 Additions for tax positions of prior years 116.6 132.6 251.5 Reductions for tax positions of prior years (45.2 ) (32.1 ) (358.2 ) Settlements (446.2 ) (4.2 ) (404.9 ) Lapses of statutes of limitation (4.0 ) (3.5 ) (24.9 ) Changes related to the impact of foreign currency translation (24.7 ) (16.8 ) (3.9 ) Ending balance at December 31 $ 1,066.6 $ 1,338.8 $ 1,136.4 We recognize both accrued interest and penalties related to unrecognized tax benefits in income tax expense. We recognized income tax (benefit) expense related to interest and penalties as follows: 2015 2014 2013 Income tax (benefit) expense $ 13.2 $ 35.9 $ (10.9 )

Retirement Benefits (Tables)

Retirement Benefits (Tables)	12 Months Ended
	Dec. 31, 2015
Schedule of Changes in Accumulated Postemployment Benefit Obligations [Table Text Block]	We use a measurement date of December 31 to develop the change in benefit obligation, change in plan assets, funded status, and amounts recognized in the consolidated balance sheets at December 31 for our defined benefit pension and retiree health benefit plans, which were as follows: Defined Benefit Pension Plans Retiree Health Benefit Plans 2015 2014 2015 2014 Change in benefit obligation: Benefit obligation at beginning of year $ 12,012.4 $ 9,976.4 $ 1,553.5 $ 1,757.2 Benefit obligation assumed in Novartis AH acquisition 334.7 — 9.9 — Service cost 315.7 240.9 45.1 33.0 Interest cost 476.8 472.6 62.6 85.6 Actuarial (gain) loss (812.4 ) 1,996.3 (113.5 ) 293.5 Benefits paid (437.8 ) (421.2 ) (77.5 ) (76.1 ) Plan amendments (0.4 ) (2.4 ) — (533.6 ) Foreign currency exchange rate changes and other adjustments (169.8 ) (250.2 ) (12.7 ) (6.1 ) Benefit obligation at end of year 11,719.2 12,012.4 1,467.4 1,553.5
Schedule of Changes in Fair Value of Plan Assets [Table Text Block]	Change in plan assets: Fair value of plan assets at beginning of year 9,835.7 9,481.7 1,918.7 1,879.6 Fair value of plan assets assumed in Novartis AH acquisition 235.9 — — — Actual return on plan assets 90.4 813.6 85.1 157.4 Employer contribution 404.1 127.2 17.4 (42.2 ) Benefits paid (437.8 ) (421.2 ) (77.5 ) (76.1 ) Foreign currency exchange rate changes and other adjustments (132.7 ) (165.6 ) — — Fair value of plan assets at end of year 9,995.6 9,835.7 1,943.7 1,918.7
Schedule of Net Funded Status [Table Text Block]	Funded status (1,723.6 ) (2,176.7 ) 476.3 365.2 Unrecognized net actuarial loss 4,552.7 5,114.9 347.9 439.5 Unrecognized prior service (benefit) cost 32.5 43.5 (574.8 ) (666.7 ) Net amount recognized $ 2,861.6 $ 2,981.7 $ 249.4 $ 138.0
Schedule of Amounts Recognized in Balance Sheet [Table Text Block]	Amounts recognized in the consolidated balance sheet consisted of: Sundry $ 261.6 $ 211.2 $ 722.1 $ 609.4 Other current liabilities (63.8 ) (62.3 ) (6.9 ) (6.9 ) Accrued retirement benefits (1,921.4 ) (2,325.6 ) (238.9 ) (237.3 ) Accumulated other comprehensive (income) loss before income taxes 4,585.2 5,158.4 (226.9 ) (227.2 ) Net amount recognized $ 2,861.6 $ 2,981.7 $ 249.4 $ 138.0
Schedule of Amounts in Accumulated Other Comprehensive Income (Loss) to be Recognized over Next Fiscal Year [Table Text Block]	During 2016 , we expect the following components of accumulated other comprehensive loss to be recognized as components of net periodic benefit cost: Defined Benefit Pension Plans Retiree Health Benefit Plans Unrecognized net actuarial loss $ 285.9 $ 19.2 Unrecognized prior service (benefit) cost 11.9 (85.8 ) Total $ 297.8 $ (66.6 )
Schedule of Assumptions Used [Table Text Block]	The following represents our weighted-average assumptions as of December 31: Defined Benefit Pension Plans Retiree Health Benefit Plans (Percents) 2015 2014 2013 2015 2014 2013 Discount rate for benefit obligation 4.3 4.0 4.9 4.5 4.1 5.0 Discount rate for net benefit costs 4.0 4.9 4.3 4.1 5.0 4.3 Rate of compensation increase for benefit obligation 3.4 3.4 3.4 Rate of compensation increase for net benefit costs 3.4 3.4 3.4 Expected return on plan assets for net benefit costs 7.4 8.1 8.4 8.0 8.5 8.8
Schedule of Expected Benefit Payments [Table Text Block]	The following benefit payments, which reflect expected future service, as appropriate, are expected to be paid as follows: 2016 2017 2018 2019 2020 2021-2025 Defined benefit pension plans $ 458.4 $ 465.2 $ 480.3 $ 498.8 $ 518.5 $ 2,987.5 Retiree health benefit plans 70.7 75.3 78.3 81.1 84.0 464.2
Schedule of Net Benefit Costs [Table Text Block]	Net pension and retiree health benefit expense included the following components: Defined Benefit Pension Plans Retiree Health Benefit Plans 2015 2014 2013 2015 2014 2013 Components of net periodic (benefit) cost: Service cost $ 315.7 $ 240.9 $ 287.1 $ 45.1 $ 33.0 $ 49.9 Interest cost 476.8 472.6 437.2 62.6 85.6 98.1 Expected return on plan assets (782.3 ) (756.6 ) (701.9 ) (150.0 ) (146.4 ) (130.7 ) Amortization of prior service (benefit) cost 10.4 3.6 3.7 (91.1 ) (37.6 ) (35.6 ) Recognized actuarial loss 383.2 282.3 414.7 38.0 20.7 100.5 Net periodic (benefit) cost $ 403.8 $ 242.8 $ 440.8 $ (95.4 ) $ (44.7 ) $ 82.2
Schedule of Amounts Recognized in Other Comprehensive Income (Loss) [Table Text Block]	The following represents the amounts recognized in other comprehensive income (loss) for the year ended December 31, 2015 : Defined Benefit Retiree Health Actuarial gain arising during period $ 120.4 $ 48.6 Plan amendments during period 0.4 — Amortization of prior service (benefit) cost included in net income 10.4 (91.1 ) Amortization of net actuarial loss included in net income 383.2 38.0 Foreign currency exchange rate changes and other 58.8 4.2 Total other comprehensive income (loss) during period $ 573.2 $ (0.3 ) Reclassifications Out of Accumulated Other Comprehensive Loss Details about Accumulated Other Comprehensive Loss Components Year Ended December 31, Affected Line Item in the Consolidated Statements of Operations 2015 2014 2013 Amortization of defined benefit items: Prior service benefits, net $ (80.7 ) $ (34.0 ) $ (31.9 ) (1) Actuarial losses 421.2 303.0 515.2 (1) Total before tax 340.5 269.0 483.3 Tax benefit (105.6 ) (83.4 ) (164.3 ) Income taxes Net of tax 234.9 185.6 319.0 Unrealized gains/losses on available-for-sale securities: Realized gains, net (209.3 ) (324.1 ) (12.0 ) Other—net, (income) expense Impairment losses 12.0 — 2.4 Other—net, (income) expense Total before tax (197.3 ) (324.1 ) (9.6 ) Tax expense 69.1 113.4 3.4 Income taxes Net of tax (128.2 ) (210.7 ) (6.2 ) Other, net of tax 9.5 5.9 5.9 Other—net, (income) expense Total reclassifications for the period (net of tax) $ 116.2 $ (19.2 ) $ 318.7 (1) These accumulated other comprehensive loss components are included in the computation of net periodic pension cost (see Note 14).
Schedule of Allocation of Plan Assets [Table Text Block]	The fair values of our defined benefit pension plan and retiree health plan assets as of December 31, 2015 by asset category are as follows: Fair Value Measurements Using Asset Class Total Quoted Prices in Active Markets for Significant Significant Defined Benefit Pension Plans Public equity securities: U.S. $ 414.8 $ 187.1 $ 227.7 $ — International 2,340.6 956.3 1,384.3 — Fixed income: Developed markets 1,316.6 175.7 1,140.9 — Emerging markets 385.7 10.1 375.3 0.3 Private alternative investments: Hedge funds 3,073.3 14.5 1,537.9 1,520.9 Equity-like funds 1,221.3 — 67.4 1,153.9 Real estate 516.3 329.5 10.8 176.0 Other 727.0 431.3 295.7 — Total $ 9,995.6 $ 2,104.5 $ 5,040.0 $ 2,851.1 Retiree Health Benefit Plans Public equity securities: U.S. $ 40.0 $ 18.2 $ 21.8 $ — International 144.7 51.5 93.2 — Fixed income: Developed markets 61.3 — 61.3 — Emerging markets 36.9 — 36.9 — Private alternative investments: Hedge funds 272.3 — 148.7 123.6 Equity-like funds 104.5 — — 104.5 Cash value of trust owned insurance contract 1,209.7 — 1,209.7 — Real estate 33.2 33.2 — — Other 41.1 25.0 16.1 — Total $ 1,943.7 $ 127.9 $ 1,587.7 $ 228.1 The fair values of our defined benefit pension plan and retiree health plan assets as of December 31, 2014 by asset category are as follows: Fair Value Measurements Using Asset Class Total Quoted Prices in Active Markets for Identical Assets (Level 1) Significant Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Defined Benefit Pension Plans Public equity securities: U.S. $ 411.4 $ 183.8 $ 227.6 $ — International 2,337.8 999.7 1,338.1 — Fixed income: Developed markets 1,230.7 112.2 1,118.5 — Emerging markets 374.7 8.7 364.2 1.8 Private alternative investments: Hedge funds 3,277.6 — 1,694.5 1,583.1 Equity-like funds 1,146.6 — 75.2 1,071.4 Real estate 569.0 403.1 — 165.9 Other 487.9 229.8 258.1 — Total $ 9,835.7 $ 1,937.3 $ 5,076.2 $ 2,822.2 Retiree Health Benefit Plans Public equity securities: U.S. $ 39.2 $ 17.2 $ 22.0 $ — International 158.9 58.8 100.1 — Fixed income: Developed markets 61.8 — 61.8 — Emerging markets 35.5 — 35.3 0.2 Private alternative investments: Hedge funds 282.7 — 158.7 124.0 Equity-like funds 92.3 — — 92.3 Cash value of trust owned insurance contract 1,189.2 — 1,189.2 — Real estate 39.0 39.0 — — Other 20.1 7.6 12.5 — Total $ 1,918.7 $ 122.6 $ 1,579.6 $ 216.5
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]	The activity in the Level 3 investments during the year ended December 31, 2014 was as follows: Fixed Income: Developed Markets Fixed Income: Emerging Markets Hedge Funds Equity-like Funds Real Estate Total Defined Benefit Pension Plans Beginning balance at January 1, 2014 $ 15.9 $ — $ 1,440.4 $ 993.5 $ 153.4 $ 2,603.2 Actual return on plan assets, including changes in foreign exchange rates: Relating to assets still held at the reporting date (0.4 ) 0.1 44.6 108.2 0.2 152.7 Relating to assets sold during the period (0.8 ) — — — — (0.8 ) Purchases, sales, and settlements, net (3.3 ) 1.7 98.1 (30.3 ) 12.3 78.5 Transfers into (out of) Level 3 (11.4 ) — — — — (11.4 ) Ending balance at December 31, 2014 $ — $ 1.8 $ 1,583.1 $ 1,071.4 $ 165.9 $ 2,822.2 Retiree Health Benefit Plans Beginning balance at January 1, 2014 $ 1.6 $ — $ 120.6 $ 88.9 $ — $ 211.1 Actual return on plan assets, including changes in foreign exchange rates: Relating to assets still held at the reporting date (0.1 ) — 1.2 6.0 — 7.1 Relating to assets sold during the period (0.1 ) — — — — (0.1 ) Purchases, sales, and settlements, net (0.3 ) 0.2 2.2 (2.6 ) — (0.5 ) Transfers into (out of) Level 3 (1.1 ) — — — — (1.1 ) Ending balance at December 31, 2014 $ — $ 0.2 $ 124.0 $ 92.3 $ — $ 216.5 The activity in the Level 3 investments during the year ended December 31, 2015 was as follows: Fixed Income: Emerging Markets Hedge Equity-like Real Total Defined Benefit Pension Plans Beginning balance at January 1, 2015 $ 1.8 $ 1,583.1 $ 1,071.4 $ 165.9 $ 2,822.2 Actual return on plan assets, including changes in foreign exchange rates: Relating to assets still held at the reporting date (0.1 ) 89.4 78.3 (6.1 ) 161.5 Relating to assets sold during the period — (111.5 ) — — (111.5 ) Purchases, sales, and settlements, net (0.3 ) (40.1 ) 4.2 16.2 (20.0 ) Transfers into (out of) Level 3 (1.1 ) — — — (1.1 ) Ending balance at December 31, 2015 $ 0.3 $ 1,520.9 $ 1,153.9 $ 176.0 $ 2,851.1 Retiree Health Benefit Plans Beginning balance at January 1, 2015 $ 0.2 $ 124.0 $ 92.3 $ — $ 216.5 Actual return on plan assets, including changes in foreign exchange rates: Relating to assets still held at the reporting date — 14.7 10.3 — 25.0 Relating to assets sold during the period — (11.2 ) — — (11.2 ) Purchases, sales, and settlements, net — (3.9 ) 1.9 — (2.0 ) Transfers into (out of) Level 3 (0.2 ) — — — (0.2 ) Ending balance at December 31, 2015 $ — $ 123.6 $ 104.5 $ — $ 228.1
Schedule of Benefit Obligations in Excess of Fair Value of Plan Assets [Table Text Block]	Amounts relating to defined benefit pension plans with projected benefit obligations in excess of plan assets were as follows at December 31: 2015 2014 Projected benefit obligation $ 10,054.1 $ 10,537.2 Fair value of plan assets 8,069.7 8,149.2
Schedule of Accumulated Benefit Obligations in Excess of Fair Value of Plan Assets [Table Text Block]	Amounts relating to defined benefit pension plans and retiree health benefit plans with accumulated benefit obligations in excess of plan assets were as follows at December 31: Defined Benefit Pension Plans Retiree Health Benefit Plans 2015 2014 2015 2014 Accumulated benefit obligation $ 2,028.1 $ 2,179.8 $ 245.8 $ 244.2 Fair value of plan assets 844.9 700.9 — —

Other Comprehensive Income (L49

Other Comprehensive Income (Loss) (Tables)	12 Months Ended
	Dec. 31, 2015
Other Comprehensive Income (Loss), Tax [Abstract]
Schedule of Amounts Recognized in Other Comprehensive Income (Loss) [Table Text Block]	The following represents the amounts recognized in other comprehensive income (loss) for the year ended December 31, 2015 : Defined Benefit Retiree Health Actuarial gain arising during period $ 120.4 $ 48.6 Plan amendments during period 0.4 — Amortization of prior service (benefit) cost included in net income 10.4 (91.1 ) Amortization of net actuarial loss included in net income 383.2 38.0 Foreign currency exchange rate changes and other 58.8 4.2 Total other comprehensive income (loss) during period $ 573.2 $ (0.3 ) Reclassifications Out of Accumulated Other Comprehensive Loss Details about Accumulated Other Comprehensive Loss Components Year Ended December 31, Affected Line Item in the Consolidated Statements of Operations 2015 2014 2013 Amortization of defined benefit items: Prior service benefits, net $ (80.7 ) $ (34.0 ) $ (31.9 ) (1) Actuarial losses 421.2 303.0 515.2 (1) Total before tax 340.5 269.0 483.3 Tax benefit (105.6 ) (83.4 ) (164.3 ) Income taxes Net of tax 234.9 185.6 319.0 Unrealized gains/losses on available-for-sale securities: Realized gains, net (209.3 ) (324.1 ) (12.0 ) Other—net, (income) expense Impairment losses 12.0 — 2.4 Other—net, (income) expense Total before tax (197.3 ) (324.1 ) (9.6 ) Tax expense 69.1 113.4 3.4 Income taxes Net of tax (128.2 ) (210.7 ) (6.2 ) Other, net of tax 9.5 5.9 5.9 Other—net, (income) expense Total reclassifications for the period (net of tax) $ 116.2 $ (19.2 ) $ 318.7 (1) These accumulated other comprehensive loss components are included in the computation of net periodic pension cost (see Note 14).
Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]	The tax effects on the net activity related to each component of other comprehensive income (loss) for the years ended December 31, were as follows: Tax (expense) benefit 2015 2014 2013 Foreign currency translation gains (losses) $ (2.0 ) $ — $ — Unrealized net gains (losses) on securities 48.5 56.7 (71.6 ) Defined benefit pension and retiree health benefit plans (183.0 ) 414.7 (886.1 ) Effective portion of cash flow hedges 14.6 5.2 43.2 Provision for income taxes related to other comprehensive income (loss) items $ (121.9 ) $ 476.6 $ (914.5 ) The following table summarizes the activity related to each component of other comprehensive income (loss): (Amounts presented net of taxes) Foreign Currency Translation Gains (Losses) Unrealized Net Gains (Losses) on Securities Defined Benefit Pension and Retiree Health Benefit Plans Effective Portion of Cash Flow Hedges Accumulated Other Comprehensive Loss Beginning balance at January 1, 2013 $ 426.8 $ 72.5 $ (4,195.2 ) $ (101.2 ) $ (3,797.1 ) Other comprehensive income (loss) before reclassifications 36.2 138.9 1,387.1 (86.5 ) 1,475.7 Net amount reclassified from accumulated other comprehensive loss — (6.2 ) 319.0 5.9 318.7 Net other comprehensive income (loss) 36.2 132.7 1,706.1 (80.6 ) 1,794.4 Balance at December 31, 2013 463.0 205.2 (2,489.1 ) (181.8 ) (2,002.7 ) Other comprehensive income (loss) before reclassifications (961.4 ) 105.2 (1,098.5 ) (15.2 ) (1,969.9 ) Net amount reclassified from accumulated other comprehensive loss — (210.7 ) 185.6 5.9 (19.2 ) Net other comprehensive income (loss) (961.4 ) (105.5 ) (912.9 ) (9.3 ) (1,989.1 ) Balance at December 31, 2014 (498.4 ) 99.7 (3,402.0 ) (191.1 ) (3,991.8 ) Other comprehensive income (loss) before reclassifications (861.8 ) 38.6 155.0 (36.9 ) (705.1 ) Net amount reclassified from accumulated other comprehensive loss — (128.2 ) 234.9 9.5 116.2 Net other comprehensive income (loss) (861.8 ) (89.6 ) 389.9 (27.4 ) (588.9 ) Ending Balance at December 31, 2015 $ (1,360.2 ) $ 10.1 $ (3,012.1 ) $ (218.5 ) $ (4,580.7 )

Other - Net, Expense (Income) (

Other - Net, Expense (Income) (Tables)	12 Months Ended
	Dec. 31, 2015
Nonoperating Income (Expense) [Abstract]
Schedule of Other Nonoperating Income (Expense) [Table Text Block]	Other–net, (income) expense consisted of the following: 2015 2014 2013 Income related to termination of the exenatide collaboration with Amylin (Note 4) $ — $ — $ (495.4 ) Interest expense 161.2 148.8 160.1 Interest income (87.0 ) (121.0 ) (119.7 ) Debt extinguishment loss (Note 10) 166.7 — — Other income (341.5 ) (368.3 ) (63.9 ) Other–net, (income) expense $ (100.6 ) $ (340.5 ) $ (518.9 )

Segment Information Segment Inf

Segment Information Segment Information (Tables)	12 Months Ended
	Dec. 31, 2015
Segment Reporting [Abstract]
Schedule of Additional Segment Information Disclosures [Table Text Block]	Depreciation and software amortization expense included in our segment profits was as follows: 2015 2014 2013 Human pharmaceutical products $ 720.7 $ 790.0 $ 838.8 Animal health 80.8 58.8 51.8 Total depreciation expense included in segment profits $ 801.5 $ 848.8 $ 890.6
Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block]	2015 2014 2013 Segment revenue—to unaffiliated customers: Human pharmaceutical products: Endocrinology: Humalog ® $ 2,841.9 $ 2,785.2 $ 2,611.2 Forteo ® 1,348.3 1,322.0 1,244.9 Humulin ® 1,307.4 1,400.1 1,315.8 Trajenta 356.8 328.8 249.2 Trulicity ® 248.7 10.2 — Evista 237.3 419.8 1,050.4 Other Endocrinology 696.4 672.9 832.9 Total Endocrinology 7,036.8 6,939.0 7,304.4 2015 2014 2013 Neuroscience: Cymbalta 1,027.6 1,614.7 5,084.4 Zyprexa ® 940.3 1,037.3 1,194.8 Strattera ® 784.0 738.5 709.2 Other Neuroscience 183.5 206.0 227.8 Total Neuroscience 2,935.4 3,596.5 7,216.2 Oncology: Alimta 2,493.1 2,792.0 2,703.0 Erbitux 485.0 373.3 373.7 Cyramza ® 383.8 75.6 — Other Oncology 147.9 152.1 191.8 Total Oncology 3,509.8 3,393.0 3,268.5 Cardiovascular: Cialis ® 2,310.7 2,291.0 2,159.4 Effient 523.0 522.2 508.7 Other Cardiovascular 234.3 240.3 255.1 Total Cardiovascular 3,068.0 3,053.5 2,923.2 Other pharmaceuticals 227.7 287.0 249.3 Total human pharmaceutical products 16,777.7 17,269.0 20,961.6 Animal health 3,181.0 2,346.6 2,151.5 Revenue $ 19,958.7 $ 19,615.6 $ 23,113.1 Segment profits: Human pharmaceutical products $ 4,026.7 $ 3,604.6 $ 5,521.0 Animal health 597.9 621.8 605.6 Total segment profits $ 4,624.6 $ 4,226.4 $ 6,126.6 Reconciliation of total segment profits to consolidated income before taxes: Segment profits $ 4,624.6 $ 4,226.4 $ 6,126.6 Other profits (losses): Inventory fair value adjustment related to Novartis AH (Note 3) (153.0 ) — — Acquired in-process research and development (Notes 3 and 4) (535.0 ) (200.2 ) (57.1 ) Asset impairment, restructuring, and other special charges (Note 5) (367.7 ) (468.7 ) (120.6 ) Debt repurchase charges, net (1) (Note 10) (152.7 ) — — Amortization of intangible assets (2) (Note 8) (626.2 ) (530.2 ) (555.0 ) Income related to transfer of linagliptin and empagliflozin rights in certain countries to Boehringer Ingelheim (Note 4) — 92.0 — U.S. Branded Prescription Drug Fee — (119.0 ) — Income related to termination of the exenatide collaboration with Amylin Pharmaceuticals, Inc. (Note 4) — — 495.4 Consolidated income before taxes $ 2,790.0 $ 3,000.3 $ 5,889.3 (1) We recognized pretax net charges of $152.7 million for the year ended December 31, 2015 , attributable to the debt extinguishment loss of $166.7 million from the purchase and redemption of certain fixed-rate notes, partially offset by net gains from non-hedging interest rate swaps and foreign currency transactions associated with the related issuance of euro-denominated notes. (2) In 2015, the measurement of segment profitability was changed to exclude certain amortization of intangible assets. The prior periods have been adjusted to conform with the 2015 presentation.
Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas [Table Text Block]	2015 2014 2013 Geographic Information Revenue—to unaffiliated customers (1) : United States $ 10,097.4 $ 9,134.1 $ 12,889.7 Europe 3,943.6 4,506.7 4,338.4 Japan 2,033.1 2,027.1 2,063.8 Other foreign countries 3,884.6 3,947.7 3,821.2 Revenue $ 19,958.7 $ 19,615.6 $ 23,113.1 Long-lived assets (2) : United States $ 4,576.8 $ 4,566.2 $ 4,649.6 Europe 2,306.4 2,401.5 2,469.7 Japan 89.2 80.4 81.1 Other foreign countries 1,724.2 1,499.1 1,540.9 Long-lived assets $ 8,696.6 $ 8,547.2 $ 8,741.3 (1) Revenue is attributed to the countries based on the location of the customer. (2) Long-lived assets consist of property and equipment, net, and certain sundry assets.

Selected Quarterly Data (Tables

Selected Quarterly Data (Tables)	12 Months Ended
	Dec. 31, 2015
Quarterly Financial Information Disclosure [Abstract]
Schedule of Quarterly Financial Information [Table Text Block]	2015 Fourth Third Second First Revenue $ 5,375.6 $ 4,959.7 $ 4,978.7 $ 4,644.7 Cost of sales 1,389.2 1,236.9 1,218.4 1,192.7 Operating expenses (1) 3,242.6 2,719.1 2,804.9 2,562.8 Acquired in-process research and development 199.0 — 80.0 256.0 Asset impairment, restructuring, and other special charges 144.9 42.4 72.4 108.0 Other—net, (income) expense (44.7 ) (86.5 ) 123.3 (92.7 ) Income before income taxes 444.6 1,047.8 679.7 617.9 Net income 478.4 799.7 600.8 529.5 Earnings per share—basic 0.45 0.75 0.57 0.50 Earnings per share—diluted 0.45 0.75 0.56 0.50 Dividends paid per share 0.50 0.50 0.50 0.50 Common stock closing prices: High 87.52 89.98 86.59 76.36 Low 76.98 78.26 70.89 68.41 2014 Fourth Third Second First Revenue $ 5,121.3 $ 4,875.6 $ 4,935.6 $ 4,683.1 Cost of sales 1,253.1 1,267.0 1,189.7 1,222.7 Operating expenses (1) 2,985.6 2,915.3 2,859.3 2,594.2 Acquired in-process research and development 105.2 95.0 — — Asset impairment, restructuring, and other special charges 401.0 36.3 — 31.4 Other—net, (income) expense (137.2 ) (93.5 ) (53.8 ) (56.0 ) Income before income taxes 513.6 655.5 940.4 890.8 Net income 428.5 500.6 733.5 727.9 Earnings per share—basic 0.40 0.47 0.68 0.68 Earnings per share—diluted 0.40 0.47 0.68 0.68 Dividends paid per share 0.49 0.49 0.49 0.49 Common stock closing prices: High 72.83 66.59 63.10 59.85 Low 61.90 60.35 58.21 50.73 (1) Includes

Summary of Significant Accoun53

Summary of Significant Accounting Policies (Details) - USD ($) $ in Millions	3 Months Ended								12 Months Ended
	Dec. 31, 2015	Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2015	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Average Remaining Maturity of Foreign Currency Derivatives									12 months
Depreciation									$ 717.6	$ 759.1	$ 774.8
Operating Leases, Rent Expense									225.7	227.3	227.2
Collaboration and other revenue									808.1	788.4	707.5
Revenue	$ 5,375.6	$ 4,959.7	$ 4,978.7	$ 4,644.7	$ 5,121.3	$ 4,875.6	$ 4,935.6	$ 4,683.1	$ 19,958.7	$ 19,615.6	$ 23,113.1
Minimum [Member]
Finite-Lived Intangible Assets, Useful Life									3 years
Minimum [Member] | Building [Member]
Property, Plant and Equipment, Useful Life									12 years
Minimum [Member] | Equipment [Member]
Property, Plant and Equipment, Useful Life									3 years
Maximum [Member]
Finite-Lived Intangible Assets, Useful Life									20 years
Maximum [Member] | Building [Member]
Property, Plant and Equipment, Useful Life									50 years
Maximum [Member] | Equipment [Member]
Property, Plant and Equipment, Useful Life									25 years

Implementation of New Financi54

Implementation of New Financial Accounting Pronouncements (Details) - New Accounting Pronouncement, Early Adoption, Effect [Member] $ in Millions	12 Months Ended
	Dec. 31, 2015USD ($)
New Accounting Pronouncement, Early Adoption [Line Items]
Prepaid expenses and other	$ (251.5)
Sundry	(584.2)
Deferred income taxes	(1,466.5)
Other noncurrent liabilities	$ 630.8

Acquisitions (Details)

Acquisitions (Details) - USD ($) $ / shares in Units, $ in Millions		Apr. 30, 2014	Jan. 31, 2015	Dec. 31, 2014	Sep. 30, 2014	Jul. 31, 2014	Dec. 31, 2013	Dec. 31, 2015	Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2015	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013	Jan. 01, 2015
Amortization of Intangible Assets																$ 631.8	$ 535.9	$ 555
Cost of sales								$ 1,389.2	$ 1,236.9	$ 1,218.4	$ 1,192.7	$ 1,253.1	$ 1,267	$ 1,189.7	$ 1,222.7	5,037.2	4,932.5	4,908.1
Interest Expense																161.2	148.8	160.1
Restricted cash				$ 5,405.6				0				5,405.6				0	5,405.6
Acquired in-process research and development							$ 57.1	199	$ 0	80	256	105.2	$ 95	$ 0	$ 0	535	200.2	57.1
Payments to Acquire Businesses, Net of Cash Acquired																5,283.1	551.4	$ 43.7
Goodwill				1,758.1				4,039.9				$ 1,758.1				4,039.9	1,758.1
Innovent Biologics, Inc. [Member]
Acquired in-process research and development											56
Hanmi Pharmaceutical Co., Ltd. [Member]
Acquired in-process research and development										50
BioNTech AG [Member]
Acquired in-process research and development										$ 30
Lohmann Animal Health [Member]
Business Combination, Consideration Transferred		$ 591.2
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles		275.4
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles, Other Intangible Assets		23.9
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net		339.6
Payments to Acquire Businesses, Net of Cash Acquired		551.4
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Long-term Debt		39.8
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment		81.9
Goodwill	[1]	251.6
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities Noncurrent		(92.7)
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets		$ 51.1
Novartis Animal Health [Member]
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life			19 years
Business Acquisition, Goodwill, Expected Tax Deductible Amount																			$ 950
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory																			380.2
Business Combination, Pro Forma Information, Revenue of Acquiree since Acquisition Date, Actual																1,020
Business Combination, Consideration Transferred			$ 5,280
Business Acquisition, Pro Forma Revenue																19,958.7	20,696.7
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles	[2]																		1,953
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Indefinite-Lived Intangible Assets																			298
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net																			3,012
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment																			199.9
Goodwill	[3]																		2,271.1
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities Noncurrent																			(60.1)
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Other																			422.7
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Other																			(108.7)
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities																			(73)
Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net																			$ 5,283.1
Business Acquisition, Pro Forma Net Income (Loss)																$ 2,518.1	$ 2,127.9
Business Acquisition, Pro Forma Earnings Per Share, Diluted																$ 2.36	$ 1.98
Immunocore Limited [Member]
Acquired in-process research and development						$ 45
Locemia Solutions [Member]
Acquired in-process research and development								149
Other Product Acquisition Counterparty [Member]
Acquired in-process research and development								25
Halozyme Therapeutics, Inc [Member]
Acquired in-process research and development								$ 25
AstraZeneca [Member]
Acquired in-process research and development					$ 50
Adocia [Member]
Acquired in-process research and development				$ 50
Tanezumab [Member]
Acquired in-process research and development											$ 200
United States [Member] | U.S. Sentinel Product Line [Member]
Proceeds from Divestiture of Businesses			$ 410
Acquisition-related Costs [Member] | Novartis Animal Health [Member]
Interest Expense																	$ 112
Fair Value Adjustment to Inventory [Member] | Novartis Animal Health [Member]
Cost of sales																$ (153.1)	153.1
Amortization of Fair Value Adjusted Intangible Assets [Member] | Novartis Animal Health [Member]
Amortization of Intangible Assets																	$ 104
[1]	(1) Goodwill associated with this acquisition is not deductible for tax purposes.
[2]	(1) These intangible assets, which will be amortized to cost of sales on a straight-line basis over their estimated useful lives, are expected to have a weighted average useful life of 19 years.
[3]	(2) The goodwill recognized from this acquisition is attributable primarily to expected synergies that we believe will result from combining the operations of Novartis AH with our legacy animal health business, future unidentified projects and products, and the assembled workforce of Novartis AH. Approximately $950 million of the goodwill associated with this acquisition is estimated to be deductible for tax purposes.

Collaborations (Details)

Collaborations (Details) - USD ($) $ in Millions		1 Months Ended							3 Months Ended									6 Months Ended	10 Months Ended	12 Months Ended
		Dec. 31, 2013	Oct. 31, 2013	Aug. 31, 2012	Nov. 30, 2011	Jan. 31, 2011	Dec. 31, 2009	Jun. 30, 2001	Mar. 31, 2016	Dec. 31, 2015	Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2015	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Jun. 30, 2011	Oct. 31, 2011	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013	Oct. 01, 2015
Collaboration and other revenue																				$ 808.1	$ 788.4	$ 707.5
Revenue										$ 5,375.6	$ 4,959.7	$ 4,978.7	$ 4,644.7	$ 5,121.3	$ 4,875.6	$ 4,935.6	$ 4,683.1			19,958.7	19,615.6	23,113.1
Other Nonoperating Income (Expense)																				341.5	368.3	63.9
Research and Development Expense																				4,796.4	4,733.6	5,531.3
Other-net, (income) expense										44.7	86.5	(123.3)	92.7	137.2	93.5	53.8	56			100.6	340.5	518.9
Marketing, selling, and administrative																				6,533	6,620.8	7,125.6
Acquired in-process research and development		$ 57.1								199	$ 0	$ 80	256	105.2	$ 95	$ 0	$ 0			535	200.2	57.1
Amortization of Intangible Assets																				631.8	535.9	555
Erbitux API [Member]
Sales Revenue, Goods, Net																				23.3	46.1	58.5
Erbitux [Member]
Sales Revenue, Goods, Net																				152.3	0	0
Collaboration and other revenue																				309.4	327.2	315.2
Revenue																				485	373.3	373.7
Effient [Member]
Sales Revenue, Goods, Net																				523	522.2	508.7
Exenatide [Member]
Revenue																						133.1
Other Nonoperating Income (Expense)	[1]																					495.4
Boerhringer Ingelheim (BI) [Member]
Collaboration and other revenue																				356.8	328.8	249.2
BI compounds [Member]
Other-net, (income) expense										$ 92
LLY compounds [Member]
Acquired in-process research and development														$ 55.2
Tanezumab [Member]
Acquired in-process research and development													$ 200
United States [Member]
Revenue	[2]																			10,097.4	9,134.1	12,889.7
Revenue Share [Member] | Amylin [Member]
Collaborative Arrangement, Rights and Obligations, Terms				$ 1,260
Milestone Payments [Member] | Solanezumab [Member]
Collaborative Arrangement, Rights and Obligations, Terms																		$ (70)
Milestone Payments, Sales-based [Member] | Baricitinib [Member]
Collaborative Arrangement, Rights and Obligations, Terms							$ (150)
Milestone Payments, Sales-based [Member] | Tanezumab [Member]
Collaborative Arrangement, Rights and Obligations, Terms			$ (1,230)
Milestone Payments, Development and Regulatory, Capitalized [Member] | Trajenta (BI) [Member]
Collaborative Arrangement, Rights and Obligations, Terms	[3],[4]																			0	0	0
Milestone Payments, Development and Regulatory, Capitalized [Member] | Jardiance [Member]
Collaborative Arrangement, Rights and Obligations, Terms	[3],[5]																			0	(299.5)	0
Milestone Payments, Development and Regulatory, Capitalized [Member] | LLY compounds [Member]
Collaborative Arrangement, Rights and Obligations, Terms	[3],[6]																			0	62.5	0
Milestone Payments, Development and Regulatory, Capitalized, Cumulative [Member] | Trajenta (BI) [Member]
Collaborative Arrangement, Rights and Obligations, Terms	[3],[4],[7]																			(446.4)
Milestone Payments, Development and Regulatory, Capitalized, Cumulative [Member] | Jardiance [Member]
Collaborative Arrangement, Rights and Obligations, Terms	[3],[5],[7]																			(299.5)
Milestone Payments, Development and Regulatory, Capitalized, Cumulative [Member] | LLY compounds [Member]
Collaborative Arrangement, Rights and Obligations, Terms	[3],[6],[7]																			$ 62.5
Profit And Development And Marketing Share [Member] | Effient [Member]
Collaborative Arrangement, Rights and Obligations Percent								50.00%
Upfront Payment [Member] | Amylin [Member]
Collaborative Arrangement, Rights and Obligations, Terms					$ 250
Sales Reported [Member] | Erbitux [Member]
Collaborative Arrangement, Rights and Obligations Percent																				38.00%
Sales Reported [Member] | Outside the United States [Member] | Exenatide [Member]
Collaborative Arrangement, Rights and Obligations Percent																			100.00%
Research And Development Exp [Member] | Baricitinib [Member]
Collaborative Arrangement, Rights and Obligations Percent							30.00%
Milestone Payments, Development and Regulatory, Expensed [Member] | Trajenta (BI) [Member]
Collaborative Arrangement, Rights and Obligations, Terms	[4],[8]																			$ 0	0	0
Milestone Payments, Development and Regulatory, Expensed [Member] | Jardiance [Member]
Collaborative Arrangement, Rights and Obligations, Terms	[5],[8]																			0	0	(97.2)
Milestone Payments, Development and Regulatory, Expensed [Member] | LLY compounds [Member]
Collaborative Arrangement, Rights and Obligations, Terms	[8]																			0	0	(50)
Milestone Payments, Development and Regulatory, Expensed [Member] | Baricitinib [Member] | Subsequent Event [Member]
Research and Development Expense									$ 55
Milestone Payments, Development and Regulatory [Member] | Amylin [Member]
Collaborative Arrangement, Rights and Obligations, Terms					$ 150
Milestone Payments, Development and Regulatory [Member] | LLY compounds [Member]
Collaborative Arrangement, Rights and Obligations, Terms						$ 187.5
Milestone Payments, Development and Regulatory [Member] | Baricitinib [Member]
Collaborative Arrangement, Rights and Obligations, Terms							$ (360)
Milestone Payments, Development and Regulatory [Member] | Tanezumab [Member]
Collaborative Arrangement, Rights and Obligations, Terms			$ (350)
Royalty Payments Received [Member] | Solanezumab [Member]
Collaborative Arrangement, Rights and Obligations, Term of Arrangement																		10 years
Royalty Payments Received [Member] | Baricitinib [Member]
Collaborative Arrangement, Rights and Obligations Percent							20.00%
Collaborative Arrangement [Member]
Marketing, selling, and administrative																				213.2	$ 211.2	$ 203.7
Erbitux Acquisition [Member]
Business Acquisition, Pro Forma Revenue																				$ 20,200
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles	[9]																						$ 602.1
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Assets Noncurrent																							232.2
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities Noncurrent																							(228.2)
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets																							57.2
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net																							663.3
Business Combination, Contingent Consideration, Liability	[10]																						$ (663.3)
[1]	(1) Presented in other-net, (income) expense.
[2]	(1) Revenue is attributed to the countries based on the location of the customer.
[3]	(2) In connection with the regulatory approvals of Basaglar in Europe and Japan, milestone payments received were recorded as deferred revenue and are being amortized through the term of the collaboration (2029) to collaboration and other revenue. In connection with the regulatory approvals of Trajenta and Jardiance, milestone payments made were capitalized as intangible assets and are being amortized through the term of the collaboration to cost of sales.
[4]	(3) Jentadueto is included in the Trajenta family of product results.
[5]	(4) Glyxambi and Synjardy are included in the Jardiance family of product results.
[6]	(5) In September 2015, we entered into a settlement agreement to resolve patent infringement litigation filed by Sanofi-Aventis U.S. LLC (Sanofi), which markets Lantus® (insulin glargine). As part of the settlement agreement, the parties agreed that Basaglar can be launched in the U.S. beginning on December 15, 2016. Basaglar received U.S. Food and Drug Administration (FDA) approval in December 2015. As a result of receiving FDA approval, we received $187.5 million in 2016, which was recorded as deferred revenue and will be amortized through the term of the collaboration to collaboration and other revenue upon product launch.
[7]	(6) The cumulative amount represents the total amounts as of the end of the reporting period that have been (deferred) or capitalized since the start of this collaboration.
[8]	(1) Milestones earned for Basaglar as a result of regulatory submissions were recorded as income in other-net, (income) expense. Milestones expensed for Jardiance as a result of regulatory submissions were recorded as research and development expenses.
[9]	(1) These intangible assets will be amortized to cost of sales using the straight-line method through the co-development period in North America as set forth in the original agreement, which was scheduled to expire in September 2018.
[10]	(2) See Note 7 for discussion on the estimation of the contingent consideration liability.

Asset Impairments, Restructur57

Asset Impairments, Restructuring, and Other Special Charges (Details) - USD ($) $ in Millions	3 Months Ended									12 Months Ended
	Mar. 31, 2016	Dec. 31, 2015	Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2015	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Unusual or Infrequent Item [Line Items]
Asset Impairment Charges										$ 226.7	$ 243.2	$ 30
Severance Costs										141	225.5	90.6
Asset impairment, restructuring, and other special charges		$ 144.9	$ 42.4	$ 72.4	$ 108	$ 401	$ 36.3	$ 0	$ 31.4	367.7	468.7	120.6
PUERTO RICO
Unusual or Infrequent Item [Line Items]
Asset Impairment Charges						$ 180.8
Human Pharmaceutical Products [Member]
Unusual or Infrequent Item [Line Items]
Asset Impairment Charges										24.6	204.4	30
Severance Costs										81.5	225.5	90.6
Animal Health Products [Member]
Unusual or Infrequent Item [Line Items]
Asset Impairment Charges										202.1	38.8	0
Severance Costs										$ 59.5	$ 0	$ 0
Subsequent Event [Member] | Animal Health Products [Member] | IRELAND
Unusual or Infrequent Item [Line Items]
Asset Impairment Charges	$ 100

Inventories (Details)

Inventories (Details) - USD ($) $ in Millions	Dec. 31, 2015	Dec. 31, 2014
Inventory [Line Items]
LIFO Inventory Amount	$ 1,300	$ 1,090
Finished products	1,053.4	838
Work in process	2,058.1	1,715.4
Raw materials and supplies	403	315
Inventory, Gross, Total	3,514.5	2,868.4
Reduction to LIFO cost	(68.7)	(128.4)
Inventories	$ 3,445.8	$ 2,740

Financial Instruments (Details)

Financial Instruments (Details) € in Millions, ¥ in Millions, £ in Millions		1 Months Ended	12 Months Ended
		Feb. 28, 2015USD ($)	Dec. 31, 2015USD ($)	Dec. 31, 2014USD ($)	Dec. 31, 2013USD ($)	Dec. 31, 2015EUR (€)	Dec. 31, 2015JPY (¥)	Dec. 31, 2015GBP (£)	Jun. 30, 2015USD ($)	Feb. 27, 2015USD ($)
Average Remaining Maturity of Foreign Currency Derivatives			12 months
Commercial Paper			$ 0	$ 2,680,600,000
Derivative Liability, Notional Amount										$ 1,350,000,000
Net proceeds from (payments for) terminations of interest rate swaps		$ (206,300,000)	(186,100,000)	340,700,000	$ 0
Proceeds from Sale of Available-for-sale Securities			$ 4,733,300,000	14,609,500,000	13,753,500,000
Available-for-sale, Securities in Unrealized Loss Positions, Qualitative Disclosure, Other, Percentage of Nonperforming Assets			85.00%
Maximum Remaining Maturity of Foreign Currency Derivatives			30 days
Long-term Debt, Percentage Bearing Variable Interest, Percentage Rate			40.00%			40.00%	40.00%	40.00%
Interest Rate Cash Flow Hedge Gain (Loss) to be Reclassified During Next 12 Months, Net			$ 14,800,000
Available-for-sale Securities, Continuous Unrealized Gain Position, Fair Value			764,500,000	1,778,800,000
Available-for-sale Securities, Continuous Unrealized Loss Position, Fair Value			2,933,400,000	3,129,200,000
Other than Temporary Impairment Losses, Investments			42,600,000	12,500,000	11,300,000
Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax			52,500,000	18,300,000
Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax			68,000,000	171,900,000
Available-for-sale Securities, Gross Realized Gains			255,100,000	353,500,000	49,500,000
Available-for-sale Securities, Gross Realized Losses			10,300,000	29,400,000	15,400,000
Available-for-sale Securities, Current [Abstract]
Available-for-sale Securities, Current, Total			785,400,000
Available-for-sale Securities, Noncurrent [Abstract]
Available-for-sale Securities, Debt Maturities, Next Twelve Months, Fair Value			785,400,000
Available-for-sale Securities, Debt Maturities, Year Two Through Five, Fair Value			2,516,800,000
Available-for-sale Securities, Debt Maturities, Year Six Through Ten, Fair Value			164,000,000
Available-for-sale Securities, Debt Maturities, after Ten Years, Fair Value			165,600,000
Available-for-sale Securities, Debt Securities			3,631,800,000
Translation Adjustment Functional to Reporting Currency, Increase (Decrease), Gross of Tax			5,600,000
Hedged Fixed-Rate Debt [Member]
Change in Unrealized Gain (Loss) on Hedged Item in Fair Value Hedge			(11,900,000)	156,900,000	(308,200,000)
Equity Contract [Member]
Derivative Instruments, Loss Reclassified from Accumulated OCI into Income, Effective Portion	[1]		0	129,000,000	0
Derivative Instruments, Gain (Loss) Recognized in Other Comprehensive Income (Loss), Effective Portion, Net			0	149,600,000	(149,600,000)
Available-for-sale Securities, Gross Realized Gains			0	260,800,000	0
Interest Rate Contract [Member]
Change in Unrealized Gain (Loss) on Fair Value Hedging Instruments			11,900,000	(156,900,000)	308,200,000
Derivative Instruments, Loss Reclassified from Accumulated OCI into Income, Effective Portion			13,700,000	9,000,000	9,000,000
Interest Rate Swap [Member]
Net proceeds from (payments for) terminations of interest rate swaps			(20,200,000)	(340,700,000)
Derivative Instruments, Gain (Loss) Recognized in Other Comprehensive Income (Loss), Effective Portion, Net			(56,700,000)	(164,700,000)	16,700,000
Foreign Exchange Contract [Member]
Gain (Loss) on Foreign Currency Derivative Instruments Not Designated as Hedging Instruments			(28,200,000)	(20,400,000)	$ 15,400,000
Available-for-Sale Securities, Amortized Cost [Member]
Cash and Cash Equivalents, Fair Value Disclosure	[2]		1,644,400,000	2,443,500,000
Available-for-sale Securities, Current [Abstract]
Available-for-sale Securities, Current, Total	[2]		786,700,000	954,800,000
Available-for-sale Securities, Noncurrent [Abstract]
Available-for-sale Securities, Noncurrent, Total	[2]		3,629,800,000	4,415,900,000
Estimate of Fair Value Measurement [Member]
Commercial Paper			0	2,680,600,000
Cash and Cash Equivalents, Fair Value Disclosure			1,644,400,000	2,443,500,000
Long-term Debt			(8,172,000,000)	(5,722,100,000)
Business Combination, Contingent Consideration, Liability, Current	[3]		(243,700,000)
Business Combination, Contingent Consideration, Liability, Noncurrent	[3]		(427,200,000)
Carrying (Reported) Amount, Fair Value Disclosure [Member]
Commercial Paper			0	2,680,600,000
Derivative Asset, Notional Amount			876,000,000	1,300,000,000
Cash and Cash Equivalents, Fair Value Disclosure			1,644,400,000	2,443,500,000
Long-term Debt			(7,978,500,000)	(5,340,900,000)
Business Combination, Contingent Consideration, Liability, Current	[3]		(243,700,000)
Business Combination, Contingent Consideration, Liability, Noncurrent	[3]		(427,200,000)
Available-for-sale Securities, Current [Abstract]
Available-for-sale Securities, Current, Total				955,400,000
Available-for-sale Securities, Noncurrent [Abstract]
Available-for-sale Securities, Noncurrent, Total			3,646,600,000	4,568,900,000
Fair Value, Inputs, Level 1 [Member]
Commercial Paper			0	0
Cash and Cash Equivalents, Fair Value Disclosure			1,637,000,000	2,415,500,000
Long-term Debt			0	0
Business Combination, Contingent Consideration, Liability, Current	[3]		0
Business Combination, Contingent Consideration, Liability, Noncurrent	[3]		0
Fair Value, Inputs, Level 2 [Member]
Commercial Paper			0	2,680,600,000
Cash and Cash Equivalents, Fair Value Disclosure			7,400,000	28,000,000
Long-term Debt			(8,172,000,000)	(5,722,100,000)
Business Combination, Contingent Consideration, Liability, Current	[3]		0
Business Combination, Contingent Consideration, Liability, Noncurrent	[3]		0
Fair Value, Inputs, Level 3 [Member]
Commercial Paper			0	0
Cash and Cash Equivalents, Fair Value Disclosure			0	0
Long-term Debt			0	0
Business Combination, Contingent Consideration, Liability, Current	[3]		(243,700,000)
Business Combination, Contingent Consideration, Liability, Noncurrent	[3]		(427,200,000)
Corporate Debt Securities [Member] | Available-for-Sale Securities, Amortized Cost [Member]
Available-for-sale Securities, Current [Abstract]
Available-for-sale Securities, Debt Securities, Current	[2]		626,900,000	766,700,000
Available-for-sale Securities, Noncurrent [Abstract]
Available-for-sale Securities, Debt Securities, Noncurrent	[2]		1,995,800,000	2,468,900,000
Corporate Debt Securities [Member] | Estimate of Fair Value Measurement [Member]
Available-for-sale Securities, Current [Abstract]
Available-for-sale Securities, Debt Securities, Current			625,800,000	767,400,000
Available-for-sale Securities, Noncurrent [Abstract]
Available-for-sale Securities, Debt Securities, Noncurrent			1,962,600,000	2,462,700,000
Corporate Debt Securities [Member] | Carrying (Reported) Amount, Fair Value Disclosure [Member]
Available-for-sale Securities, Current [Abstract]
Available-for-sale Securities, Debt Securities, Current			625,800,000	767,400,000
Available-for-sale Securities, Noncurrent [Abstract]
Available-for-sale Securities, Debt Securities, Noncurrent			1,962,600,000	2,462,700,000
Corporate Debt Securities [Member] | Fair Value, Inputs, Level 1 [Member]
Available-for-sale Securities, Current [Abstract]
Available-for-sale Securities, Debt Securities, Current			0	0
Available-for-sale Securities, Noncurrent [Abstract]
Available-for-sale Securities, Debt Securities, Noncurrent			0	0
Corporate Debt Securities [Member] | Fair Value, Inputs, Level 2 [Member]
Available-for-sale Securities, Current [Abstract]
Available-for-sale Securities, Debt Securities, Current			625,800,000	767,400,000
Available-for-sale Securities, Noncurrent [Abstract]
Available-for-sale Securities, Debt Securities, Noncurrent			1,962,600,000	2,462,700,000
Corporate Debt Securities [Member] | Fair Value, Inputs, Level 3 [Member]
Available-for-sale Securities, Current [Abstract]
Available-for-sale Securities, Debt Securities, Current			0	0
Available-for-sale Securities, Noncurrent [Abstract]
Available-for-sale Securities, Debt Securities, Noncurrent			0	0
US Government Agencies Debt Securities [Member] | Available-for-Sale Securities, Amortized Cost [Member]
Available-for-sale Securities, Current [Abstract]
Available-for-sale Securities, Debt Securities, Current	[2]		153,400,000	185,600,000
Available-for-sale Securities, Noncurrent [Abstract]
Available-for-sale Securities, Debt Securities, Noncurrent	[2]		286,000,000	757,500,000
US Government Agencies Debt Securities [Member] | Estimate of Fair Value Measurement [Member]
Available-for-sale Securities, Current [Abstract]
Available-for-sale Securities, Debt Securities, Current			153,200,000	185,500,000
Available-for-sale Securities, Noncurrent [Abstract]
Available-for-sale Securities, Debt Securities, Noncurrent			284,500,000	756,700,000
US Government Agencies Debt Securities [Member] | Carrying (Reported) Amount, Fair Value Disclosure [Member]
Available-for-sale Securities, Current [Abstract]
Available-for-sale Securities, Debt Securities, Current			153,200,000	185,500,000
Available-for-sale Securities, Noncurrent [Abstract]
Available-for-sale Securities, Debt Securities, Noncurrent			284,500,000	756,700,000
US Government Agencies Debt Securities [Member] | Fair Value, Inputs, Level 1 [Member]
Available-for-sale Securities, Current [Abstract]
Available-for-sale Securities, Debt Securities, Current			153,200,000	156,500,000
Available-for-sale Securities, Noncurrent [Abstract]
Available-for-sale Securities, Debt Securities, Noncurrent			283,500,000	747,500,000
US Government Agencies Debt Securities [Member] | Fair Value, Inputs, Level 2 [Member]
Available-for-sale Securities, Current [Abstract]
Available-for-sale Securities, Debt Securities, Current			0	29,000,000
Available-for-sale Securities, Noncurrent [Abstract]
Available-for-sale Securities, Debt Securities, Noncurrent			1,000,000	9,200,000
US Government Agencies Debt Securities [Member] | Fair Value, Inputs, Level 3 [Member]
Available-for-sale Securities, Current [Abstract]
Available-for-sale Securities, Debt Securities, Current			0	0
Available-for-sale Securities, Noncurrent [Abstract]
Available-for-sale Securities, Debt Securities, Noncurrent			0	0
Other Debt Obligations [Member] | Available-for-Sale Securities, Amortized Cost [Member]
Available-for-sale Securities, Current [Abstract]
Available-for-sale Securities, Debt Securities, Current	[2]		3,100,000	2,500,000
Available-for-sale Securities, Noncurrent [Abstract]
Available-for-sale Securities, Debt Securities, Noncurrent	[2]		4,100,000	3,200,000
Other Debt Obligations [Member] | Estimate of Fair Value Measurement [Member]
Available-for-sale Securities, Current [Abstract]
Available-for-sale Securities, Debt Securities, Current			3,100,000	2,500,000
Available-for-sale Securities, Noncurrent [Abstract]
Available-for-sale Securities, Debt Securities, Noncurrent			4,100,000	3,200,000
Other Debt Obligations [Member] | Carrying (Reported) Amount, Fair Value Disclosure [Member]
Available-for-sale Securities, Current [Abstract]
Available-for-sale Securities, Debt Securities, Current			3,100,000	2,500,000
Available-for-sale Securities, Noncurrent [Abstract]
Available-for-sale Securities, Debt Securities, Noncurrent			4,100,000	3,200,000
Other Debt Obligations [Member] | Fair Value, Inputs, Level 1 [Member]
Available-for-sale Securities, Current [Abstract]
Available-for-sale Securities, Debt Securities, Current			0	0
Available-for-sale Securities, Noncurrent [Abstract]
Available-for-sale Securities, Debt Securities, Noncurrent			0	0
Other Debt Obligations [Member] | Fair Value, Inputs, Level 2 [Member]
Available-for-sale Securities, Current [Abstract]
Available-for-sale Securities, Debt Securities, Current			3,100,000	2,500,000
Available-for-sale Securities, Noncurrent [Abstract]
Available-for-sale Securities, Debt Securities, Noncurrent			4,100,000	3,200,000
Other Debt Obligations [Member] | Fair Value, Inputs, Level 3 [Member]
Available-for-sale Securities, Current [Abstract]
Available-for-sale Securities, Debt Securities, Current			0	0
Available-for-sale Securities, Noncurrent [Abstract]
Available-for-sale Securities, Debt Securities, Noncurrent			0	0
Collateralized Mortgage Backed Securities [Member] | Available-for-Sale Securities, Amortized Cost [Member]
Available-for-sale Securities, Noncurrent [Abstract]
Available-for-sale Securities, Debt Securities, Noncurrent	[2]		154,700,000	217,600,000
Collateralized Mortgage Backed Securities [Member] | Estimate of Fair Value Measurement [Member]
Available-for-sale Securities, Noncurrent [Abstract]
Available-for-sale Securities, Debt Securities, Noncurrent			153,300,000	217,000,000
Collateralized Mortgage Backed Securities [Member] | Carrying (Reported) Amount, Fair Value Disclosure [Member]
Available-for-sale Securities, Noncurrent [Abstract]
Available-for-sale Securities, Debt Securities, Noncurrent			153,300,000	217,000,000
Collateralized Mortgage Backed Securities [Member] | Fair Value, Inputs, Level 1 [Member]
Available-for-sale Securities, Noncurrent [Abstract]
Available-for-sale Securities, Debt Securities, Noncurrent			0	0
Collateralized Mortgage Backed Securities [Member] | Fair Value, Inputs, Level 2 [Member]
Available-for-sale Securities, Noncurrent [Abstract]
Available-for-sale Securities, Debt Securities, Noncurrent			153,300,000	217,000,000
Collateralized Mortgage Backed Securities [Member] | Fair Value, Inputs, Level 3 [Member]
Available-for-sale Securities, Noncurrent [Abstract]
Available-for-sale Securities, Debt Securities, Noncurrent			0	0
Asset-backed Securities [Member] | Available-for-Sale Securities, Amortized Cost [Member]
Available-for-sale Securities, Current [Abstract]
Available-for-sale Securities, Debt Securities, Current	[2]		3,300,000
Available-for-sale Securities, Noncurrent [Abstract]
Available-for-sale Securities, Debt Securities, Noncurrent	[2]		443,100,000	478,000,000
Asset-backed Securities [Member] | Estimate of Fair Value Measurement [Member]
Available-for-sale Securities, Current [Abstract]
Available-for-sale Securities, Debt Securities, Current			3,300,000
Available-for-sale Securities, Noncurrent [Abstract]
Available-for-sale Securities, Debt Securities, Noncurrent			441,900,000	477,800,000
Asset-backed Securities [Member] | Carrying (Reported) Amount, Fair Value Disclosure [Member]
Available-for-sale Securities, Current [Abstract]
Available-for-sale Securities, Debt Securities, Current			3,300,000
Available-for-sale Securities, Noncurrent [Abstract]
Available-for-sale Securities, Debt Securities, Noncurrent			441,900,000	477,800,000
Asset-backed Securities [Member] | Fair Value, Inputs, Level 1 [Member]
Available-for-sale Securities, Current [Abstract]
Available-for-sale Securities, Debt Securities, Current			0
Available-for-sale Securities, Noncurrent [Abstract]
Available-for-sale Securities, Debt Securities, Noncurrent			0	0
Asset-backed Securities [Member] | Fair Value, Inputs, Level 2 [Member]
Available-for-sale Securities, Current [Abstract]
Available-for-sale Securities, Debt Securities, Current			3,300,000
Available-for-sale Securities, Noncurrent [Abstract]
Available-for-sale Securities, Debt Securities, Noncurrent			441,900,000	477,800,000
Asset-backed Securities [Member] | Fair Value, Inputs, Level 3 [Member]
Available-for-sale Securities, Current [Abstract]
Available-for-sale Securities, Debt Securities, Current			0
Available-for-sale Securities, Noncurrent [Abstract]
Available-for-sale Securities, Debt Securities, Noncurrent			0	0
Equity Securities [Member] | Available-for-Sale Securities, Amortized Cost [Member]
Available-for-sale Securities, Noncurrent [Abstract]
Available-for-sale Securities, Equity Securities, Noncurrent	[2]		74,800,000	44,000,000
Equity Securities [Member] | Estimate of Fair Value Measurement [Member]
Available-for-sale Securities, Noncurrent [Abstract]
Available-for-sale Securities, Equity Securities, Noncurrent			128,900,000	204,800,000
Equity Securities [Member] | Carrying (Reported) Amount, Fair Value Disclosure [Member]
Available-for-sale Securities, Noncurrent [Abstract]
Available-for-sale Securities, Equity Securities, Noncurrent			128,900,000	204,800,000
Equity Securities [Member] | Fair Value, Inputs, Level 1 [Member]
Available-for-sale Securities, Noncurrent [Abstract]
Available-for-sale Securities, Equity Securities, Noncurrent			128,900,000	204,800,000
Equity Securities [Member] | Fair Value, Inputs, Level 2 [Member]
Available-for-sale Securities, Noncurrent [Abstract]
Available-for-sale Securities, Equity Securities, Noncurrent			0	0
Equity Securities [Member] | Fair Value, Inputs, Level 3 [Member]
Available-for-sale Securities, Noncurrent [Abstract]
Available-for-sale Securities, Equity Securities, Noncurrent			0	0
Equity Method and Other Investments [Member] | Available-for-Sale Securities, Amortized Cost [Member]
Available-for-sale Securities, Noncurrent [Abstract]
Other Long-term Investments	[2],[4]		671,300,000	446,700,000
Equity Method and Other Investments [Member] | Carrying (Reported) Amount, Fair Value Disclosure [Member]
Available-for-sale Securities, Noncurrent [Abstract]
Other Long-term Investments	[4]		671,300,000	446,700,000
Buy euro Sell US dollar [Member]
Derivative Liability, Notional Amount | €						€ 1,850
Derivative Asset, Notional Amount			2,040,000,000
Buy USD Sell Euro [Member]
Derivative Liability, Notional Amount			1,170,000,000
Derivative Asset, Notional Amount | €						1,060
Buy GBP Sell Euro [Member]
Derivative Liability, Notional Amount | £								£ 187.7
Derivative Asset, Notional Amount | €						€ 258.4
Buy US dollar Sell British pound [Member]
Derivative Liability, Notional Amount			288,300,000
Derivative Asset, Notional Amount | £								£ 190.6
Buy USD Sell Japanese Yen [Member]
Derivative Liability, Notional Amount			561,700,000
Derivative Asset, Notional Amount | ¥							¥ 67,780
Designated as Hedging Instrument [Member] | Estimate of Fair Value Measurement [Member] | Interest Rate Contract [Member]
Derivative Assets, Noncurrent			70,100,000	102,500,000
Derivative Liability, Noncurrent			(400,000)	(700,000)
Derivative Liabilities, Current				149,500,000
Designated as Hedging Instrument [Member] | Carrying (Reported) Amount, Fair Value Disclosure [Member] | Interest Rate Contract [Member]
Derivative Assets, Noncurrent			70,100,000	102,500,000
Derivative Liability, Noncurrent			(400,000)	(700,000)
Derivative Liabilities, Current				149,500,000
Designated as Hedging Instrument [Member] | Fair Value, Inputs, Level 1 [Member] | Interest Rate Contract [Member]
Derivative Assets, Noncurrent			0	0
Derivative Liability, Noncurrent			0	0
Derivative Liabilities, Current				0
Designated as Hedging Instrument [Member] | Fair Value, Inputs, Level 2 [Member] | Interest Rate Contract [Member]
Derivative Assets, Noncurrent			70,100,000	102,500,000
Derivative Liability, Noncurrent			(400,000)	(700,000)
Derivative Liabilities, Current				149,500,000
Designated as Hedging Instrument [Member] | Fair Value, Inputs, Level 3 [Member] | Interest Rate Contract [Member]
Derivative Assets, Noncurrent			0	0
Derivative Liability, Noncurrent			0	0
Derivative Liabilities, Current				0
Not Designated as Hedging Instrument [Member] | Estimate of Fair Value Measurement [Member] | Foreign Exchange Contract [Member]
Derivative Assets, Current			13,100,000	9,100,000
Derivative Liabilities, Current			17,300,000	14,000,000
Not Designated as Hedging Instrument [Member] | Carrying (Reported) Amount, Fair Value Disclosure [Member] | Foreign Exchange Contract [Member]
Derivative Assets, Current			13,100,000	9,100,000
Derivative Liabilities, Current			17,300,000	14,000,000
Not Designated as Hedging Instrument [Member] | Fair Value, Inputs, Level 1 [Member] | Foreign Exchange Contract [Member]
Derivative Assets, Current			0	0
Derivative Liabilities, Current			0	0
Not Designated as Hedging Instrument [Member] | Fair Value, Inputs, Level 2 [Member] | Foreign Exchange Contract [Member]
Derivative Assets, Current			13,100,000	9,100,000
Derivative Liabilities, Current			17,300,000	14,000,000
Not Designated as Hedging Instrument [Member] | Fair Value, Inputs, Level 3 [Member] | Foreign Exchange Contract [Member]
Derivative Assets, Current			0	0
Derivative Liabilities, Current			$ 0	$ 0
Euro-Denominated Debt Issuance [Member]
Long-term Debt									$ (2,270,000,000)
[1]	(1) Realized gains on the sale of underlying equity securities recognized in other-net, (income) expense were $260.8 million during the year ended December 31, 2014. There were no realized gains on the sale of underlying equity securities during the years ended December 31, 2015 and 2013.
[2]	(1) For available-for-sale debt securities, amounts disclosed represent the securities' amortized cost.
[3]	(1) The contingent consideration liability relates to the Erbitux arrangement with BMS discussed in Note 4.
[4]	(2) Primarily includes investments accounted for under the cost method and equity method for which fair value disclosures are not applicable.

Goodwill and Other Intangible60

Goodwill and Other Intangibles (Details) - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Finite-Lived Intangible Assets, Gross	$ 7,679,100,000	$ 5,833,600,000
Impairment of Intangible Assets, Finite-lived	0
Goodwill, Impairment Loss	0	0	$ 0
Goodwill	4,039,900,000	1,758,100,000
Indefinite-Lived Intangible Assets (Excluding Goodwill)	177,600,000	11,400,000
Intangible Assets, Gross (Excluding Goodwill)	7,856,700,000	5,845,000,000
Finite-Lived Intangible Assets, Accumulated Amortization	(2,821,900,000)	(2,960,800,000)
Other intangibles, net	5,034,800,000	2,884,200,000
Finite-Lived Intangible Assets, Net	$ 4,857,200,000	2,872,800,000
Finite-Lived Intangible Assets, Weighted-Average Useful Life	12 years
Amortization of Intangible Assets	$ 631,800,000	535,900,000	$ 555,000,000
Future Amortization Expense, Year One	674,700,000
Future Amortization Expense, Year Two	641,800,000
Future Amortization Expense, Year Three	480,400,000
Future Amortization Expense, Year Four	302,700,000
Future Amortization Expense, Year Five	301,400,000
In-process Research and Development [Member]
Finite-Lived Intangible Assets, Accumulated Amortization	0	0
Human Pharmaceutical Products [Member]
Goodwill	1,366,500,000	1,359,400,000
Animal Health Products [Member]
Goodwill	2,673,400,000	398,700,000
Developed Technology Rights [Member]
Finite-Lived Intangible Assets, Gross	7,528,000,000	5,684,300,000
Finite-Lived Intangible Assets, Accumulated Amortization	(2,706,400,000)	(2,915,600,000)
Finite-Lived Intangible Assets, Net	4,821,600,000	2,768,700,000
Other Intangible Assets [Member]
Finite-Lived Intangible Assets, Gross	151,100,000	149,300,000
Finite-Lived Intangible Assets, Accumulated Amortization	(115,500,000)	(45,200,000)
Finite-Lived Intangible Assets, Net	$ 35,600,000	$ 104,100,000
Maximum [Member]
Finite-Lived Intangible Assets, Useful Life	20 years
Minimum [Member]
Finite-Lived Intangible Assets, Useful Life	3 years

Property and Equipment (Details

Property and Equipment (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Property, Plant and Equipment [Line Items]
Depreciation	$ 717.6	$ 759.1	$ 774.8
Land	220.6	205.2
Buildings	6,786.5	6,516.2
Equipment	7,988.5	7,609.7
Construction in progress	1,665.3	1,698.2
Property and equipment, gross	16,660.9	16,029.3
Less accumulated depreciation	(8,607.4)	(8,065.4)
Property and equipment, net	8,053.5	7,963.9
Operating Leases, Rent Expense	$ 225.7	$ 227.3	$ 227.2
Building [Member] | Minimum [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	12 years
Building [Member] | Maximum [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	50 years
Equipment [Member] | Minimum [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	3 years
Equipment [Member] | Maximum [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	25 years

Borrowings (Details)

Borrowings (Details) € in Millions, $ in Millions	3 Months Ended		12 Months Ended
	Jun. 30, 2015USD ($)	Mar. 31, 2014USD ($)	Dec. 31, 2015USD ($)	Dec. 31, 2014USD ($)	Dec. 31, 2013USD ($)	Jun. 30, 2015EUR (€)	Mar. 31, 2015USD ($)	Aug. 31, 2014USD ($)	Feb. 28, 2014USD ($)
Commercial Paper			$ 0	$ 2,680.6
Short-term borrowings and current maturities of long-term debt			$ (6.1)	(2,688.7)
Short-term Debt, Weighted Average Interest Rate			0.18%
Debt Instrument, Interest Rate, Stated Percentage Rate Range, Minimum			1.00%
Repayments of Long-term Debt	$ 1,950	$ 1,000	$ 1,955.7	1,034.8	$ 10.5
Extinguishment of Debt, Amount	$ 1,650
Gains (Losses) on Extinguishment of Debt			166.7	0	0
Notes Payable			7,700.1	4,872.8
Other Notes Payable			23.1	33.1
Unamortized Debt Issuance Expense			(37.1)	(20.4)
Long-term Debt, Fair Value Adjustment			292.4	455.4
Debt, Long-term and Short-term, Combined Amount			7,978.5	8,021.5
Long-term debt			$ 7,972.4	5,332.8
Description of Derivative Activity Volume Percent			40.00%
Proceeds from issuance of long-term debt			$ 4,454.7	992.9	0
Long-term Debt, Maturities, Repayments of Principal in Next Twelve Months			6.1
Long-term Debt, Maturities, Repayments of Principal in Year Two			635.2
Long-term Debt, Maturities, Repayments of Principal in Year Three			803.2
Long-term Debt, Maturities, Repayments of Principal in Year Four			601.8
Long-term Debt, Maturities, Repayments of Principal in Year Five			0.6
Line of Credit Facility, Remaining Borrowing Capacity			1,300
Line of Credit Facility, Amount Outstanding			0	0
Interest Paid, Net			$ 129.6	$ 140.4	$ 139.7
Debt Instrument, Interest Rate, Effective Percentage			2.67%	3.69%
Debt Instrument, Interest Rate, Stated Percentage Rate Range, Maximum			7.13%
Maturity Date, 2020 [Member]
Line of Credit Facility, Maximum Borrowing Capacity								$ 1,200
Maturity Date, 2019 [Member]
Debt Instrument, Interest Rate, Stated Percentage									1.95%
Long-term Debt									$ 600
Maturity Date, 2015 [Member]
Line of Credit Facility, Maximum Borrowing Capacity								$ 2,000
Maturity Date, 2018 [Member]
Debt Instrument, Interest Rate, Stated Percentage							1.25%
Long-term Debt							$ 600
Maturity Date, 2025 [Member]
Debt Instrument, Interest Rate, Stated Percentage							2.75%
Long-term Debt							$ 800
Maturity Date, 2045 [Member]
Debt Instrument, Interest Rate, Stated Percentage							3.70%
Long-term Debt							$ 800
Maturity Date, 2022 [Member] [Member]
Debt Instrument, Interest Rate, Stated Percentage	1.00%					1.00%
Long-term Debt | €						€ 600
Maturity Date, 2026 [Member]
Debt Instrument, Interest Rate, Stated Percentage	1.63%					1.63%
Long-term Debt | €						€ 750
Maturity Date, 2030 [Member]
Debt Instrument, Interest Rate, Stated Percentage	2.13%					2.13%
Long-term Debt | €						€ 750
Euro-Denominated Debt Issuance [Member]
Proceeds from issuance of long-term debt	$ 2,270
Long-term Debt	2,270
Maturity Date, 2044 [Member]
Debt Instrument, Interest Rate, Stated Percentage									4.65%
Long-term Debt									$ 400
Carrying (Reported) Amount, Fair Value Disclosure [Member]
Commercial Paper			$ 0	$ 2,680.6
Extinguishment of Debt, Amount	$ 1,780
Long-term Debt			$ 7,978.5	$ 5,340.9

Stock-Based Compensation (Detai

Stock-Based Compensation (Details) - USD ($) $ / shares in Units, shares in Millions, $ in Millions	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Allocated Share-based Compensation Expense	$ 217.8	$ 156	$ 144.9
Employee Service Share-based Compensation, Tax Benefit from Compensation Expense	$ 76.2	$ 54.6	$ 50.7
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant	100.6
Performance Shares [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Employee Service Share-based Compensation, Nonvested Awards, Total Compensation Cost Not yet Recognized	$ 69.5
Employee Service Share-based Compensation, Nonvested Awards, Total Compensation Cost Not yet Recognized, Period for Recognition	12 months
Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period	0.5	0.7	0.7
Share Based Compensation Arrangement by Share-based Payment Award, Expected Shares To Be Issued	0.5
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value	$ 70.34	$ 48.81	$ 50.19
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period	2 years
Shareholder Value Awards [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Employee Service Share-based Compensation, Nonvested Awards, Total Compensation Cost Not yet Recognized	$ 59.9
Employee Service Share-based Compensation, Nonvested Awards, Total Compensation Cost Not yet Recognized, Period for Recognition	20 months
Share Based Compensation Arrangement by Share-based Payment Award, Expected Shares To Be Issued	1
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value	$ 54.81	$ 41.97	$ 45.17
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate	2.50%	3.50%	3.50%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate	0.79%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum		0.71%	0.43%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate	20.37%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum		0.08%	0.08%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum		18.87%	18.95%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum		21.56%	22.37%
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period	(1.4)	(1.4)	(1.5)
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period	3 years
Restricted Stock Units (RSUs) [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Employee Service Share-based Compensation, Nonvested Awards, Total Compensation Cost Not yet Recognized	$ 103
Employee Service Share-based Compensation, Nonvested Awards, Total Compensation Cost Not yet Recognized, Period for Recognition	24 months
Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period	0.9	0.9	0.8
Share Based Compensation Arrangement by Share-based Payment Award, Expected Shares To Be Issued	0.6
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value	$ 71.69	$ 52.72	$ 54.10
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period	0.9	1.2	1.1
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period	3 years

Shareholders' Equity (Details)

Shareholders' Equity (Details) - USD ($) shares in Thousands, $ in Millions	3 Months Ended								12 Months Ended
	Dec. 31, 2015	Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2015	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013	Oct. 31, 2013
Purchase for treasury									$ 749.5	$ 800	$ 1,600
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest	$ 14,590.3				$ 15,388.1				$ 14,590.3	$ 15,388.1
Common stock shares in treasury, shares in thousands	796				810				796	810
Net income	$ 478.4	$ 799.7	$ 600.8	$ 529.5	$ 428.5	$ 500.6	$ 733.5	$ 727.9	$ 2,408.4	$ 2,390.5	4,684.8
Treasury Stock, Retired, Cost Method, Amount									$ 0	$ 0	0
Preferred Stock, Shares Authorized	5,000								5,000
Preferred Stock, Shares Issued	0				0				0	0
Common Stock, Shares Held in Employee Trust, Shares	50,000				50,000				50,000	50,000
Employee benefit trust	$ 3,013.2				$ 3,013.2				$ 3,013.2	$ 3,013.2
Other comprehensive income (loss)									(588.9)	(1,989.1)	1,794.4
Allocated Share-based Compensation Expense									$ 217.8	$ 156	144.9
Issued shares, shares in thousands	1,106,063				1,111,437				1,106,063	1,111,437
Retained Earnings [Member]
Net income									$ 2,408.4	$ 2,390.5	4,684.8
Treasury Stock, Retired, Cost Method, Amount									(743.3)	(792.1)	(1,677.8)
Treasury Stock [Member]
Purchase for treasury									749.5	800	1,600
Treasury Stock, Retired, Cost Method, Amount									$ (749.5)	$ (800)	$ (1,698.1)
Treasury Stock, Shares, Retired									(9,877)	(12,579)	(32,406)
2012 Share Repurchase Program [Member]
Purchase for treasury											$ 1,100
Stock Repurchase Program, Authorized Amount											1,500
2013 Share Repurchase Program [Member]
Purchase for treasury									$ 749.5	$ 800	$ 500
Stock Repurchase Program, Authorized Amount												$ 5,000
Stock Repurchase Program, Remaining Authorized Repurchase Amount	$ 2,950								$ 2,950

Earnings (Loss) Per Share (Deta

Earnings (Loss) Per Share (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Millions	3 Months Ended								12 Months Ended
	Dec. 31, 2015	Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2015	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Net income	$ 478.4	$ 799.7	$ 600.8	$ 529.5	$ 428.5	$ 500.6	$ 733.5	$ 727.9	$ 2,408.4	$ 2,390.5	$ 4,684.8
Basic									1,061,913	1,069,932	1,080,874
Basic	$ 0.45	$ 0.75	$ 0.57	$ 0.50	$ 0.40	$ 0.47	$ 0.68	$ 0.68	$ 2.27	$ 2.23	$ 4.33
Diluted									1,065,720	1,074,286	1,084,766
Diluted	$ 0.45	$ 0.75	$ 0.56	$ 0.50	$ 0.40	$ 0.47	$ 0.68	$ 0.68	$ 2.26	$ 2.23	$ 4.32

Income Taxes (Composition and D

Income Taxes (Composition and Deferreds) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Unremitted Earnings of Foreign Subsidiaries	$ 26,500
Current Federal Tax Expense (Benefit)	660.5	$ 168.9	$ 259.1
Current Foreign Tax Expense (Benefit)	422	406.2	553.2
Current State and Local Tax Expense (Benefit)	47.5	(2.1)	126.3
Current Income Tax Expense (Benefit), Total	1,130	573	938.6
Deferred Federal Income Tax Expense (Benefit)	(689.6)	(83.3)	297
Deferred Foreign Income Tax Expense (Benefit)	(66)	120.2	(28.2)
Deferred State and Local Income Tax Expense (Benefit)	7.2	(0.1)	(2.9)
Deferred Income Tax Expense (Benefit), Total	(748.4)	36.8	265.9
Income taxes	381.6	609.8	$ 1,204.5
Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits	1,034.6	976.3
Tax Credit Carryforward, Deferred Tax Asset	294.2	279.4
Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Reserves	212.1	241.8
Deferred Tax Assets, Other Comprehensive Loss	129.7	115.3
Deferred Tax Assets, Operating Loss Carryforwards	247.8	265.5
Deferred Tax Assets, Goodwill and Intangible Assets	637.2	473.3
Deferred Tax Asset, Fair Value Adjustments	111.3	176
Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Contingencies	214.6	0
Deferred Tax Assets, Other	628.6	623.2
Deferred Tax Assets, Gross, Total	3,510.1	3,150.8
Deferred Tax Assets, Valuation Allowance	(590.3)	(601.1)
Deferred Tax Assets, Net, Total	2,919.8	2,549.7
Deferred Tax Liabilities, Undistributed Foreign Earnings	(218.8)	(737.1)
Deferred Tax Liabilities, Goodwill and Intangible Assets	(756.3)	(582.6)
Deferred Tax Liabilities, Prepaid Expenses	(317.8)	(275.8)
Deferred Tax Liabilities, Deferred Expense, Capitalized Inventory Costs	(771.3)	(684.6)
Deferred Tax Liabilities, Property, Plant and Equipment	(411.6)	(424.7)
Deferred Tax Liabilities, Derivatives	152.6	276.8
Deferred Tax Liabilities, Total	2,628.4	2,981.6
Deferred Tax Assets, Net	291.4
Deferred Tax Assets, Operating Loss Carryforwards, State and Local	93.2
Deferred Tax Liabilities, Net		$ (431.9)
Carryforward [Member]
Operating Loss Carryforwards	462
Tax Credit Carryforward, Amount	668.5
Expiration 5 years [Member]
Operating Loss Carryforwards	38
Expiration 5-20 years [Member]
Operating Loss Carryforwards	$ 354
Expiration 5-20 years, Minimum [Member]
Operating Loss Carryforwards, Expiration Date	Dec. 31, 2020
Expiration 5-20 years, Maximum [Member]
Operating Loss Carryforwards, Expiration Date	Dec. 31, 2035
Expiration 10-20 years [Member]
Tax Credit Carryforward, Amount	$ 180.5
Expiration 10-20 years, Maximum [Member]
Other Tax Carryforward, Expiration Dates	Dec. 31, 2021
No Expiration [Member]
Operating Loss Carryforwards	$ 70
Internal Revenue Service (IRS) [Member] | Designated Unusable [Member]
Tax Credit Carryforward, Amount	93.4
State and Local Jurisdiction [Member] | Designated Unusable [Member]
Tax Credit Carryforward, Amount	294
Deferred Tax Assets, Tax Credit Carryforwards, Other	8.8
Foreign Tax Authority [Member] | Designated Unusable [Member]
Tax Credit Carryforward, Amount	$ 100.6

Income Taxes (Income Tax Expens

Income Taxes (Income Tax Expense and Unrecognized Tax Benefits) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2010
Significant Change in Unrecognized Tax Benefits is Reasonably Possible [Line Items]
Income Tax Examination, Year under Examination	2,015	2,014	2,013	2,012	2,011	2,010
Income Tax Examination, Estimate of Cash Payment for Taxes from Settlement with Taxing Authority	$ 250
Domestic and Puerto Rican Contribution to Income before Income Taxes	35.00%	20.00%	60.00%
Income Tax Holiday, Termination Date	Dec. 31, 2016
Income Tax Holiday, Commencement Date	Dec. 31, 2017
Income Tax Holiday, Description	P15Y
Income Taxes Paid	$ 969	$ 729.7	$ 1,255.6
Income Tax Reconciliation, Income Tax Expense (Benefit), at Federal Statutory Income Tax Rate	976.5	1,050.1	2,061.3
Effective Income Tax Rate Reconciliation, Tax Credit, Foreign, Amount	565.2	344.8	778.3
Income Tax Reconciliation, Tax Credits	(69.2)	(44.3)	(175.6)
Income Tax Reconciliation, Other Adjustments	39.5	(51.2)	97.1
Income taxes	381.6	609.8	1,204.5
Unrecognized Tax Benefits, Beginning Balance	1,338.8	1,136.4	1,534.3
Unrecognized Tax Benefits, Increases Resulting from Current Period Tax Positions	131.3	126.4	142.5
Unrecognized Tax Benefits, Increases Resulting from Prior Period Tax Positions	116.6	132.6	251.5
Unrecognized Tax Benefits, Decreases Resulting from Prior Period Tax Positions	(45.2)	(32.1)	(358.2)
Unrecognized Tax Benefits, Reductions Resulting from Lapse of Applicable Statute of Limitations	(4)	(3.5)	(24.9)
Unrecognized Tax Benefits, Decreases Resulting from Settlements with Taxing Authorities	(446.2)	(4.2)	(404.9)
Unrecognized Tax Benefits, Increases Resulting from Foreign Currency Translation	(24.7)	(16.8)	(3.9)
Unrecognized Tax Benefits, Ending Balance	1,066.6	1,338.8	1,136.4	$ 1,534.3
Unrecognized Tax Benefits that Would Impact Effective Tax Rate	404.1	638.8
Income Tax Examination, Liability (Refund) Adjustment from Settlement with Taxing Authority	135
Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense	13.2	35.9	$ (10.9)
Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued	216.3	$ 207.2
Minimum [Member]
Significant Change in Unrecognized Tax Benefits is Reasonably Possible [Line Items]
Decrease in Unrecognized Tax Benefits is Reasonably Possible	100
Maximum [Member]
Significant Change in Unrecognized Tax Benefits is Reasonably Possible [Line Items]
Decrease in Unrecognized Tax Benefits is Reasonably Possible	$ 150
Expiration 5-20 years, Minimum [Member]
Significant Change in Unrecognized Tax Benefits is Reasonably Possible [Line Items]
Operating Loss Carryforwards, Expiration Date	Dec. 31, 2020
Expiration 5-20 years [Member]
Significant Change in Unrecognized Tax Benefits is Reasonably Possible [Line Items]
Operating Loss Carryforwards	$ 354
Expiration 5-20 years, Maximum [Member]
Significant Change in Unrecognized Tax Benefits is Reasonably Possible [Line Items]
Operating Loss Carryforwards, Expiration Date	Dec. 31, 2035
Tax Years 2010-2012 [Member]
Significant Change in Unrecognized Tax Benefits is Reasonably Possible [Line Items]
Unrecognized Tax Benefits, Decreases Resulting from Settlements with Taxing Authorities	$ (320)

Retirement Benefits (Schedule o

Retirement Benefits (Schedule of Benefit Obligations and Plan Assets) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Pension Plans, Defined Benefit [Member]
Defined Benefit Plan, Business Combinations and Acquisitions, Benefit Obligation	$ 334.7	$ 0
Defined Benefit Plan, Benefit Obligation, Beginning Balance	12,012.4	9,976.4
Defined Benefit Plan, Service Cost	315.7	240.9	$ 287.1
Defined Benefit Plan, Interest Cost	476.8	472.6	437.2
Defined Benefit Plan, Actuarial Net (Gains) Losses	(812.4)	1,996.3
Defined Benefit Plan, Benefits Paid	(437.8)	(421.2)
Defined Benefit Plan, Plan Amendments	(0.4)	(2.4)
Defined Benefit Plan, Foreign Currency Exchange Rate Changes, Benefit Obligation	(169.8)	(250.2)
Defined Benefit Plan, Benefit Obligation, Ending Balance	11,719.2	12,012.4	9,976.4
Defined Benefit Plan, Fair Value of Plan Assets, Beginning Balance	9,835.7	9,481.7
Defined Benefit Plan, Actual Return on Plan Assets	90.4	813.6
Defined Benefit Plan, Contributions by Employer	(404.1)	(127.2)
Defined Benefit Plan, Foreign Currency Exchange Rate Changes, Plan Assets	(132.7)	(165.6)
Defined Benefit Plan, Fair Value of Plan Assets, Ending Balance	9,995.6	9,835.7	9,481.7
Defined Benefit Plan, Funded Status of Plan	(1,723.6)	(2,176.7)
Pension and Other Postretirement Benefit Plans, Accumulated Other Comprehensive Income (Loss), Net Gains (Losses), before Tax	4,552.7	5,114.9
Pension and Other Postretirement Benefit Plans, Accumulated Other Comprehensive Income (Loss), Net Prior Service Cost (Credit), before Tax	32.5	43.5
Defined Benefit Plan, Amounts Recognized in Balance Sheet, Total	2,861.6	2,981.7
Other Postretirement Benefit Plans, Defined Benefit [Member]
Defined Benefit Plan, Business Combinations and Acquisitions, Benefit Obligation	9.9	0
Defined Benefit Plan, Benefit Obligation, Beginning Balance	1,553.5	1,757.2
Defined Benefit Plan, Service Cost	45.1	33	49.9
Defined Benefit Plan, Interest Cost	62.6	85.6	98.1
Defined Benefit Plan, Actuarial Net (Gains) Losses	(113.5)	293.5
Defined Benefit Plan, Benefits Paid	(77.5)	(76.1)
Defined Benefit Plan, Plan Amendments	0	(533.6)
Defined Benefit Plan, Foreign Currency Exchange Rate Changes, Benefit Obligation	(12.7)	(6.1)
Defined Benefit Plan, Benefit Obligation, Ending Balance	1,467.4	1,553.5	1,757.2
Defined Benefit Plan, Fair Value of Plan Assets, Beginning Balance	1,918.7	1,879.6
Defined Benefit Plan, Actual Return on Plan Assets	85.1	157.4
Defined Benefit Plan, Contributions by Employer	(17.4)	(42.2)
Defined Benefit Plan, Foreign Currency Exchange Rate Changes, Plan Assets	0	0
Defined Benefit Plan, Fair Value of Plan Assets, Ending Balance	1,943.7	1,918.7	1,879.6
Defined Benefit Plan, Funded Status of Plan	476.3	365.2
Pension and Other Postretirement Benefit Plans, Accumulated Other Comprehensive Income (Loss), Net Gains (Losses), before Tax	347.9	439.5
Pension and Other Postretirement Benefit Plans, Accumulated Other Comprehensive Income (Loss), Net Prior Service Cost (Credit), before Tax	(574.8)	(666.7)
Defined Benefit Plan, Amounts Recognized in Balance Sheet, Total	249.4	138
Fair Value, Inputs, Level 2 [Member] | Pension Plans, Defined Benefit [Member]
Defined Benefit Plan, Fair Value of Plan Assets, Beginning Balance	5,076.2
Defined Benefit Plan, Fair Value of Plan Assets, Ending Balance	5,040	5,076.2
Fair Value, Inputs, Level 2 [Member] | Other Postretirement Benefit Plans, Defined Benefit [Member]
Defined Benefit Plan, Fair Value of Plan Assets, Beginning Balance	1,579.6
Defined Benefit Plan, Fair Value of Plan Assets, Ending Balance	1,587.7	1,579.6
Fair Value, Inputs, Level 3 [Member] | Pension Plans, Defined Benefit [Member]
Defined Benefit Plan, Fair Value of Plan Assets, Beginning Balance	2,822.2	2,603.2
Defined Benefit Plan, Fair Value of Plan Assets, Ending Balance	2,851.1	2,822.2	2,603.2
Fair Value, Inputs, Level 3 [Member] | Other Postretirement Benefit Plans, Defined Benefit [Member]
Defined Benefit Plan, Fair Value of Plan Assets, Beginning Balance	216.5	211.1
Defined Benefit Plan, Fair Value of Plan Assets, Ending Balance	228.1	216.5	$ 211.1
Fair Value, Inputs, Level 1 [Member] | Pension Plans, Defined Benefit [Member]
Defined Benefit Plan, Fair Value of Plan Assets, Beginning Balance	1,937.3
Defined Benefit Plan, Fair Value of Plan Assets, Ending Balance	2,104.5	1,937.3
Fair Value, Inputs, Level 1 [Member] | Other Postretirement Benefit Plans, Defined Benefit [Member]
Defined Benefit Plan, Fair Value of Plan Assets, Beginning Balance	122.6
Defined Benefit Plan, Fair Value of Plan Assets, Ending Balance	127.9	122.6
Equity Securities [Member] | Pension Plans, Defined Benefit [Member]
Defined Benefit Plan, Fair Value of Plan Assets, Beginning Balance	411.4
Defined Benefit Plan, Fair Value of Plan Assets, Ending Balance	414.8	411.4
Equity Securities [Member] | Other Postretirement Benefit Plans, Defined Benefit [Member]
Defined Benefit Plan, Fair Value of Plan Assets, Beginning Balance	39.2
Defined Benefit Plan, Fair Value of Plan Assets, Ending Balance	40	39.2
Equity Securities [Member] | Fair Value, Inputs, Level 2 [Member] | Pension Plans, Defined Benefit [Member]
Defined Benefit Plan, Fair Value of Plan Assets, Beginning Balance	227.6
Defined Benefit Plan, Fair Value of Plan Assets, Ending Balance	227.7	227.6
Equity Securities [Member] | Fair Value, Inputs, Level 2 [Member] | Other Postretirement Benefit Plans, Defined Benefit [Member]
Defined Benefit Plan, Fair Value of Plan Assets, Beginning Balance	22
Defined Benefit Plan, Fair Value of Plan Assets, Ending Balance	21.8	22
Equity Securities [Member] | Fair Value, Inputs, Level 3 [Member] | Pension Plans, Defined Benefit [Member]
Defined Benefit Plan, Fair Value of Plan Assets, Beginning Balance	0
Defined Benefit Plan, Fair Value of Plan Assets, Ending Balance	0	0
Equity Securities [Member] | Fair Value, Inputs, Level 3 [Member] | Other Postretirement Benefit Plans, Defined Benefit [Member]
Defined Benefit Plan, Fair Value of Plan Assets, Beginning Balance	0
Defined Benefit Plan, Fair Value of Plan Assets, Ending Balance	0	0
Equity Securities [Member] | Fair Value, Inputs, Level 1 [Member] | Pension Plans, Defined Benefit [Member]
Defined Benefit Plan, Fair Value of Plan Assets, Beginning Balance	183.8
Defined Benefit Plan, Fair Value of Plan Assets, Ending Balance	187.1	183.8
Equity Securities [Member] | Fair Value, Inputs, Level 1 [Member] | Other Postretirement Benefit Plans, Defined Benefit [Member]
Defined Benefit Plan, Fair Value of Plan Assets, Beginning Balance	17.2
Defined Benefit Plan, Fair Value of Plan Assets, Ending Balance	18.2	17.2
Equity Securities - International [Member] | Pension Plans, Defined Benefit [Member]
Defined Benefit Plan, Fair Value of Plan Assets, Beginning Balance	2,337.8
Defined Benefit Plan, Fair Value of Plan Assets, Ending Balance	2,340.6	2,337.8
Equity Securities - International [Member] | Other Postretirement Benefit Plans, Defined Benefit [Member]
Defined Benefit Plan, Fair Value of Plan Assets, Beginning Balance	158.9
Defined Benefit Plan, Fair Value of Plan Assets, Ending Balance	144.7	158.9
Equity Securities - International [Member] | Fair Value, Inputs, Level 2 [Member] | Pension Plans, Defined Benefit [Member]
Defined Benefit Plan, Fair Value of Plan Assets, Beginning Balance	1,338.1
Defined Benefit Plan, Fair Value of Plan Assets, Ending Balance	1,384.3	1,338.1
Equity Securities - International [Member] | Fair Value, Inputs, Level 2 [Member] | Other Postretirement Benefit Plans, Defined Benefit [Member]
Defined Benefit Plan, Fair Value of Plan Assets, Beginning Balance	100.1
Defined Benefit Plan, Fair Value of Plan Assets, Ending Balance	93.2	100.1
Equity Securities - International [Member] | Fair Value, Inputs, Level 3 [Member] | Pension Plans, Defined Benefit [Member]
Defined Benefit Plan, Fair Value of Plan Assets, Beginning Balance	0
Defined Benefit Plan, Fair Value of Plan Assets, Ending Balance	0	0
Equity Securities - International [Member] | Fair Value, Inputs, Level 3 [Member] | Other Postretirement Benefit Plans, Defined Benefit [Member]
Defined Benefit Plan, Fair Value of Plan Assets, Beginning Balance	0
Defined Benefit Plan, Fair Value of Plan Assets, Ending Balance	0	0
Equity Securities - International [Member] | Fair Value, Inputs, Level 1 [Member] | Pension Plans, Defined Benefit [Member]
Defined Benefit Plan, Fair Value of Plan Assets, Beginning Balance	999.7
Defined Benefit Plan, Fair Value of Plan Assets, Ending Balance	956.3	999.7
Equity Securities - International [Member] | Fair Value, Inputs, Level 1 [Member] | Other Postretirement Benefit Plans, Defined Benefit [Member]
Defined Benefit Plan, Fair Value of Plan Assets, Beginning Balance	58.8
Defined Benefit Plan, Fair Value of Plan Assets, Ending Balance	$ 51.5	$ 58.8

Retirement Benefits (Schedule69

Retirement Benefits (Schedule of Components in Consolidated Balance Sheets) (Details) - USD ($) $ in Millions		12 Months Ended
		Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Pension and Other Postretirement Defined Benefit Plans, Liabilities, Noncurrent		$ 2,160.3	$ 2,562.9
Other Comprehensive Income (Loss), Amortization, Pension and Other Postretirement Benefit Plans, Net Prior Service Cost (Credit) Recognized in Net Periodic Benefit Cost, before Tax	[1]	(80.7)	(34)	$ (31.9)
Pension Plans, Defined Benefit [Member]
Defined Benefit Plan, Amortization of Net Gains (Losses)		(285.9)
Defined Benefit Plan, Assets for Plan Benefits, Noncurrent		261.6	211.2
Pension and Other Postretirement Defined Benefit Plans, Current Liabilities		(63.8)	(62.3)
Pension and Other Postretirement Defined Benefit Plans, Liabilities, Noncurrent		1,921.4	2,325.6
Pension and Other Postretirement Benefit Plans, Accumulated Other Comprehensive Income (Loss), before Tax		4,585.2	5,158.4
Defined Benefit Plan, Amounts Recognized in Balance Sheet, Total		2,861.6	2,981.7
Defined Benefit Plan, Amounts Recognized in Other Comprehensive Income (Loss), Net Gain (Loss), before Tax		(383.2)
Other Comprehensive Income (Loss), Amortization, Pension and Other Postretirement Benefit Plans, Net Prior Service Cost (Credit) Recognized in Net Periodic Benefit Cost, before Tax		(10.4)
Other Postretirement Benefit Plans, Defined Benefit [Member]
Change in Retiree Health Plan - Impact on Unrecognized Prior Service Cost		520.8
Defined Benefit Plan, Amortization of Net Gains (Losses)		(19.2)
Defined Benefit Plan, Assets for Plan Benefits, Noncurrent		722.1	609.4
Pension and Other Postretirement Defined Benefit Plans, Current Liabilities		(6.9)	(6.9)
Pension and Other Postretirement Defined Benefit Plans, Liabilities, Noncurrent		238.9	237.3
Pension and Other Postretirement Benefit Plans, Accumulated Other Comprehensive Income (Loss), before Tax		(226.9)	(227.2)
Defined Benefit Plan, Amounts Recognized in Balance Sheet, Total		249.4	$ 138
Defined Benefit Plan, Amounts Recognized in Other Comprehensive Income (Loss), Net Gain (Loss), before Tax		(38)
Other Comprehensive Income (Loss), Amortization, Pension and Other Postretirement Benefit Plans, Net Prior Service Cost (Credit) Recognized in Net Periodic Benefit Cost, before Tax		$ 91.1
[1]	(1) These accumulated other comprehensive loss components are included in the computation of net periodic pension cost (see Note 14).

Retirement Benefits (Schedule70

Retirement Benefits (Schedule of Weighted Average Assumptions) (Details)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Pension Plans, Defined Benefit [Member]
Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Discount Rate	4.30%	4.00%	4.90%
Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Discount Rate	4.00%	4.90%	4.30%
Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Rate of Compensation Increase	3.40%	3.40%	3.40%
Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Rate of Compensation Increase	3.40%	3.40%	3.40%
Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Expected Long-term Return on Assets	7.40%	8.10%	8.40%
Other Postretirement Benefit Plans, Defined Benefit [Member]
Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Discount Rate	4.50%	4.10%	5.00%
Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Discount Rate	4.10%	5.00%	4.30%
Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Expected Long-term Return on Assets	8.00%	8.50%	8.80%

Retirement Benefits (Schedule71

Retirement Benefits (Schedule of Expected Benefit Payments, Contributions and Expense) (Details) - USD ($) $ in Millions		12 Months Ended
		Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Defined Benefit Plan, Estimated Future Employer Contributions in Next Fiscal Year, Description		$ 40
Defined Benefit Plan, Accumulated Benefit Obligation		10,750	$ 10,880
Defined Benefit Plan, Plans with Benefit Obligations in Excess of Plan Assets, Aggregate Benefit Obligation		10,054.1	10,537.2
Defined Benefit Plan, Plans with Benefit Obligations in Excess of Plan Assets, Aggregate Fair Value of Plan Assets		8,069.7	8,149.2
Other Comprehensive Income (Loss), Amortization, Pension and Other Postretirement Benefit Plans, Net Prior Service Cost (Credit) Recognized in Net Periodic Benefit Cost, before Tax	[1]	(80.7)	(34)	$ (31.9)
Change in defined benefit pension and retiree health benefit plans		(572.9)	1,327.6	(2,592.2)
Defined Contribution Plan, Cost Recognized		162.4	153.3	147.7
Defined Benefit Plan, Estimated Future Employer Contributions in Current Fiscal Year, Description		5
Pension Plans, Defined Benefit [Member]
Defined Benefit Plan, Expected Future Benefit Payments in Year One		(458.4)
Defined Benefit Plan, Expected Future Benefit Payments in Year Two		(465.2)
Defined Benefit Plan, Expected Future Benefit Payments in Year Three		(480.3)
Defined Benefit Plan, Expected Future Benefit Payments in Year Four		(498.8)
Defined Benefit Plan, Expected Future Benefit Payments in Year Five		(518.5)
Defined Benefit Plan, Expected Future Benefit Payments in Five Fiscal Years Thereafter		(2,987.5)
Defined Benefit Plan, Pension Plans with Accumulated Benefit Obligations in Excess of Plan Assets, Aggregate Accumulated Benefit Obligation		2,028.1	2,179.8
Defined Benefit Plan, Pension Plans with Accumulated Benefit Obligations in Excess of Plan Assets, Aggregate Fair Value of Plan Assets		844.9	700.9
Defined Benefit Plan, Service Cost		315.7	240.9	287.1
Defined Benefit Plan, Interest Cost		476.8	472.6	437.2
Defined Benefit Plan, Expected Return on Plan Assets		(782.3)	(756.6)	(701.9)
Defined Benefit Plan, Amortization of Prior Service Cost (Credit)		10.4	3.6	3.7
Defined Benefit Plan, Amortization of Gains (Losses)		383.2	282.3	414.7
Defined Benefit Plan, Amortization of Net Gains (Losses)		285.9
Defined Benefit Plan, Future Amortization of Prior Service Cost (Credit)		11.9
Defined Benefit Plan, Net Periodic Benefit Cost, Total		403.8	242.8	440.8
Other Comprehensive Income (Loss), Pension and Other Postretirement Benefit Plans, Net Unamortized Gain (Loss) Arising During Period, before Tax		(120.4)
Other Comprehensive Income (Loss), Pension and Other Postretirement Benefit Plans, Net Prior Service Cost (Credit) Arising During Period, before Tax		0.4
Other Comprehensive Income (Loss), Amortization, Pension and Other Postretirement Benefit Plans, Net Prior Service Cost (Credit) Recognized in Net Periodic Benefit Cost, before Tax		(10.4)
Defined Benefit Plan, Amounts Recognized in Other Comprehensive Income (Loss), Net Gain (Loss), before Tax		(383.2)
Defined Benefit Plan, Amount to be Amortized from Accumulated Other Comprehensive Income (Loss) Next Fiscal Year		297.8
Foreign currency translation gains (losses)		58.8
Change in defined benefit pension and retiree health benefit plans		573.2
Other Postretirement Benefit Plans, Defined Benefit [Member]
Defined Benefit Plan, Expected Future Benefit Payments in Year One		(70.7)
Defined Benefit Plan, Expected Future Benefit Payments in Year Two		(75.3)
Defined Benefit Plan, Expected Future Benefit Payments in Year Three		(78.3)
Defined Benefit Plan, Expected Future Benefit Payments in Year Four		(81.1)
Defined Benefit Plan, Expected Future Benefit Payments in Year Five		(84)
Defined Benefit Plan, Expected Future Benefit Payments in Five Fiscal Years Thereafter		(464.2)
Defined Benefit Plan, Pension Plans with Accumulated Benefit Obligations in Excess of Plan Assets, Aggregate Accumulated Benefit Obligation		245.8	244.2
Defined Benefit Plan, Pension Plans with Accumulated Benefit Obligations in Excess of Plan Assets, Aggregate Fair Value of Plan Assets		0	0
Defined Benefit Plan, Service Cost		45.1	33	49.9
Defined Benefit Plan, Interest Cost		62.6	85.6	98.1
Defined Benefit Plan, Expected Return on Plan Assets		(150)	(146.4)	(130.7)
Defined Benefit Plan, Amortization of Prior Service Cost (Credit)		(91.1)	(37.6)	(35.6)
Defined Benefit Plan, Amortization of Gains (Losses)		38	20.7	100.5
Defined Benefit Plan, Amortization of Net Gains (Losses)		19.2
Defined Benefit Plan, Future Amortization of Prior Service Cost (Credit)		(85.8)
Defined Benefit Plan, Net Periodic Benefit Cost, Total		(95.4)	$ (44.7)	$ 82.2
Other Comprehensive Income (Loss), Pension and Other Postretirement Benefit Plans, Net Unamortized Gain (Loss) Arising During Period, before Tax		(48.6)
Other Comprehensive Income (Loss), Pension and Other Postretirement Benefit Plans, Net Prior Service Cost (Credit) Arising During Period, before Tax		0
Other Comprehensive Income (Loss), Amortization, Pension and Other Postretirement Benefit Plans, Net Prior Service Cost (Credit) Recognized in Net Periodic Benefit Cost, before Tax		91.1
Defined Benefit Plan, Amounts Recognized in Other Comprehensive Income (Loss), Net Gain (Loss), before Tax		(38)
Defined Benefit Plan, Amount to be Amortized from Accumulated Other Comprehensive Income (Loss) Next Fiscal Year		(66.6)
Foreign currency translation gains (losses)		4.2
Change in defined benefit pension and retiree health benefit plans		$ (0.3)
[1]	(1) These accumulated other comprehensive loss components are included in the computation of net periodic pension cost (see Note 14).

Retirement Benefits (Fair Value

Retirement Benefits (Fair Value Disclosures) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Defined Benefit Plan, Percentage of Global Investments in Plan Assets	75.00%
Other Postretirement Benefit Plans, Defined Benefit [Member]
Defined Benefit Plan, Fair Value of Plan Assets, Ending Balance	$ 1,943.7	$ 1,918.7
Defined Benefit Plan, Fair Value of Plan Assets, Beginning Balance	1,918.7	1,879.6
Defined Benefit Plan, Business Combinations and Acquisitions, Plan Assets	0	0
Pension Plans, Defined Benefit [Member]
Defined Benefit Plan, Fair Value of Plan Assets, Ending Balance	9,995.6	9,835.7
Defined Benefit Plan, Fair Value of Plan Assets, Beginning Balance	9,835.7	9,481.7
Defined Benefit Plan, Business Combinations and Acquisitions, Plan Assets	$ 235.9	0
Fixed Income Funds [Member]
Defined Benefit Plan, Target Allocation Percentage of Assets	20.00%
Fixed Income Funds [Member] | Other Postretirement Benefit Plans, Defined Benefit [Member]
Defined Benefit Plan, Fair Value of Plan Assets, Ending Balance	$ 61.3	61.8
Defined Benefit Plan, Fair Value of Plan Assets, Beginning Balance	61.8
Fixed Income Funds [Member] | Pension Plans, Defined Benefit [Member]
Defined Benefit Plan, Fair Value of Plan Assets, Ending Balance	1,316.6	1,230.7
Defined Benefit Plan, Fair Value of Plan Assets, Beginning Balance	1,230.7
Equity Funds [Member] | Other Postretirement Benefit Plans, Defined Benefit [Member]
Defined Benefit Plan, Fair Value of Plan Assets, Ending Balance	104.5	92.3
Defined Benefit Plan, Fair Value of Plan Assets, Beginning Balance	92.3
Equity Funds [Member] | Pension Plans, Defined Benefit [Member]
Defined Benefit Plan, Fair Value of Plan Assets, Ending Balance	1,221.3	1,146.6
Defined Benefit Plan, Fair Value of Plan Assets, Beginning Balance	$ 1,146.6
Equity Securities [Member]
Defined Benefit Plan, Target Allocation Percentage of Assets	80.00%
Equity Securities [Member] | Other Postretirement Benefit Plans, Defined Benefit [Member]
Defined Benefit Plan, Fair Value of Plan Assets, Ending Balance	$ 40	39.2
Defined Benefit Plan, Fair Value of Plan Assets, Beginning Balance	39.2
Equity Securities [Member] | Pension Plans, Defined Benefit [Member]
Defined Benefit Plan, Fair Value of Plan Assets, Ending Balance	414.8	411.4
Defined Benefit Plan, Fair Value of Plan Assets, Beginning Balance	411.4
Equity Securities - International [Member] | Other Postretirement Benefit Plans, Defined Benefit [Member]
Defined Benefit Plan, Fair Value of Plan Assets, Ending Balance	144.7	158.9
Defined Benefit Plan, Fair Value of Plan Assets, Beginning Balance	158.9
Equity Securities - International [Member] | Pension Plans, Defined Benefit [Member]
Defined Benefit Plan, Fair Value of Plan Assets, Ending Balance	2,340.6	2,337.8
Defined Benefit Plan, Fair Value of Plan Assets, Beginning Balance	2,337.8
Fixed Income Funds, Emerging Markets [Member] | Other Postretirement Benefit Plans, Defined Benefit [Member]
Defined Benefit Plan, Fair Value of Plan Assets, Ending Balance	36.9	35.5
Defined Benefit Plan, Fair Value of Plan Assets, Beginning Balance	35.5
Fixed Income Funds, Emerging Markets [Member] | Pension Plans, Defined Benefit [Member]
Defined Benefit Plan, Fair Value of Plan Assets, Ending Balance	385.7	374.7
Defined Benefit Plan, Fair Value of Plan Assets, Beginning Balance	374.7
Hedge Funds [Member] | Other Postretirement Benefit Plans, Defined Benefit [Member]
Defined Benefit Plan, Fair Value of Plan Assets, Ending Balance	272.3	282.7
Defined Benefit Plan, Fair Value of Plan Assets, Beginning Balance	282.7
Hedge Funds [Member] | Pension Plans, Defined Benefit [Member]
Defined Benefit Plan, Fair Value of Plan Assets, Ending Balance	3,073.3	3,277.6
Defined Benefit Plan, Fair Value of Plan Assets, Beginning Balance	3,277.6
Real Estate [Member] | Other Postretirement Benefit Plans, Defined Benefit [Member]
Defined Benefit Plan, Fair Value of Plan Assets, Ending Balance	33.2	39
Defined Benefit Plan, Fair Value of Plan Assets, Beginning Balance	39
Real Estate [Member] | Pension Plans, Defined Benefit [Member]
Defined Benefit Plan, Fair Value of Plan Assets, Ending Balance	516.3	569
Defined Benefit Plan, Fair Value of Plan Assets, Beginning Balance	569
Other Assets [Member] | Other Postretirement Benefit Plans, Defined Benefit [Member]
Defined Benefit Plan, Fair Value of Plan Assets, Ending Balance	41.1	20.1
Defined Benefit Plan, Fair Value of Plan Assets, Beginning Balance	20.1
Other Assets [Member] | Pension Plans, Defined Benefit [Member]
Defined Benefit Plan, Fair Value of Plan Assets, Ending Balance	727	487.9
Defined Benefit Plan, Fair Value of Plan Assets, Beginning Balance	487.9
Other Contract [Member] | Other Postretirement Benefit Plans, Defined Benefit [Member]
Defined Benefit Plan, Fair Value of Plan Assets, Ending Balance	1,209.7	1,189.2
Defined Benefit Plan, Fair Value of Plan Assets, Beginning Balance	1,189.2
Fair Value, Inputs, Level 1 [Member] | Other Postretirement Benefit Plans, Defined Benefit [Member]
Defined Benefit Plan, Fair Value of Plan Assets, Ending Balance	127.9	122.6
Defined Benefit Plan, Fair Value of Plan Assets, Beginning Balance	122.6
Fair Value, Inputs, Level 1 [Member] | Pension Plans, Defined Benefit [Member]
Defined Benefit Plan, Fair Value of Plan Assets, Ending Balance	2,104.5	1,937.3
Defined Benefit Plan, Fair Value of Plan Assets, Beginning Balance	1,937.3
Fair Value, Inputs, Level 1 [Member] | Fixed Income Funds [Member] | Other Postretirement Benefit Plans, Defined Benefit [Member]
Defined Benefit Plan, Fair Value of Plan Assets, Ending Balance	0	0
Defined Benefit Plan, Fair Value of Plan Assets, Beginning Balance	0
Fair Value, Inputs, Level 1 [Member] | Fixed Income Funds [Member] | Pension Plans, Defined Benefit [Member]
Defined Benefit Plan, Fair Value of Plan Assets, Ending Balance	175.7	112.2
Defined Benefit Plan, Fair Value of Plan Assets, Beginning Balance	112.2
Fair Value, Inputs, Level 1 [Member] | Equity Funds [Member] | Other Postretirement Benefit Plans, Defined Benefit [Member]
Defined Benefit Plan, Fair Value of Plan Assets, Ending Balance	0	0
Defined Benefit Plan, Fair Value of Plan Assets, Beginning Balance	0
Fair Value, Inputs, Level 1 [Member] | Equity Funds [Member] | Pension Plans, Defined Benefit [Member]
Defined Benefit Plan, Fair Value of Plan Assets, Ending Balance	0	0
Defined Benefit Plan, Fair Value of Plan Assets, Beginning Balance	0
Fair Value, Inputs, Level 1 [Member] | Equity Securities [Member] | Other Postretirement Benefit Plans, Defined Benefit [Member]
Defined Benefit Plan, Fair Value of Plan Assets, Ending Balance	18.2	17.2
Defined Benefit Plan, Fair Value of Plan Assets, Beginning Balance	17.2
Fair Value, Inputs, Level 1 [Member] | Equity Securities [Member] | Pension Plans, Defined Benefit [Member]
Defined Benefit Plan, Fair Value of Plan Assets, Ending Balance	187.1	183.8
Defined Benefit Plan, Fair Value of Plan Assets, Beginning Balance	183.8
Fair Value, Inputs, Level 1 [Member] | Equity Securities - International [Member] | Other Postretirement Benefit Plans, Defined Benefit [Member]
Defined Benefit Plan, Fair Value of Plan Assets, Ending Balance	51.5	58.8
Defined Benefit Plan, Fair Value of Plan Assets, Beginning Balance	58.8
Fair Value, Inputs, Level 1 [Member] | Equity Securities - International [Member] | Pension Plans, Defined Benefit [Member]
Defined Benefit Plan, Fair Value of Plan Assets, Ending Balance	956.3	999.7
Defined Benefit Plan, Fair Value of Plan Assets, Beginning Balance	999.7
Fair Value, Inputs, Level 1 [Member] | Fixed Income Funds, Emerging Markets [Member] | Other Postretirement Benefit Plans, Defined Benefit [Member]
Defined Benefit Plan, Fair Value of Plan Assets, Ending Balance	0	0
Defined Benefit Plan, Fair Value of Plan Assets, Beginning Balance	0
Fair Value, Inputs, Level 1 [Member] | Fixed Income Funds, Emerging Markets [Member] | Pension Plans, Defined Benefit [Member]
Defined Benefit Plan, Fair Value of Plan Assets, Ending Balance	10.1	8.7
Defined Benefit Plan, Fair Value of Plan Assets, Beginning Balance	8.7
Fair Value, Inputs, Level 1 [Member] | Hedge Funds [Member] | Other Postretirement Benefit Plans, Defined Benefit [Member]
Defined Benefit Plan, Fair Value of Plan Assets, Ending Balance	0	0
Defined Benefit Plan, Fair Value of Plan Assets, Beginning Balance	0
Fair Value, Inputs, Level 1 [Member] | Hedge Funds [Member] | Pension Plans, Defined Benefit [Member]
Defined Benefit Plan, Fair Value of Plan Assets, Ending Balance	14.5	0
Defined Benefit Plan, Fair Value of Plan Assets, Beginning Balance	0
Fair Value, Inputs, Level 1 [Member] | Real Estate [Member] | Other Postretirement Benefit Plans, Defined Benefit [Member]
Defined Benefit Plan, Fair Value of Plan Assets, Ending Balance	33.2	39
Defined Benefit Plan, Fair Value of Plan Assets, Beginning Balance	39
Fair Value, Inputs, Level 1 [Member] | Real Estate [Member] | Pension Plans, Defined Benefit [Member]
Defined Benefit Plan, Fair Value of Plan Assets, Ending Balance	329.5	403.1
Defined Benefit Plan, Fair Value of Plan Assets, Beginning Balance	403.1
Fair Value, Inputs, Level 1 [Member] | Other Assets [Member] | Other Postretirement Benefit Plans, Defined Benefit [Member]
Defined Benefit Plan, Fair Value of Plan Assets, Ending Balance	25	7.6
Defined Benefit Plan, Fair Value of Plan Assets, Beginning Balance	7.6
Fair Value, Inputs, Level 1 [Member] | Other Assets [Member] | Pension Plans, Defined Benefit [Member]
Defined Benefit Plan, Fair Value of Plan Assets, Ending Balance	431.3	229.8
Defined Benefit Plan, Fair Value of Plan Assets, Beginning Balance	229.8
Fair Value, Inputs, Level 1 [Member] | Other Contract [Member] | Other Postretirement Benefit Plans, Defined Benefit [Member]
Defined Benefit Plan, Fair Value of Plan Assets, Ending Balance	0	0
Defined Benefit Plan, Fair Value of Plan Assets, Beginning Balance	0
Fair Value, Inputs, Level 2 [Member] | Other Postretirement Benefit Plans, Defined Benefit [Member]
Defined Benefit Plan, Fair Value of Plan Assets, Ending Balance	1,587.7	1,579.6
Defined Benefit Plan, Fair Value of Plan Assets, Beginning Balance	1,579.6
Fair Value, Inputs, Level 2 [Member] | Pension Plans, Defined Benefit [Member]
Defined Benefit Plan, Fair Value of Plan Assets, Ending Balance	5,040	5,076.2
Defined Benefit Plan, Fair Value of Plan Assets, Beginning Balance	5,076.2
Fair Value, Inputs, Level 2 [Member] | Fixed Income Funds [Member] | Other Postretirement Benefit Plans, Defined Benefit [Member]
Defined Benefit Plan, Fair Value of Plan Assets, Ending Balance	61.3	61.8
Defined Benefit Plan, Fair Value of Plan Assets, Beginning Balance	61.8
Fair Value, Inputs, Level 2 [Member] | Fixed Income Funds [Member] | Pension Plans, Defined Benefit [Member]
Defined Benefit Plan, Fair Value of Plan Assets, Ending Balance	1,140.9	1,118.5
Defined Benefit Plan, Fair Value of Plan Assets, Beginning Balance	1,118.5
Fair Value, Inputs, Level 2 [Member] | Equity Funds [Member] | Other Postretirement Benefit Plans, Defined Benefit [Member]
Defined Benefit Plan, Fair Value of Plan Assets, Ending Balance	0	0
Defined Benefit Plan, Fair Value of Plan Assets, Beginning Balance	0
Fair Value, Inputs, Level 2 [Member] | Equity Funds [Member] | Pension Plans, Defined Benefit [Member]
Defined Benefit Plan, Fair Value of Plan Assets, Ending Balance	67.4	75.2
Defined Benefit Plan, Fair Value of Plan Assets, Beginning Balance	75.2
Fair Value, Inputs, Level 2 [Member] | Equity Securities [Member] | Other Postretirement Benefit Plans, Defined Benefit [Member]
Defined Benefit Plan, Fair Value of Plan Assets, Ending Balance	21.8	22
Defined Benefit Plan, Fair Value of Plan Assets, Beginning Balance	22
Fair Value, Inputs, Level 2 [Member] | Equity Securities [Member] | Pension Plans, Defined Benefit [Member]
Defined Benefit Plan, Fair Value of Plan Assets, Ending Balance	227.7	227.6
Defined Benefit Plan, Fair Value of Plan Assets, Beginning Balance	227.6
Fair Value, Inputs, Level 2 [Member] | Equity Securities - International [Member] | Other Postretirement Benefit Plans, Defined Benefit [Member]
Defined Benefit Plan, Fair Value of Plan Assets, Ending Balance	93.2	100.1
Defined Benefit Plan, Fair Value of Plan Assets, Beginning Balance	100.1
Fair Value, Inputs, Level 2 [Member] | Equity Securities - International [Member] | Pension Plans, Defined Benefit [Member]
Defined Benefit Plan, Fair Value of Plan Assets, Ending Balance	1,384.3	1,338.1
Defined Benefit Plan, Fair Value of Plan Assets, Beginning Balance	1,338.1
Fair Value, Inputs, Level 2 [Member] | Fixed Income Funds, Emerging Markets [Member] | Other Postretirement Benefit Plans, Defined Benefit [Member]
Defined Benefit Plan, Fair Value of Plan Assets, Ending Balance	36.9	35.3
Defined Benefit Plan, Fair Value of Plan Assets, Beginning Balance	35.3
Fair Value, Inputs, Level 2 [Member] | Fixed Income Funds, Emerging Markets [Member] | Pension Plans, Defined Benefit [Member]
Defined Benefit Plan, Fair Value of Plan Assets, Ending Balance	375.3	364.2
Defined Benefit Plan, Fair Value of Plan Assets, Beginning Balance	364.2
Fair Value, Inputs, Level 2 [Member] | Hedge Funds [Member] | Other Postretirement Benefit Plans, Defined Benefit [Member]
Defined Benefit Plan, Fair Value of Plan Assets, Ending Balance	148.7	158.7
Defined Benefit Plan, Fair Value of Plan Assets, Beginning Balance	158.7
Fair Value, Inputs, Level 2 [Member] | Hedge Funds [Member] | Pension Plans, Defined Benefit [Member]
Defined Benefit Plan, Fair Value of Plan Assets, Ending Balance	1,537.9	1,694.5
Defined Benefit Plan, Fair Value of Plan Assets, Beginning Balance	1,694.5
Fair Value, Inputs, Level 2 [Member] | Real Estate [Member] | Other Postretirement Benefit Plans, Defined Benefit [Member]
Defined Benefit Plan, Fair Value of Plan Assets, Ending Balance	0	0
Defined Benefit Plan, Fair Value of Plan Assets, Beginning Balance	0
Fair Value, Inputs, Level 2 [Member] | Real Estate [Member] | Pension Plans, Defined Benefit [Member]
Defined Benefit Plan, Fair Value of Plan Assets, Ending Balance	10.8	0
Defined Benefit Plan, Fair Value of Plan Assets, Beginning Balance	0
Fair Value, Inputs, Level 2 [Member] | Other Assets [Member] | Other Postretirement Benefit Plans, Defined Benefit [Member]
Defined Benefit Plan, Fair Value of Plan Assets, Ending Balance	16.1	12.5
Defined Benefit Plan, Fair Value of Plan Assets, Beginning Balance	12.5
Fair Value, Inputs, Level 2 [Member] | Other Assets [Member] | Pension Plans, Defined Benefit [Member]
Defined Benefit Plan, Fair Value of Plan Assets, Ending Balance	295.7	258.1
Defined Benefit Plan, Fair Value of Plan Assets, Beginning Balance	258.1
Fair Value, Inputs, Level 2 [Member] | Other Contract [Member] | Other Postretirement Benefit Plans, Defined Benefit [Member]
Defined Benefit Plan, Fair Value of Plan Assets, Ending Balance	1,209.7	1,189.2
Defined Benefit Plan, Fair Value of Plan Assets, Beginning Balance	1,189.2
Fair Value, Inputs, Level 3 [Member] | Other Postretirement Benefit Plans, Defined Benefit [Member]
Defined Benefit Plan, Fair Value of Plan Assets, Ending Balance	228.1	216.5
Defined Benefit Plan, Fair Value of Plan Assets, Beginning Balance	216.5	211.1
Defined Benefit Plan, Actual Return on Plan Assets Still Held	25	7.1
Defined Benefit Plan, Actual Return on Plan Assets Sold During Period	(11.2)	(0.1)
Defined Benefit Plan, Purchases, Sales, and Settlements	(2)	(0.5)
Defined Benefit Plan, Transfers Between Measurement Levels	(0.2)	(1.1)
Fair Value, Inputs, Level 3 [Member] | Pension Plans, Defined Benefit [Member]
Defined Benefit Plan, Fair Value of Plan Assets, Ending Balance	2,851.1	2,822.2
Defined Benefit Plan, Fair Value of Plan Assets, Beginning Balance	2,822.2	2,603.2
Defined Benefit Plan, Actual Return on Plan Assets Still Held	161.5	152.7
Defined Benefit Plan, Actual Return on Plan Assets Sold During Period	(111.5)	(0.8)
Defined Benefit Plan, Purchases, Sales, and Settlements	(20)	78.5
Defined Benefit Plan, Transfers Between Measurement Levels	(1.1)	(11.4)
Fair Value, Inputs, Level 3 [Member] | Fixed Income Funds [Member] | Other Postretirement Benefit Plans, Defined Benefit [Member]
Defined Benefit Plan, Fair Value of Plan Assets, Ending Balance	0	0
Defined Benefit Plan, Fair Value of Plan Assets, Beginning Balance	0	1.6
Defined Benefit Plan, Actual Return on Plan Assets Still Held		(0.1)
Defined Benefit Plan, Actual Return on Plan Assets Sold During Period		(0.1)
Defined Benefit Plan, Purchases, Sales, and Settlements		(0.3)
Defined Benefit Plan, Transfers Between Measurement Levels		(1.1)
Fair Value, Inputs, Level 3 [Member] | Fixed Income Funds [Member] | Pension Plans, Defined Benefit [Member]
Defined Benefit Plan, Fair Value of Plan Assets, Ending Balance	0	0
Defined Benefit Plan, Fair Value of Plan Assets, Beginning Balance	0	15.9
Defined Benefit Plan, Actual Return on Plan Assets Still Held		(0.4)
Defined Benefit Plan, Actual Return on Plan Assets Sold During Period		(0.8)
Defined Benefit Plan, Purchases, Sales, and Settlements		(3.3)
Defined Benefit Plan, Transfers Between Measurement Levels		(11.4)
Fair Value, Inputs, Level 3 [Member] | Equity Funds [Member] | Other Postretirement Benefit Plans, Defined Benefit [Member]
Defined Benefit Plan, Fair Value of Plan Assets, Ending Balance	104.5	92.3
Defined Benefit Plan, Fair Value of Plan Assets, Beginning Balance	92.3	88.9
Defined Benefit Plan, Actual Return on Plan Assets Still Held	10.3	6
Defined Benefit Plan, Actual Return on Plan Assets Sold During Period	0	0
Defined Benefit Plan, Purchases, Sales, and Settlements	1.9	(2.6)
Defined Benefit Plan, Transfers Between Measurement Levels	0	0
Fair Value, Inputs, Level 3 [Member] | Equity Funds [Member] | Pension Plans, Defined Benefit [Member]
Defined Benefit Plan, Fair Value of Plan Assets, Ending Balance	1,153.9	1,071.4
Defined Benefit Plan, Fair Value of Plan Assets, Beginning Balance	1,071.4	993.5
Defined Benefit Plan, Actual Return on Plan Assets Still Held	78.3	108.2
Defined Benefit Plan, Actual Return on Plan Assets Sold During Period	0	0
Defined Benefit Plan, Purchases, Sales, and Settlements	4.2	(30.3)
Defined Benefit Plan, Transfers Between Measurement Levels	0	0
Fair Value, Inputs, Level 3 [Member] | Equity Securities [Member] | Other Postretirement Benefit Plans, Defined Benefit [Member]
Defined Benefit Plan, Fair Value of Plan Assets, Ending Balance	0	0
Defined Benefit Plan, Fair Value of Plan Assets, Beginning Balance	0
Fair Value, Inputs, Level 3 [Member] | Equity Securities [Member] | Pension Plans, Defined Benefit [Member]
Defined Benefit Plan, Fair Value of Plan Assets, Ending Balance	0	0
Defined Benefit Plan, Fair Value of Plan Assets, Beginning Balance	0
Fair Value, Inputs, Level 3 [Member] | Equity Securities - International [Member] | Other Postretirement Benefit Plans, Defined Benefit [Member]
Defined Benefit Plan, Fair Value of Plan Assets, Ending Balance	0	0
Defined Benefit Plan, Fair Value of Plan Assets, Beginning Balance	0
Fair Value, Inputs, Level 3 [Member] | Equity Securities - International [Member] | Pension Plans, Defined Benefit [Member]
Defined Benefit Plan, Fair Value of Plan Assets, Ending Balance	0	0
Defined Benefit Plan, Fair Value of Plan Assets, Beginning Balance	0
Fair Value, Inputs, Level 3 [Member] | Fixed Income Funds, Emerging Markets [Member] | Other Postretirement Benefit Plans, Defined Benefit [Member]
Defined Benefit Plan, Fair Value of Plan Assets, Ending Balance	0	0.2
Defined Benefit Plan, Fair Value of Plan Assets, Beginning Balance	0.2	0
Defined Benefit Plan, Actual Return on Plan Assets Still Held	0	0
Defined Benefit Plan, Actual Return on Plan Assets Sold During Period	0	0
Defined Benefit Plan, Purchases, Sales, and Settlements	0	0.2
Defined Benefit Plan, Transfers Between Measurement Levels	(0.2)	0
Fair Value, Inputs, Level 3 [Member] | Fixed Income Funds, Emerging Markets [Member] | Pension Plans, Defined Benefit [Member]
Defined Benefit Plan, Fair Value of Plan Assets, Ending Balance	0.3	1.8
Defined Benefit Plan, Fair Value of Plan Assets, Beginning Balance	1.8	0
Defined Benefit Plan, Actual Return on Plan Assets Still Held	(0.1)	0.1
Defined Benefit Plan, Actual Return on Plan Assets Sold During Period	0	0
Defined Benefit Plan, Purchases, Sales, and Settlements	(0.3)	1.7
Defined Benefit Plan, Transfers Between Measurement Levels	(1.1)	0
Fair Value, Inputs, Level 3 [Member] | Hedge Funds [Member] | Other Postretirement Benefit Plans, Defined Benefit [Member]
Defined Benefit Plan, Fair Value of Plan Assets, Ending Balance	123.6	124
Defined Benefit Plan, Fair Value of Plan Assets, Beginning Balance	124	120.6
Defined Benefit Plan, Actual Return on Plan Assets Still Held	14.7	1.2
Defined Benefit Plan, Actual Return on Plan Assets Sold During Period	(11.2)	0
Defined Benefit Plan, Purchases, Sales, and Settlements	(3.9)	2.2
Defined Benefit Plan, Transfers Between Measurement Levels	0	0
Fair Value, Inputs, Level 3 [Member] | Hedge Funds [Member] | Pension Plans, Defined Benefit [Member]
Defined Benefit Plan, Fair Value of Plan Assets, Ending Balance	1,520.9	1,583.1
Defined Benefit Plan, Fair Value of Plan Assets, Beginning Balance	1,583.1	1,440.4
Defined Benefit Plan, Actual Return on Plan Assets Still Held	89.4	44.6
Defined Benefit Plan, Actual Return on Plan Assets Sold During Period	(111.5)	0
Defined Benefit Plan, Purchases, Sales, and Settlements	(40.1)	98.1
Defined Benefit Plan, Transfers Between Measurement Levels	0	0
Fair Value, Inputs, Level 3 [Member] | Real Estate [Member] | Other Postretirement Benefit Plans, Defined Benefit [Member]
Defined Benefit Plan, Fair Value of Plan Assets, Ending Balance	0	0
Defined Benefit Plan, Fair Value of Plan Assets, Beginning Balance	0	0
Defined Benefit Plan, Actual Return on Plan Assets Still Held	0	0
Defined Benefit Plan, Actual Return on Plan Assets Sold During Period	0	0
Defined Benefit Plan, Purchases, Sales, and Settlements	0	0
Defined Benefit Plan, Transfers Between Measurement Levels	0	0
Fair Value, Inputs, Level 3 [Member] | Real Estate [Member] | Pension Plans, Defined Benefit [Member]
Defined Benefit Plan, Fair Value of Plan Assets, Ending Balance	176	165.9
Defined Benefit Plan, Fair Value of Plan Assets, Beginning Balance	165.9	153.4
Defined Benefit Plan, Actual Return on Plan Assets Still Held	(6.1)	0.2
Defined Benefit Plan, Actual Return on Plan Assets Sold During Period	0	0
Defined Benefit Plan, Purchases, Sales, and Settlements	16.2	12.3
Defined Benefit Plan, Transfers Between Measurement Levels	0	0
Fair Value, Inputs, Level 3 [Member] | Other Assets [Member] | Other Postretirement Benefit Plans, Defined Benefit [Member]
Defined Benefit Plan, Fair Value of Plan Assets, Ending Balance	0	0
Defined Benefit Plan, Fair Value of Plan Assets, Beginning Balance	0
Fair Value, Inputs, Level 3 [Member] | Other Assets [Member] | Pension Plans, Defined Benefit [Member]
Defined Benefit Plan, Fair Value of Plan Assets, Ending Balance	0	0
Defined Benefit Plan, Fair Value of Plan Assets, Beginning Balance	0
Fair Value, Inputs, Level 3 [Member] | Other Contract [Member] | Other Postretirement Benefit Plans, Defined Benefit [Member]
Defined Benefit Plan, Fair Value of Plan Assets, Ending Balance	0	$ 0
Defined Benefit Plan, Fair Value of Plan Assets, Beginning Balance	$ 0

Contingencies (Details)

Contingencies (Details) $ in Millions, BRL in Billions	1 Months Ended	12 Months Ended
	Sep. 30, 2014USD ($)	Dec. 31, 2015USD ($)	Dec. 31, 2015BRL
Actos [Member] | Product Liability Litigation [Member]
Loss Contingency, Number of Cases		6,500	6,500
Byetta [Member] | Multi District Litigation Mdl [Member]
Loss Contingency, Number of Lawsuits		395	395
Loss Contingency, Number of Plaintiffs		400	400
Byetta [Member] | Product Liability Litigation [Member]
Loss Contingency, Number of Claimants		10	10
Loss Contingency, Number of Lawsuits		510	510
Loss Contingency, Number of Plaintiffs		1,035	1,035
Cymbalta [Member] | Product Liability Litigation [Member]
Loss Contingency, Number of Lawsuits		140	140
Loss Contingency, Number of Plaintiffs		1,300	1,300
Prozac [Member] | Product Liability Litigation [Member]
Loss Contingency, Number of Claimants		515	515
Loss Contingency, Number of Lawsuits		10	10
Compensatory Damages [Member] | Actos [Member]
Loss Contingency, Damages Awarded, Value	$ 2,400
Compensatory Damages [Member] | Actos [Member] | Takeda Portion [Member]
Loss Contingency, Parties Jointly and Severally Liable in Litigation, Percent Share	2800000000.00%
Compensatory Damages [Member] | Actos [Member] | Lilly Portion [Member]
Loss Contingency, Parties Jointly and Severally Liable in Litigation, Percent Share	900000000.00%
Punitive Damages [Member] | Actos [Member] | Takeda Portion [Member]
Loss Contingency, Damages Awarded, Value	$ 0
Damages from Product, Cancer [Member] | Byetta [Member] | Product Liability Litigation [Member]
Loss Contingency, Number of Lawsuits		450	450
Loss Contingency, Number of Plaintiffs		690	690
CANADA | Actos [Member] | Product Liability Litigation [Member]
Loss Contingency, Number of Cases		4	4
CALIFORNIA | Byetta [Member] | Product Liability Litigation [Member]
Loss Contingency, Number of Lawsuits		110	110
Loss Contingency, Number of Plaintiffs		630	630
CALIFORNIA | Cymbalta [Member] | Product Liability Litigation [Member]
Loss Contingency, Number of Lawsuits		35	35
Other states [Member] | Byetta [Member] | Product Liability Litigation [Member]
Loss Contingency, Number of Lawsuits		5	5
Loss Contingency, Number of Plaintiffs		5	5
Brazil [Member] | Employee Litigation [Member]
Loss Contingency, Damages Awarded, Value		$ 255	BRL 1
Loss Contingency, Number of Lawsuits		25	25
ONTARIO | Actos [Member] | Product Liability Litigation [Member]
Loss Contingency, Number of Cases		2	2
QUEBEC | Actos [Member] | Product Liability Litigation [Member]
Loss Contingency, Number of Cases		1	1
ALBERTA | Actos [Member] | Product Liability Litigation [Member]
Loss Contingency, Number of Cases		1	1

Other Comprehensive Income (L74

Other Comprehensive Income (Loss) (Details) - USD ($) $ in Millions		12 Months Ended
		Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Other Comprehensive Income (Loss), Amortization, Pension and Other Postretirement Benefit Plans, Net Prior Service Cost (Credit) Recognized in Net Periodic Benefit Cost, before Tax	[1]	$ (80.7)	$ (34)	$ (31.9)
Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax		(2)	0	0
Other Comprehensive Income (Loss), Unrealized Holding Gain (Loss) on Securities Arising During Period, Tax		(48.5)	(56.7)	71.6
Accumulated Other Comprehensive Income (Loss), Net of Tax		(4,580.7)	(3,991.8)
Other comprehensive income (loss)		(588.9)	(1,989.1)	1,794.4
Other Comprehensive (Income) Loss, Reclassification Adjustment from AOCI, Pension and Other Postretirement Benefit Plans, before Tax		340.5	269	483.3
Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI, Pension and Other Postretirement Benefit Plans, for Net Gain (Loss), before Tax	[1]	421.2	303	515.2
Other Comprehensive (Income) Loss, Reclassification Adjustment from AOCI, Pension and Other Postretirement Benefit Plans, Tax		(105.6)	(83.4)	(164.3)
Other Comprehensive (Income) Loss, Reclassification Adjustment from AOCI, Pension and Other Postretirement Benefit Plans, Net of Tax		234.9	185.6	319
Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI for Sale of Securities, before Tax		(209.3)	(324.1)	(12)
Other Comprehensive (Income) Loss, Reclassification Adjustment from AOCI for Write-down of Securities, before Tax		12	0	2.4
Other Comprehensive Income (Loss), Reclasification Adjustment from AOCI, Available-for-Sale Securities, before Tax, Total		(197.3)	(324.1)	(9.6)
Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI for Sale of Securities, Tax		69.1	113.4	3.4
Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI, Available-for-Sale Securities, Net of Tax, Total		(128.2)	(210.7)	(6.2)
Other Comprehensive Income, Other, Net of Tax		9.5	5.9	5.9
Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax		116.2	(19.2)	318.7
Other Comprehensive Income (Loss), Unrealized Gain (Loss) on Derivatives Arising During Period, Tax		14.6	5.2	43.2
Other Comprehensive (Income) Loss, Pension and Other Postretirement Benefit Plans, before Reclassification Adjustments, Tax		(183)	414.7	(886.1)
Other Comprehensive Income (Loss), Tax		(121.9)	476.6	(914.5)
Accumulated Other Comprehensive Income (Loss) [Member]
Accumulated Other Comprehensive Income (Loss), Net of Tax		(4,580.7)	(3,991.8)	(2,002.7)	$ (3,797.1)
Other Comprehensive Income (Loss), before Reclassifications, Net of Tax		705.1	1,969.9	(1,475.7)
Other comprehensive income (loss)		(588.9)	(1,989.1)	1,794.4
Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax		(116.2)	19.2	(318.7)
Accumulated Translation Adjustment [Member]
Accumulated Other Comprehensive Income (Loss), Net of Tax		(1,360.2)	(498.4)	463	426.8
Other Comprehensive Income (Loss), before Reclassifications, Net of Tax		861.8	961.4	(36.2)
Other comprehensive income (loss)		(861.8)	(961.4)	36.2
Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax		0	0	0
Accumulated Net Unrealized Investment Gain (Loss) [Member]
Accumulated Other Comprehensive Income (Loss), Net of Tax		10.1	99.7	205.2	72.5
Other Comprehensive Income (Loss), before Reclassifications, Net of Tax		(38.6)	(105.2)	(138.9)
Other comprehensive income (loss)		(89.6)	(105.5)	132.7
Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax		128.2	210.7	6.2
Accumulated Defined Benefit Plans Adjustment [Member]
Accumulated Other Comprehensive Income (Loss), Net of Tax		(3,012.1)	(3,402)	(2,489.1)	(4,195.2)
Other Comprehensive Income (Loss), before Reclassifications, Net of Tax		(155)	1,098.5	(1,387.1)
Other comprehensive income (loss)		389.9	(912.9)	1,706.1
Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax		(234.9)	(185.6)	(319)
Accumulated Net Gain (Loss) from Designated or Qualifying Cash Flow Hedges [Member]
Accumulated Other Comprehensive Income (Loss), Net of Tax		(218.5)	(191.1)	(181.8)	$ (101.2)
Other Comprehensive Income (Loss), before Reclassifications, Net of Tax		36.9	15.2	86.5
Other comprehensive income (loss)		(27.4)	(9.3)	(80.6)
Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax		$ (9.5)	$ (5.9)	$ (5.9)
[1]	(1) These accumulated other comprehensive loss components are included in the computation of net periodic pension cost (see Note 14).

Other - Net, Expense (Income)75

Other - Net, Expense (Income) (Details) - USD ($) $ in Millions		3 Months Ended								12 Months Ended
		Dec. 31, 2015	Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2015	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Other Revenue, Net										$ 808.1	$ 788.4	$ 707.5
Income related to termination of the exenatide collaboration with Amylin										0	0	(495.4)
Interest Expense										161.2	148.8	160.1
Investment Income, Interest										(87)	(121)	(119.7)
Gains (Losses) on Extinguishment of Debt										166.7	0	0
Other (income)expense										(341.5)	(368.3)	(63.9)
Nonoperating Income (Expense), Total		$ (44.7)	$ (86.5)	$ 123.3	$ (92.7)	$ (137.2)	$ (93.5)	$ (53.8)	$ (56)	$ (100.6)	$ (340.5)	(518.9)
Exenatide [Member]
Other (income)expense	[1]											$ (495.4)
[1]	(1) Presented in other-net, (income) expense.

Segment Information Segment I76

Segment Information Segment Information (Details) - USD ($) $ in Millions		1 Months Ended	3 Months Ended								12 Months Ended
		Dec. 31, 2013	Dec. 31, 2015	Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2015	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Segment Reporting Information [Line Items]
Depreciation and amortization											$ 1,427.7	$ 1,379	$ 1,445.6
Revenue			$ 5,375.6	$ 4,959.7	$ 4,978.7	$ 4,644.7	$ 5,121.3	$ 4,875.6	$ 4,935.6	$ 4,683.1	19,958.7	19,615.6	23,113.1
Other Revenue, Net											808.1	788.4	707.5
Long-Lived Assets	[1]	$ 8,741.3	8,696.6				8,547.2				8,696.6	8,547.2	8,741.3
Asset impairment, restructuring, and other special charges			(144.9)	(42.4)	(72.4)	(108)	(401)	(36.3)	0	(31.4)	(367.7)	(468.7)	(120.6)
Selling, General and Administrative Expense											(6,533)	(6,620.8)	(7,125.6)
Income before income taxes											2,790	3,000.3	5,889.3
Cost of sales			1,389.2	1,236.9	1,218.4	1,192.7	1,253.1	1,267	1,189.7	1,222.7	5,037.2	4,932.5	4,908.1
Acquired in-process research and development		(57.1)	(199)	0	(80)	(256)	(105.2)	(95)	0	0	(535)	(200.2)	(57.1)
Gain (Loss) on Contract Termination											0	0	495.4
Other-net, (income) expense			44.7	$ 86.5	$ (123.3)	$ 92.7	137.2	$ 93.5	$ 53.8	$ 56	100.6	340.5	518.9
Amortization of Intangible Assets											631.8	535.9	555
Gains (Losses) on Extinguishment of Debt											166.7	0	0
United States [Member]
Segment Reporting Information [Line Items]
Revenue	[2]										10,097.4	9,134.1	12,889.7
Long-Lived Assets	[1]	4,649.6	4,576.8				4,566.2				4,576.8	4,566.2	4,649.6
Europe [Member]
Segment Reporting Information [Line Items]
Revenue	[2]										3,943.6	4,506.7	4,338.4
Long-Lived Assets	[1]	2,469.7	2,306.4				2,401.5				2,306.4	2,401.5	2,469.7
JAPAN
Segment Reporting Information [Line Items]
Revenue	[2]										2,033.1	2,027.1	2,063.8
Long-Lived Assets	[1]	81.1	89.2				80.4				89.2	80.4	81.1
Other Foreign Countries [Member]
Segment Reporting Information [Line Items]
Revenue	[2]										3,884.6	3,947.7	3,821.2
Long-Lived Assets	[1]	$ 1,540.9	1,724.2				$ 1,499.1				1,724.2	1,499.1	1,540.9
Human Pharmaceutical Products [Member]
Segment Reporting Information [Line Items]
Other Depreciation and Amortization											720.7	790	838.8
Total segment [Member]
Segment Reporting Information [Line Items]
Other Depreciation and Amortization											801.5	848.8	890.6
Income before income taxes											4,624.6	4,226.4	6,126.6
Endocrinology [Member]
Segment Reporting Information [Line Items]
Revenue											7,036.8	6,939	7,304.4
Neuroscience [Member]
Segment Reporting Information [Line Items]
Revenue											2,935.4	3,596.5	7,216.2
Oncology [Member]
Segment Reporting Information [Line Items]
Revenue											3,509.8	3,393	3,268.5
Cardiovascular [Member]
Segment Reporting Information [Line Items]
Revenue											3,068	3,053.5	2,923.2
Other Pharmaceuticals [Member]
Segment Reporting Information [Line Items]
Revenue											227.7	287	249.3
Human Pharmaceutical Products Total [Member]
Segment Reporting Information [Line Items]
Revenue											16,777.7	17,269	20,961.6
Income before income taxes											4,026.7	3,604.6	5,521
Animal Health Products [Member]
Segment Reporting Information [Line Items]
Other Depreciation and Amortization											80.8	58.8	51.8
Revenue											3,181	2,346.6	2,151.5
Income before income taxes											597.9	621.8	605.6
Corporate, Non-Segment [Member]
Segment Reporting Information [Line Items]
Asset impairment, restructuring, and other special charges											(367.7)	(468.7)	(120.6)
Selling, General and Administrative Expense											0	(119)	0
Acquired in-process research and development											(535)	(200.2)	(57.1)
Amortization of Intangible Assets	[3]										(626.2)	(530.2)	(555)
Amylin [Member] | Corporate, Non-Segment [Member]
Segment Reporting Information [Line Items]
Gain (Loss) on Contract Termination											0	0	495.4
Cymbalta [Member] | Neuroscience [Member]
Segment Reporting Information [Line Items]
Revenue											1,027.6	1,614.7	5,084.4
Humalog [Member] | Endocrinology [Member]
Segment Reporting Information [Line Items]
Revenue											2,841.9	2,785.2	2,611.2
Humulin [Member] | Endocrinology [Member]
Segment Reporting Information [Line Items]
Revenue											1,307.4	1,400.1	1,315.8
Forteo [Member] | Endocrinology [Member]
Segment Reporting Information [Line Items]
Revenue											1,348.3	1,322	1,244.9
Evista [Member] | Endocrinology [Member]
Segment Reporting Information [Line Items]
Revenue											237.3	419.8	1,050.4
Trajenta (BI) [Member] | Endocrinology [Member]
Segment Reporting Information [Line Items]
Revenue											356.8	328.8	249.2
Trulicity [Member] [Member] | Endocrinology [Member]
Segment Reporting Information [Line Items]
Revenue											248.7	10.2	0
Other Endocrinology [Member] | Endocrinology [Member]
Segment Reporting Information [Line Items]
Revenue											696.4	672.9	832.9
Zyprexa [Member] | Neuroscience [Member]
Segment Reporting Information [Line Items]
Revenue											940.3	1,037.3	1,194.8
Strattera [Member] | Neuroscience [Member]
Segment Reporting Information [Line Items]
Revenue											784	738.5	709.2
Other Neuroscience [Member] | Neuroscience [Member]
Segment Reporting Information [Line Items]
Revenue											183.5	206	227.8
Alimta [Member] | Oncology [Member]
Segment Reporting Information [Line Items]
Revenue											2,493.1	2,792	2,703
Erbitux [Member]
Segment Reporting Information [Line Items]
Revenue											485	373.3	373.7
Other Revenue, Net											309.4	327.2	315.2
Erbitux [Member] | Oncology [Member]
Segment Reporting Information [Line Items]
Revenue												373.3	373.7
Other Revenue, Net											485
Cyramza [Member] | Oncology [Member]
Segment Reporting Information [Line Items]
Revenue											383.8	75.6	0
Other Oncology [Member] | Oncology [Member]
Segment Reporting Information [Line Items]
Revenue											147.9	152.1	191.8
Cialis [Member] | Cardiovascular [Member]
Segment Reporting Information [Line Items]
Revenue											2,310.7	2,291	2,159.4
Effient [Member] | Cardiovascular [Member]
Segment Reporting Information [Line Items]
Revenue											523	522.2	508.7
Other Cardiovascular [Member] | Cardiovascular [Member]
Segment Reporting Information [Line Items]
Revenue											234.3	240.3	255.1
BI compounds [Member]
Segment Reporting Information [Line Items]
Other-net, (income) expense			$ 92
BI compounds [Member] | Corporate, Non-Segment [Member]
Segment Reporting Information [Line Items]
Other-net, (income) expense											$ 0	$ 92	$ 0
Minimum [Member] | Sales Revenue, Goods, Net [Member]
Segment Reporting Information [Line Items]
Concentration Risk, Percentage											9.00%	8.00%	13.00%
Minimum [Member] | Accounts Receivable [Member]
Segment Reporting Information [Line Items]
Concentration Risk, Percentage											12.00%	9.00%
Maximum [Member] | Sales Revenue, Goods, Net [Member]
Segment Reporting Information [Line Items]
Concentration Risk, Percentage											15.00%	14.00%	19.00%
Maximum [Member] | Accounts Receivable [Member]
Segment Reporting Information [Line Items]
Concentration Risk, Percentage											16.00%	15.00%
Fair Value Adjustment to Inventory [Member] | Corporate, Non-Segment [Member]
Segment Reporting Information [Line Items]
Cost of sales											$ (153)	$ 0	$ 0
Long-term Debt [Member] | Corporate, Non-Segment [Member]
Segment Reporting Information [Line Items]
Other-net, (income) expense	[4]										$ (152.7)	$ 0	$ 0
[1]	(2) Long-lived assets consist of property and equipment, net, and certain sundry assets.
[2]	(1) Revenue is attributed to the countries based on the location of the customer.
[3]	(2) In 2015, the measurement of segment profitability was changed to exclude certain amortization of intangible assets. The prior periods have been adjusted to conform with the 2015 presentation.
[4]	(1) We recognized pretax net charges of $152.7 million for the year ended December 31, 2015, attributable to the debt extinguishment loss of $166.7 million from the purchase and redemption of certain fixed-rate notes, partially offset by net gains from non-hedging interest rate swaps and foreign currency transactions associated with the related issuance of euro-denominated notes.

Selected Quarterly Data (Detail

Selected Quarterly Data (Details) - USD ($) $ / shares in Units, $ in Millions		1 Months Ended	3 Months Ended								12 Months Ended
		Dec. 31, 2013	Dec. 31, 2015	Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2015	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Revenue			$ 5,375.6	$ 4,959.7	$ 4,978.7	$ 4,644.7	$ 5,121.3	$ 4,875.6	$ 4,935.6	$ 4,683.1	$ 19,958.7	$ 19,615.6	$ 23,113.1
Cost of sales			1,389.2	1,236.9	1,218.4	1,192.7	1,253.1	1,267	1,189.7	1,222.7	5,037.2	4,932.5	4,908.1
Operating Expenses	[1]		3,242.6	2,719.1	2,804.9	2,562.8	2,985.6	2,915.3	2,859.3	2,594.2
Acquired in-process research and development		$ 57.1	199	0	80	256	105.2	95	0	0	535	200.2	57.1
Asset impairment, restructuring, and other special charges			144.9	42.4	72.4	108	401	36.3	0	31.4	367.7	468.7	120.6
Other-net, (income) expense			(44.7)	(86.5)	123.3	(92.7)	(137.2)	(93.5)	(53.8)	(56)	(100.6)	(340.5)	(518.9)
Income before income taxes			444.6	1,047.8	679.7	617.9	513.6	655.5	940.4	890.8
Net income			$ 478.4	$ 799.7	$ 600.8	$ 529.5	$ 428.5	$ 500.6	$ 733.5	$ 727.9	$ 2,408.4	$ 2,390.5	$ 4,684.8
Basic			$ 0.45	$ 0.75	$ 0.57	$ 0.50	$ 0.40	$ 0.47	$ 0.68	$ 0.68	$ 2.27	$ 2.23	$ 4.33
Diluted			0.45	0.75	0.56	0.50	0.40	0.47	0.68	0.68	2.26	2.23	$ 4.32
Common Stock, Dividends, Per Share, Cash Paid			0.50	0.50	0.50	0.50	0.49	0.49	0.49	0.49
Maximum [Member]
Share Price			87.52	89.98	86.59	76.36	72.83	66.59	63.10	59.85	87.52	72.83
Minimum [Member]
Share Price			$ 76.98	$ 78.26	$ 70.89	$ 68.41	$ 61.90	$ 60.35	$ 58.21	$ 50.73	$ 76.98	$ 61.90
[1]	(1) Includes